A Dose Escalation Study of a Combination Antihypertensive Drug in the Treatment of Various Groups of Patients Who do Not Respond to Single Drug Treatment of Their High Blood Pressure

A Prospective, Open-Label, Titration Study to Evaluate the Efficacy and Safety Safety of AZOR in Multiple Subgroups of Hypertensive Subjects Who Are Non-Responders to Anti-Hypertensive Monotherapy

Status

Completed

Phases

Phase 4

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT00791258

Acronym

BP CRUSH

Enrollment

999

Registered

2008-11-14

Start date

2008-11-30

Completion date

2009-09-30

Last updated

2019-01-09

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Hypertension

Brief summary

The initial 12 week portion of this 20 week study will examine the ability of a combination of olmesartan medoxomil and amlodipine to lower the blood pressure of patients with high blood pressure who have not had sufficient blood pressure reduction using one anti-hypertension drug (monotherapy). The final 8 weeks of this 20 week study will examine the ability of a combination of olmesartan medoxomil, amlodipine and hydrochlorothiazide to lower blood pressure in the same patient population. All three medications being tested have been approved by the FDA for the treatment of high blood pressure, but only amlodipine and olmesartan are currently approved for use in combination form.

Interventions

DRUGamlodipine and olmesartan medoxomil tablets

amlodipine and olmesartan medoxomil tablets administered orally, once daily for up to 20 weeks

DRUGhydrochlorothiazide tablets

hydrochlorothiazide tablets may be administered orally, if necessary once daily, for up to 8 weeks

Study design

Allocation

Intervention model

SINGLE_GROUP

Primary purpose

TREATMENT

Masking

NONE

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

* \>= to 18 years of age * Hypertension uncontrolled on current monotherapy * Females: * negative serum pregnancy test at screening * post menopausal or have had a hysterectomy or tubal ligation or practicing approved methods of birth control

Exclusion criteria

* Pregnant females * Uncontrolled hypertension with multiple drugs, except for hydrochlorothiazide/triamterene * Diabetes requiring insulin * Serious disorders that may limit the ability to evaluate the efficacy or safety of treatment * History of myocardial infarction, bypass graft, angioplasty or heart failure within the past 6 months * History of Class III or IV congestive heart failure * History of stroke or transient ischemic attack within the last 1 year

Design outcomes

Primary

Measure	Time frame
The Percentage of Patients Who Achieve Seated Systolic Blood Pressure Goal (<140 mm Hg for Non-diabetics and <130 mm Hg for Diabetics) From Baseline to 12 Weeks	baseline to 12 weeks

Secondary

Measure	Time frame	Description
The Percentage of Subjects Achieving Seated Diastolic BP Goal (<90 mmHg for Non-diabetics or < 80 mmHg for Subjects With Diabetes) From Baseline to 12 Weeks	baseline to 12 weeks	—
The Percentage of Subjects Who Achieve BP Goal (<140/90 mmHg for Non-diabetics or <130/80 mmHg for Diabetics) From Baseline to 12 and 20 Weeks	Baseline to 12 and 20 weeks	—
Change in Mean Seated Systolic Blood Pressure From Baseline to 4, 8, 12, 16, 20 Weeks	Baseline to 4, 8, 12, 16, 20 weeks	—
Change in Mean Seated Diastolic Blood Pressure From Baseline to 4, 8, 12, 16, 20 Weeks	Baseline to 4, 8, 12, 16, 20 weeks	—
Percentage of Patients Achieving Seated Diastolic Blood Pressure Goal From Baseline to 4, 8, 12, 16, 20 Weeks	Baseline to 4, 8, 12, 16, 20 weeks	—
Percentage of Patients Achieving Seated Systolic Blood Pressure Goal From Baseline to 4, 8, 12, 16, 20 Weeks	Baseline to 4, 8, 12, 16, 20 weeks	—
Percentage of Patients Achieving Seated Blood Pressure Goal From Baseline to 4, 8, 12, 16, 20 Weeks	Baseline to 4, 8, 12, 16, 20 weeks	—
Percentage of Patients Achieving Seated Systolic Blood Pressure Reduction Ranges From Baseline to 4, 8, 12, 16, 20 Weeks	Baseline to 4, 8, 12, 16, 20 weeks	—
Percentage of Patients Achieving Seated Diastolic Blood Pressure Reduction Ranges From Baseline to 4, 8, 12, 16, 20 Weeks	Baseline to 4, 8, 12, 16, 20 weeks	—
Percentage of Participants Achieving the Mean Daytime Blood Pressure Goals, as Measured by Ambulatory Blood Pressure Monitor, From Baseline to 12 Weeks	Baseline to 12 weeks	Once the Ambulatory Blood Pressure Monitor (ABPM) has been applied, the dose of medication was taken and the subject wore the ABPM for a period of 24 hours. Daytime is defined as 8AM - 4PM.
Percentage of Participants Achieving the Mean Daytime Blood Pressure Goals, as Measured by Ambulatory Blood Pressure Monitor, From Baseline to 20 Weeks	Baseline to 20 weeks	Once the Ambulatory Blood Pressure Monitor (ABPM) has been applied, the dose of medication was taken and the subject wore the ABPM for a period of 24 hours. Daytime is defined as 8AM - 4PM.
Percentage of Participants Achieving the Mean Nighttime Blood Pressure Goals, as Measured by Ambulatory Blood Pressure Monitor, From Baseline to 12 Weeks	Baseline to 12 weeks	Once the Ambulatory Blood Pressure Monitor (ABPM) has been applied, the dose of medication was taken and the subject wore the ABPM for a period of 24 hours. Nighttime is defined as 10p.m. - 6 a.m.
Percentage of Participants Achieving the Mean Nighttime Blood Pressure Goals, as Measured by Ambulatory Blood Pressure Monitor, From Baseline to 20 Weeks	Baseline to 20 weeks	Once the Ambulatory Blood Pressure Monitor (ABPM) has been applied, the dose of medication was taken and the subject wore the ABPM for a period of 24 hours. Nighttime is defined as 10 p.m. - 6 a.m.
Percentage of Participants Achieving the Mean 24-hour Blood Pressure Goals, as Measured by Ambulatory Blood Pressure Monitor, From Baseline to 12 Weeks	Baseline to 12 weeks	Once the Ambulatory Blood Pressure Monitor (ABPM) has been applied, the dose of medication was taken and the subject wore the ABPM for a period of 24 hours.
Percentage of Participants Achieving the Mean 24-hour Blood Pressure Goals, as Measured by Ambulatory Blood Pressure Monitor, From Baseline to 20 Weeks	Baseline to 20 weeks	Once the Ambulatory Blood Pressure Monitor (ABPM) has been applied, the dose of medication was taken and the subject wore the ABPM for a period of 24 hours.
Change From Baseline to Week 12 in Ambulatory Systolic and Diastolic Blood Pressure Values	Baseline to 12 weeks	Once the Ambulatory Blood Pressure Monitor (ABPM) has been applied, the dose of medication was taken and the subject wore the ABPM for a period of 24 hours. Daytime is defined as 8 a.m. to 4 p.m. Nighttime is defined as 10 p.m. to 6 a.m.
Change From Baseline to Week 20 in Ambulatory Systolic and Diastolic Blood Pressure Values	Baseline to 20 weeks	Once the Ambulatory Blood Pressure Monitor (ABPM) has been applied, the dose of medication was taken and the subject wore the ABPM for a period of 24 hours. Daytime is defined as 8 a.m. to 4 p.m. Nighttime is defined as 10 p.m. to 6 a.m.
Percentage of African American/Black Patients Achieving Seated Systolic Blood Pressure Goal From Baseline to 4, 8, 12, 16, 20 Weeks	Baseline to 4, 8, 12, 16, 20 weeks	—
Percentage of African American/Black Patients Achieving Seated Diastolic Blood Pressure Goal From Baseline to 4, 8, 12, 16, 20 Weeks	Baseline to 4, 8, 12, 16, 20 weeks	—
Percentage of African American/Black Patients Achieving Seated Blood Pressure Goal From Baseline to 4, 8, 12, 16, 20 Weeks	Baseline to 4, 8, 12, 16, 20 weeks	—
Percentage of African American/Black Patients Achieving Seated Systolic Blood Pressure Reduction Ranges From Baseline to 4, 8, 12, 16, 20 Weeks	Baseline to 4, 8, 12, 16, 20 weeks	—
Percentage of African American/Black Patients Achieving Seated Diastolic Blood Pressure Reduction Ranges From Baseline to 4, 8, 12, 16, 20 Weeks	Baseline to 4, 8, 12, 16, 20 weeks	—
Percentage of Asian Patients Achieving Seated Systolic Blood Pressure Goal From Baseline to 4, 8, 12, 16, 20 Weeks	Baseline to 4, 8, 12, 16, 20 weeks	—
Percentage of Asain Patients Achieving Seated Diastolic Blood Pressure Goal From Baseline to 4, 8, 12, 16, 20 Weeks	Baseline to 4, 8, 12, 16, 20 weeks	—
Percentage of Asian Patients Achieving Seated Systolic Blood Pressure Reduction Ranges From Baseline to 4, 8, 12, 16, 20 Weeks	Baseline to 4, 8, 12, 16, 20 weeks	—
Percentage of Asian Patients Achieving Seated Diastolic Blood Pressure Reduction Ranges From Baseline to 4, 8, 12, 16, 20 Weeks	Baseline to 4, 8, 12, 16, 20 weeks	—
Percentage of Hispanic Patients Achieving Seated Systolic Blood Pressure Goal From Baseline to 4, 8, 12, 16, 20 Weeks	Baseline to 4, 8, 12, 16, 20 weeks	—
Percentage of Hispanic Patients Achieving Seated Diastolic Blood Pressure Goal From Baseline to 4, 8, 12, 16, 20 Weeks	Baseline to 4, 8, 12, 16, 20 weeks	—
Percentage of Hispanic Patients Achieving Seated Systolic Blood Pressure Reduction Ranges From Baseline to 4, 8, 12, 16, 20 Weeks	Baseline to 4, 8, 12, 16, 20 weeks	—
Percentage of Elderly Patients Achieving Seated Systolic Blood Pressure Goal From Baseline to 4, 8, 12, 16, 20 Weeks	Baseline to 4, 8, 12, 16, 20 weeks	—
Percentage of Elderly Patients Achieving Seated Diastolic Blood Pressure Goal From Baseline to 4, 8, 12, 16, 20 Weeks	Baseline to 4, 8, 12, 16, 20 weeks	—
Percentage of Elderly Patients Achieving Seated Systolic Blood Pressure Reduction Ranges From Baseline to 4, 8, 12, 16, 20 Weeks	Baseline to 4, 8, 12, 16, 20 weeks	—
Percentage of Elderly Patients Achieving Seated Diastolic Blood Pressure Reduction Ranges From Baseline to 4, 8, 12, 16, 20 Weeks	Baseline to 4, 8, 12, 16, 20 weeks	—
Percentage of Type 2 Diabetic Patients Achieving Seated Systolic Blood Pressure Goal From Baseline to 4, 8, 12, 16, 20 Weeks	Baseline to 4, 8, 12, 16, 20 weeks	—
Percentage of Type 2 Diabetic Patients Achieving Seated Diastolic Blood Pressure Goal From Baseline to 4, 8, 12, 16, 20 Weeks	Baseline to 4, 8, 12, 16, 20 weeks	—
Percentage of Type 2 Diabetic Patients Achieving Seated Systolic Blood Pressure Reduction Ranges From Baseline to 4, 8, 12, 16, 20 Weeks	Baseline to 4, 8, 12, 16, 20 weeks	—
Percentage of Type 2 Diabetic Patients Achieving Seated Diastolic Blood Pressure Reduction Ranges From Baseline to 4, 8, 12, 16, 20 Weeks	Baseline to 4, 8, 12, 16, 20 weeks	—
Percentage of Obese Patients Achieving Seated Systolic Blood Pressure Goal From Baseline to 4, 8, 12, 16, 20 Weeks	Baseline to 4, 8, 12, 16, 20 weeks	—
Percentage of Obese Patients Achieving Seated Diastolic Blood Pressure Goal From Baseline to 4, 8, 12, 16, 20 Weeks	Baseline to 4, 8, 12, 16, 20 weeks	—
Percentage of Obese Patients Achieving Seated Systolic Blood Pressure Reduction Ranges From Baseline to 4, 8, 12, 16, 20 Weeks	Baseline to 4, 8, 12, 16, 20 weeks	—
Percentage of Obese Patients Achieving Seated Diastolic Blood Pressure Reduction Ranges From Baseline to 4, 8, 12, 16, 20 Weeks	Baseline to 4, 8, 12, 16, 20 weeks	—
Percentage of Patients With Metabolic Syndrome Achieving Seated Systolic Blood Pressure Goal From Baseline to 4, 8, 12, 16, 20 Weeks	Baseline to 4, 8, 12, 16, 20 weeks	—
Percentage of Patients With Metabolic Syndrome Achieving Seated Diastolic Blood Pressure Goal From Baseline to 4, 8, 12, 16, 20 Weeks	Baseline to 4, 8, 12, 16, 20 weeks	—
Percentage of Patients With Metabolic Syndrome Achieving Seated Systolic Blood Pressure Reduction Ranges From Baseline to 4, 8, 12, 16, 20 Weeks	Baseline to 4, 8, 12, 16, 20 weeks	—
Percentage of Patients With Metabolic Syndrome Achieving Seated Diastolic Blood Pressure Reduction Ranges From Baseline to 4, 8, 12, 16, 20 Weeks	Baseline to 4, 8, 12, 16, 20 weeks	—
Percentage of Participants Previously on a Dihydropyridine Calcium Channel Blocker Achieving the Blood Pressure Goals From Baseline to 12 Weeks	Baseline to 12 weeks	—
Percentage of Participants Previously on a Dihydropyridine Calcium Channel Blocker Achieving the Blood Pressure Goals From Baseline to 20 Weeks	Baseline to 20 weeks	—
Percentage of Participants Previously on a Diuretic Achieving the Blood Pressure Goals From Baseline to 12 Weeks	Baseline to 12 weeks	—
Percentage of Participants Previously on a Diuretic Achieving the Blood Pressure Goals From Baseline to 20 Weeks	Baseline to 20 weeks	—
Percentage of Participants Previously on an Angiotensin Converting Enzyme Inhibitor Achieving the Blood Pressure Goals From Baseline to 12 Weeks	Baseline to 12 weeks	—
Percentage of Hispanic Patients Achieving Seated Diastolic Blood Pressure Reduction Ranges From Baseline to 4, 8, 12, 16, 20 Weeks	Baseline to 4, 8, 12, 16, 20 weeks	—
Percentage of Participants Previously on an Angiotensin II Receptor Blocker Achieving the Blood Pressure Goals From Baseline to 12 Weeks	Baseline to 12 weeks	—
Percentage of Participants Previously on an Angiotensin II Receptor Blocker Achieving the Blood Pressure Goals From Baseline to 20 Weeks	Baseline to 20 weeks	—
Percentage of Participants Previously on a Beta Blocker Achieving the Blood Pressure Goals From Baseline to 12 Weeks	Baseline to 12 weeks	—
Percentage of Participants Previously on a Beta Blocker Achieving the Blood Pressure Goals From Baseline to 20 Weeks	Baseline to 20 weeks	—
Percentage of Participants Previously on a Nondihydropyridine Calcium Channel Blocker Achieving the Blood Pressure Goals From Baseline to 12 Weeks	Baseline to 12 weeks	—
Percentage of Participants Previously on a Nondihydropyridine Calcium Channel Blocker Achieving the Blood Pressure Goals From Baseline to 20 Weeks	Baseline to 20 weeks	—
Percentage of Participants Previously on an Angiotensin Converting Enzyme Inhibitor Achieving the Blood Pressure Goals From Baseline to 20 Weeks	Baseline to 20 weeks	—

Countries

United States

Participant flow

Recruitment details

Recruitment occurred at approximately 140 outpatient medical clinics in the United States and South Africa from December 2008 through March 2009. 1406 uncontrolled hypertensive subjects were screened to place 999 subjects into active treatment.

Participants by arm

Arm	Count
Olmesartan Medoxomil/Amlodipine Tablets + Hydrochlorothiazide Amlodipine and olmesartan medoxomil (Azor) oral tablets and hydrochlorothiazide oral tablets (if necessary) will be administered once a day for up to 20 weeks	999
Total	999

Withdrawals & dropouts

Period	Reason	FG000
Overall Study	Adverse Event	87
Overall Study	Did not take medication for >3 days	1
Overall Study	Lack of Efficacy	1
Overall Study	Lost to Follow-up	18
Overall Study	non-compliance	3
Overall Study	Protocol Violation	109
Overall Study	Subject incarcerated	1
Overall Study	subject left area	2
Overall Study	Subject required restricted medication	1
Overall Study	Withdrawal by Subject	40

Baseline characteristics

Characteristic	Olmesartan Medoxomil/Amlodipine Tablets + Hydrochlorothiazide
24-Hour mean diastolic ambulatory blood pressure	81.09 mm Hg STANDARD_DEVIATION 9.346
24-Hour mean systolic ambulatory blood pressure	135.74 mm Hg STANDARD_DEVIATION 11.698
Age, Categorical <=18 years	0 Participants
Age, Categorical >=65 years	228 Participants
Age, Categorical Between 18 and 65 years	771 Participants
Body Mass Index	31.02 Kg/m٨2 STANDARD_DEVIATION 6.37
Hispanic or Latino Hispanic or Latino	105 Participants
Hispanic or Latino Non-Hispanic or Latino	894 Participants
Mean seated diastolic blood pressure	91.92 mm Hg STANDARD_DEVIATION 8.616
Mean seated systolic blood pressure	153.66 mm Hg STANDARD_DEVIATION 9.178
Metabolic syndrome No	537 Participants
Metabolic syndrome Yes	462 Participants
Pulse rate	74.77 beats/minute STANDARD_DEVIATION 11.621
Race (NIH/OMB) American Indian or Alaska Native	6 Participants
Race (NIH/OMB) Asian	129 Participants
Race (NIH/OMB) Black or African American	234 Participants
Race (NIH/OMB) More than one race	0 Participants
Race (NIH/OMB) Native Hawaiian or Other Pacific Islander	0 Participants
Race (NIH/OMB) Unknown or Not Reported	0 Participants
Race (NIH/OMB) White	630 Participants
Region of Enrollment South Africa	267 participants
Region of Enrollment United States	732 participants
Sex: Female, Male Female	491 Participants
Sex: Female, Male Male	508 Participants
Type 2 Diabetes No	807 Participants
Type 2 Diabetes Yes	192 Participants
Weight	88.20 kg STANDARD_DEVIATION 21.466

Adverse events

Event type	EG000 affected / at risk
deaths Total, all-cause mortality	— / —
other Total, other adverse events	241 / 999
serious Total, serious adverse events	13 / 999

Outcome results

Primary

The Percentage of Patients Who Achieve Seated Systolic Blood Pressure Goal (<140 mm Hg for Non-diabetics and <130 mm Hg for Diabetics) From Baseline to 12 Weeks

Time frame: baseline to 12 weeks

Population: The analysis population consists of those participants who have a baseline and at least 1 post-baseline measurement and who received at least one dose of study medication.

Arm	Measure	Value (NUMBER)
Olmesartan Medoxomil/Amlodipine Tablets + Hydrochlorothiazide	The Percentage of Patients Who Achieve Seated Systolic Blood Pressure Goal (<140 mm Hg for Non-diabetics and <130 mm Hg for Diabetics) From Baseline to 12 Weeks	75.8 Percentage of participants

95% CI: [73, 78.5]

Secondary

Change From Baseline to Week 12 in Ambulatory Systolic and Diastolic Blood Pressure Values

Once the Ambulatory Blood Pressure Monitor (ABPM) has been applied, the dose of medication was taken and the subject wore the ABPM for a period of 24 hours. Daytime is defined as 8 a.m. to 4 p.m. Nighttime is defined as 10 p.m. to 6 a.m.

Time frame: Baseline to 12 weeks

Population: Ambulatory blood pressure (ABPM) subset of participants who have both technically successful baseline and 12 week ABPM data.

Arm	Measure	Group	Value (MEAN)	Dispersion
Olmesartan Medoxomil/Amlodipine Tablets + Hydrochlorothiazide	Change From Baseline to Week 12 in Ambulatory Systolic and Diastolic Blood Pressure Values	24-hour mean systolic blood pressure	-14.8 mm Hg	Standard Error 0.72
Olmesartan Medoxomil/Amlodipine Tablets + Hydrochlorothiazide	Change From Baseline to Week 12 in Ambulatory Systolic and Diastolic Blood Pressure Values	Mean daytime systolic blood pressure	-16.3 mm Hg	Standard Error 0.77
Olmesartan Medoxomil/Amlodipine Tablets + Hydrochlorothiazide	Change From Baseline to Week 12 in Ambulatory Systolic and Diastolic Blood Pressure Values	Mean nighttime systolic blood pressure	-12.5 mm Hg	Standard Error 0.84
Olmesartan Medoxomil/Amlodipine Tablets + Hydrochlorothiazide	Change From Baseline to Week 12 in Ambulatory Systolic and Diastolic Blood Pressure Values	Systolic blood pressure - last 2 hours of dose	-13.6 mm Hg	Standard Error 1.04
Olmesartan Medoxomil/Amlodipine Tablets + Hydrochlorothiazide	Change From Baseline to Week 12 in Ambulatory Systolic and Diastolic Blood Pressure Values	Systolic blood pressure - last 4 hours of dose	-13.0 mm Hg	Standard Error 0.9
Olmesartan Medoxomil/Amlodipine Tablets + Hydrochlorothiazide	Change From Baseline to Week 12 in Ambulatory Systolic and Diastolic Blood Pressure Values	Systolic blood pressure - last 6 hours of dose	-12.6 mm Hg	Standard Error 0.85
Olmesartan Medoxomil/Amlodipine Tablets + Hydrochlorothiazide	Change From Baseline to Week 12 in Ambulatory Systolic and Diastolic Blood Pressure Values	24-hour mean diastolic blood pressure	-9.4 mm Hg	Standard Error 0.46
Olmesartan Medoxomil/Amlodipine Tablets + Hydrochlorothiazide	Change From Baseline to Week 12 in Ambulatory Systolic and Diastolic Blood Pressure Values	Mean daytime diastolic blood pressure	-10.6 mm Hg	Standard Error 0.51
Olmesartan Medoxomil/Amlodipine Tablets + Hydrochlorothiazide	Change From Baseline to Week 12 in Ambulatory Systolic and Diastolic Blood Pressure Values	Mean nighttime diastolic blood pressure	-7.6 mm Hg	Standard Error 0.59
Olmesartan Medoxomil/Amlodipine Tablets + Hydrochlorothiazide	Change From Baseline to Week 12 in Ambulatory Systolic and Diastolic Blood Pressure Values	Diastolic blood pressure - last 2 hours of dose	-8.6 mm Hg	Standard Error 0.7
Olmesartan Medoxomil/Amlodipine Tablets + Hydrochlorothiazide	Change From Baseline to Week 12 in Ambulatory Systolic and Diastolic Blood Pressure Values	Diastolic blood pressure - last 4 hours of dose	-8.0 mm Hg	Standard Error 0.6
Olmesartan Medoxomil/Amlodipine Tablets + Hydrochlorothiazide	Change From Baseline to Week 12 in Ambulatory Systolic and Diastolic Blood Pressure Values	Diastolic blood pressure - last 6 hours of dose	-7.7 mm Hg	Standard Error 0.57

Comparison: Mean nighttime systolic blood pressurep-value: <0.000195% CI: [-14.1, -10.8]t-test, 1 sided

Comparison: systolic blood pressure during last 2 hours of dosep-value: <0.000195% CI: [-15.7, -11.6]t-test, 1 sided

Comparison: Mean 24-hour systolic blood pressurep-value: <0.000195% CI: [-16.2, -13.4]t-test, 1 sided

Comparison: Mean daytime systolic blood pressurep-value: <0.000195% CI: [-17.8, -14.8]t-test, 1 sided

Comparison: systolic blood pressure during last 4 hours of dosep-value: <0.000195% CI: [-14.7, -11.2]t-test, 1 sided

Comparison: systolic blood pressure during last 6 hours of dosep-value: <0.000195% CI: [-14.3, -10.9]t-test, 1 sided

Comparison: Mean 24-hour diastolic blood pressurep-value: <0.000195% CI: [-10.3, -8.5]t-test, 1 sided

Comparison: Mean daytime diastolic blood pressurep-value: <0.000195% CI: [-11.7, -9.6]t-test, 1 sided

Comparison: Mean nighttime diastolic blood pressurep-value: <0.000195% CI: [-8.8, -6.4]t-test, 1 sided

Comparison: diastolic blood pressure during last 2 hours of dosep-value: <0.000195% CI: [-10, -7.2]t-test, 1 sided

Comparison: diastolic blood pressure during last 4 hours of dosep-value: <0.000195% CI: [-9.2, -6.8]t-test, 1 sided

Comparison: diastolic blood pressure during last 6 hours of dosep-value: <0.000195% CI: [-8.8, -6.6]t-test, 1 sided

Secondary

Change From Baseline to Week 20 in Ambulatory Systolic and Diastolic Blood Pressure Values

Time frame: Baseline to 20 weeks

Population: Ambulatory blood pressure (ABPM) subset of participants who have both technically successful baseline and 20 week ABPM data.

Arm	Measure	Group	Value (MEAN)	Dispersion
Olmesartan Medoxomil/Amlodipine Tablets + Hydrochlorothiazide	Change From Baseline to Week 20 in Ambulatory Systolic and Diastolic Blood Pressure Values	24-hour mean systolic blood pressure	-21.0 mm Hg	Standard Error 0.84
Olmesartan Medoxomil/Amlodipine Tablets + Hydrochlorothiazide	Change From Baseline to Week 20 in Ambulatory Systolic and Diastolic Blood Pressure Values	Mean daytime systolic blood pressure	-23.2 mm Hg	Standard Error 0.94
Olmesartan Medoxomil/Amlodipine Tablets + Hydrochlorothiazide	Change From Baseline to Week 20 in Ambulatory Systolic and Diastolic Blood Pressure Values	Mean nighttime systolic blood pressure	-17.5 mm Hg	Standard Error 0.94
Olmesartan Medoxomil/Amlodipine Tablets + Hydrochlorothiazide	Change From Baseline to Week 20 in Ambulatory Systolic and Diastolic Blood Pressure Values	Systolic blood pressure - last 2 hours of dose	-19.6 mm Hg	Standard Error 1.1
Olmesartan Medoxomil/Amlodipine Tablets + Hydrochlorothiazide	Change From Baseline to Week 20 in Ambulatory Systolic and Diastolic Blood Pressure Values	Systolic blood pressure - last 4 hours of dose	-18.2 mm Hg	Standard Error 1
Olmesartan Medoxomil/Amlodipine Tablets + Hydrochlorothiazide	Change From Baseline to Week 20 in Ambulatory Systolic and Diastolic Blood Pressure Values	Systolic blood pressure - last 6 hours of dose	-17.9 mm Hg	Standard Error 0.95
Olmesartan Medoxomil/Amlodipine Tablets + Hydrochlorothiazide	Change From Baseline to Week 20 in Ambulatory Systolic and Diastolic Blood Pressure Values	24-hour mean diastolic blood pressure	-13.3 mm Hg	Standard Error 0.55
Olmesartan Medoxomil/Amlodipine Tablets + Hydrochlorothiazide	Change From Baseline to Week 20 in Ambulatory Systolic and Diastolic Blood Pressure Values	Mean daytime diastolic blood pressure	-15.0 mm Hg	Standard Error 0.62
Olmesartan Medoxomil/Amlodipine Tablets + Hydrochlorothiazide	Change From Baseline to Week 20 in Ambulatory Systolic and Diastolic Blood Pressure Values	Mean nighttime diastolic blood pressure	-11.1 mm Hg	Standard Error 0.69
Olmesartan Medoxomil/Amlodipine Tablets + Hydrochlorothiazide	Change From Baseline to Week 20 in Ambulatory Systolic and Diastolic Blood Pressure Values	Diastolic blood pressure - last 2 hours of dose	-12.3 mm Hg	Standard Error 0.77
Olmesartan Medoxomil/Amlodipine Tablets + Hydrochlorothiazide	Change From Baseline to Week 20 in Ambulatory Systolic and Diastolic Blood Pressure Values	Diastolic blood pressure - last 4 hours of dose	-11.6 mm Hg	Standard Error 0.69
Olmesartan Medoxomil/Amlodipine Tablets + Hydrochlorothiazide	Change From Baseline to Week 20 in Ambulatory Systolic and Diastolic Blood Pressure Values	Diastolic blood pressure - last 6 hours of dose	-11.3 mm Hg	Standard Error 0.66

Comparison: 24-hour mean systolic blood pressurep-value: <0.000195% CI: [-22.6, -19.3]t-test, 1 sided

Comparison: Mean daytime systolic blood pressurep-value: <0.000195% CI: [-25.1, -21.4]t-test, 1 sided

Comparison: Mean nighttime systolic blood pressurep-value: <0.000195% CI: [-19.4, -15.6]t-test, 1 sided

Comparison: Systolic blood pressure - last 2 hours of dosep-value: <0.000195% CI: [-21.7, -17.4]t-test, 1 sided

Comparison: Systolic blood pressure - last 4 hours of dosep-value: <0.000195% CI: [-20.2, -16.3]t-test, 1 sided

Comparison: Systolic blood pressure - last 6 hours of dosep-value: <0.000195% CI: [-19.7, -16]t-test, 1 sided

Comparison: 24-hour mean diastolic blood pressurep-value: <0.000195% CI: [-14.4, -12.2]t-test, 1 sided

Comparison: Mean daytime diastolic blood pressurep-value: <0.000195% CI: [-16.2, -13.8]t-test, 1 sided

Comparison: Mean nighttime diastolic blood pressurep-value: <0.000195% CI: [-12.4, -9.8]t-test, 1 sided

Comparison: Diastolic blood pressure - last 2 hours of dosep-value: <0.000195% CI: [-13.8, -10.8]t-test, 1 sided

Comparison: Diastolic blood pressure - last 4 hours of dosep-value: <0.000195% CI: [-12.9, -10.2]t-test, 1 sided

Comparison: Diastolic blood pressure - last 6 hours of dosep-value: <0.000195% CI: [-12.6, -10]t-test, 1 sided

Secondary

Change in Mean Seated Diastolic Blood Pressure From Baseline to 4, 8, 12, 16, 20 Weeks

Time frame: Baseline to 4, 8, 12, 16, 20 weeks

Population: The analysis population consists of those participants who have a baseline and at least 1 post-baseline measurement and who received at least one dose of study medication. However, the number of participants included will vary because of missing data and the number of dropouts.

Arm	Measure	Group	Value (MEAN)	Dispersion
Olmesartan Medoxomil/Amlodipine Tablets + Hydrochlorothiazide	Change in Mean Seated Diastolic Blood Pressure From Baseline to 4, 8, 12, 16, 20 Weeks	4 weeks, N=975	-8.1 mm Hg	Standard Error 0.27
Olmesartan Medoxomil/Amlodipine Tablets + Hydrochlorothiazide	Change in Mean Seated Diastolic Blood Pressure From Baseline to 4, 8, 12, 16, 20 Weeks	8 weeks, N=929	-9.1 mm Hg	Standard Error 0.29
Olmesartan Medoxomil/Amlodipine Tablets + Hydrochlorothiazide	Change in Mean Seated Diastolic Blood Pressure From Baseline to 4, 8, 12, 16, 20 Weeks	12 weeks, N=865	-11.9 mm Hg	Standard Error 0.28
Olmesartan Medoxomil/Amlodipine Tablets + Hydrochlorothiazide	Change in Mean Seated Diastolic Blood Pressure From Baseline to 4, 8, 12, 16, 20 Weeks	16 weeks, N=797	-14.6 mm Hg	Standard Error 0.31
Olmesartan Medoxomil/Amlodipine Tablets + Hydrochlorothiazide	Change in Mean Seated Diastolic Blood Pressure From Baseline to 4, 8, 12, 16, 20 Weeks	20 weeks, N=745	-14.5 mm Hg	Standard Error 0.34

Comparison: 4 week analysisp-value: <0.000195% CI: [-8.6, -7.6]t-test, 1 sided

Comparison: 8 week analysisp-value: <0.000195% CI: [-9.7, -8.5]t-test, 1 sided

Comparison: 12 week analysisp-value: <0.000195% CI: [-12.5, -11.4]t-test, 1 sided

Comparison: 16 week analysisp-value: <0.000195% CI: [-15.2, -14]t-test, 1 sided

Comparison: 20 week analysisp-value: 0.000195% CI: [-15.1, -13.8]t-test, 1 sided

Secondary

Change in Mean Seated Systolic Blood Pressure From Baseline to 4, 8, 12, 16, 20 Weeks

Time frame: Baseline to 4, 8, 12, 16, 20 weeks

Population: The analysis population consists of those participants who have a baseline and at lease 1 post-baseline measurement and who received at least one dose of study medication. However, the number of participants included will vary because of missing data and the number of dropouts.

Arm	Measure	Group	Value (MEAN)	Dispersion
Olmesartan Medoxomil/Amlodipine Tablets + Hydrochlorothiazide	Change in Mean Seated Systolic Blood Pressure From Baseline to 4, 8, 12, 16, 20 Weeks	4 weeks, N=975	-14.6 mm Hg	Standard Error 0.42
Olmesartan Medoxomil/Amlodipine Tablets + Hydrochlorothiazide	Change in Mean Seated Systolic Blood Pressure From Baseline to 4, 8, 12, 16, 20 Weeks	8 weeks, N=929	-16.6 mm Hg	Standard Error 0.46
Olmesartan Medoxomil/Amlodipine Tablets + Hydrochlorothiazide	Change in Mean Seated Systolic Blood Pressure From Baseline to 4, 8, 12, 16, 20 Weeks	12 weeks, N=865	-21.8 mm Hg	Standard Error 0.46
Olmesartan Medoxomil/Amlodipine Tablets + Hydrochlorothiazide	Change in Mean Seated Systolic Blood Pressure From Baseline to 4, 8, 12, 16, 20 Weeks	16 weeks, N=797	-26.0 mm Hg	Standard Error 0.51
Olmesartan Medoxomil/Amlodipine Tablets + Hydrochlorothiazide	Change in Mean Seated Systolic Blood Pressure From Baseline to 4, 8, 12, 16, 20 Weeks	20 weeks, N=745	-26.8 mm Hg	Standard Error 0.53

Comparison: 4 week analysisp-value: <0.000195% CI: [-15.4, -13.8]t-test, 1 sided

Comparison: 8 week analysisp-value: <0.000195% CI: [-17.7, -15.7]t-test, 1 sided

Comparison: 12 week analysisp-value: <0.000195% CI: [-22.7, -20.9]t-test, 1 sided

Comparison: 16 week analysisp-value: <0.000195% CI: [-27, -25]t-test, 1 sided

Comparison: 20 week analysisp-value: <0.000195% CI: [-27.8, -25.7]t-test, 1 sided

Secondary

Percentage of African American/Black Patients Achieving Seated Blood Pressure Goal From Baseline to 4, 8, 12, 16, 20 Weeks

Time frame: Baseline to 4, 8, 12, 16, 20 weeks

Population: The analysis population consists of those African American/Black participants who have a baseline and at least 1 post-baseline measurement and who received at least one dose of study medication. However, the number of participants included will vary because of missing data and the number of dropouts.

Arm	Measure	Group	Value (NUMBER)
Olmesartan Medoxomil/Amlodipine Tablets + Hydrochlorothiazide	Percentage of African American/Black Patients Achieving Seated Blood Pressure Goal From Baseline to 4, 8, 12, 16, 20 Weeks	4 weeks: <140/90 mm Hg, N=230	45.7 Percentage of Participants
Olmesartan Medoxomil/Amlodipine Tablets + Hydrochlorothiazide	Percentage of African American/Black Patients Achieving Seated Blood Pressure Goal From Baseline to 4, 8, 12, 16, 20 Weeks	4 weeks: <135/80 mm Hg, N=230	14.8 Percentage of Participants
Olmesartan Medoxomil/Amlodipine Tablets + Hydrochlorothiazide	Percentage of African American/Black Patients Achieving Seated Blood Pressure Goal From Baseline to 4, 8, 12, 16, 20 Weeks	4 weeks: <130/80 mm Hg, N=230	10.4 Percentage of Participants
Olmesartan Medoxomil/Amlodipine Tablets + Hydrochlorothiazide	Percentage of African American/Black Patients Achieving Seated Blood Pressure Goal From Baseline to 4, 8, 12, 16, 20 Weeks	4 weeks: <120/80 mm Hg, N=230	3.9 Percentage of Participants
Olmesartan Medoxomil/Amlodipine Tablets + Hydrochlorothiazide	Percentage of African American/Black Patients Achieving Seated Blood Pressure Goal From Baseline to 4, 8, 12, 16, 20 Weeks	8 weeks: <140/90 mm Hg, N=231	55.0 Percentage of Participants
Olmesartan Medoxomil/Amlodipine Tablets + Hydrochlorothiazide	Percentage of African American/Black Patients Achieving Seated Blood Pressure Goal From Baseline to 4, 8, 12, 16, 20 Weeks	8 weeks: <135/80 mm Hg, N=231	23.8 Percentage of Participants
Olmesartan Medoxomil/Amlodipine Tablets + Hydrochlorothiazide	Percentage of African American/Black Patients Achieving Seated Blood Pressure Goal From Baseline to 4, 8, 12, 16, 20 Weeks	8 weeks: <130/80 mm Hg, N=232	20.8 Percentage of Participants
Olmesartan Medoxomil/Amlodipine Tablets + Hydrochlorothiazide	Percentage of African American/Black Patients Achieving Seated Blood Pressure Goal From Baseline to 4, 8, 12, 16, 20 Weeks	8 weeks: <120/80 mm Hg, N=232	10.4 Percentage of Participants
Olmesartan Medoxomil/Amlodipine Tablets + Hydrochlorothiazide	Percentage of African American/Black Patients Achieving Seated Blood Pressure Goal From Baseline to 4, 8, 12, 16, 20 Weeks	12 weeks: <140/90mm Hg, N=232	68.5 Percentage of Participants
Olmesartan Medoxomil/Amlodipine Tablets + Hydrochlorothiazide	Percentage of African American/Black Patients Achieving Seated Blood Pressure Goal From Baseline to 4, 8, 12, 16, 20 Weeks	12 weeks: <135/80 mm Hg, N=232	38.4 Percentage of Participants
Olmesartan Medoxomil/Amlodipine Tablets + Hydrochlorothiazide	Percentage of African American/Black Patients Achieving Seated Blood Pressure Goal From Baseline to 4, 8, 12, 16, 20 Weeks	12 weeks: <130/80 mm Hg, N=232	35.8 Percentage of Participants
Olmesartan Medoxomil/Amlodipine Tablets + Hydrochlorothiazide	Percentage of African American/Black Patients Achieving Seated Blood Pressure Goal From Baseline to 4, 8, 12, 16, 20 Weeks	12 weeks: <120/80 mm Hg, N=232	16.4 Percentage of Participants
Olmesartan Medoxomil/Amlodipine Tablets + Hydrochlorothiazide	Percentage of African American/Black Patients Achieving Seated Blood Pressure Goal From Baseline to 4, 8, 12, 16, 20 Weeks	16 weeks: <140/90 mm Hg, N=232	80.6 Percentage of Participants
Olmesartan Medoxomil/Amlodipine Tablets + Hydrochlorothiazide	Percentage of African American/Black Patients Achieving Seated Blood Pressure Goal From Baseline to 4, 8, 12, 16, 20 Weeks	16 weeks: <135/80 mm Hg, N=232	49.1 Percentage of Participants
Olmesartan Medoxomil/Amlodipine Tablets + Hydrochlorothiazide	Percentage of African American/Black Patients Achieving Seated Blood Pressure Goal From Baseline to 4, 8, 12, 16, 20 Weeks	16 weeks: <130/80 mm Hg, N=232	47.4 Percentage of Participants
Olmesartan Medoxomil/Amlodipine Tablets + Hydrochlorothiazide	Percentage of African American/Black Patients Achieving Seated Blood Pressure Goal From Baseline to 4, 8, 12, 16, 20 Weeks	16 weeks: <120/80 mm Hg, N=232	30.6 Percentage of Participants
Olmesartan Medoxomil/Amlodipine Tablets + Hydrochlorothiazide	Percentage of African American/Black Patients Achieving Seated Blood Pressure Goal From Baseline to 4, 8, 12, 16, 20 Weeks	20 weeks: <140/90 mm Hg, N=232	86.6 Percentage of Participants
Olmesartan Medoxomil/Amlodipine Tablets + Hydrochlorothiazide	Percentage of African American/Black Patients Achieving Seated Blood Pressure Goal From Baseline to 4, 8, 12, 16, 20 Weeks	20 weeks: <135/80 mm Hg, N=232	57.8 Percentage of Participants
Olmesartan Medoxomil/Amlodipine Tablets + Hydrochlorothiazide	Percentage of African American/Black Patients Achieving Seated Blood Pressure Goal From Baseline to 4, 8, 12, 16, 20 Weeks	20 weeks: <130/80 mm Hg, N=232	55.2 Percentage of Participants
Olmesartan Medoxomil/Amlodipine Tablets + Hydrochlorothiazide	Percentage of African American/Black Patients Achieving Seated Blood Pressure Goal From Baseline to 4, 8, 12, 16, 20 Weeks	20 weeks: <120/80 mm Hg, N=232	39.7 Percentage of Participants

Secondary

Percentage of African American/Black Patients Achieving Seated Diastolic Blood Pressure Goal From Baseline to 4, 8, 12, 16, 20 Weeks

Time frame: Baseline to 4, 8, 12, 16, 20 weeks

Arm	Measure	Group	Value (NUMBER)
Olmesartan Medoxomil/Amlodipine Tablets + Hydrochlorothiazide	Percentage of African American/Black Patients Achieving Seated Diastolic Blood Pressure Goal From Baseline to 4, 8, 12, 16, 20 Weeks	4 weeks: <90 mm Hg, N=230	60.9 Percentage of Participants
Olmesartan Medoxomil/Amlodipine Tablets + Hydrochlorothiazide	Percentage of African American/Black Patients Achieving Seated Diastolic Blood Pressure Goal From Baseline to 4, 8, 12, 16, 20 Weeks	4 weeks: <85 mm Hg, N=230	42.2 Percentage of Participants
Olmesartan Medoxomil/Amlodipine Tablets + Hydrochlorothiazide	Percentage of African American/Black Patients Achieving Seated Diastolic Blood Pressure Goal From Baseline to 4, 8, 12, 16, 20 Weeks	4 weeks: <80 mm Hg, N=230	19.6 Percentage of Participants
Olmesartan Medoxomil/Amlodipine Tablets + Hydrochlorothiazide	Percentage of African American/Black Patients Achieving Seated Diastolic Blood Pressure Goal From Baseline to 4, 8, 12, 16, 20 Weeks	8 weeks: <90 mm Hg, N=231	71.9 Percentage of Participants
Olmesartan Medoxomil/Amlodipine Tablets + Hydrochlorothiazide	Percentage of African American/Black Patients Achieving Seated Diastolic Blood Pressure Goal From Baseline to 4, 8, 12, 16, 20 Weeks	8 weeks: <85 mm Hg, N=231	53.7 Percentage of Participants
Olmesartan Medoxomil/Amlodipine Tablets + Hydrochlorothiazide	Percentage of African American/Black Patients Achieving Seated Diastolic Blood Pressure Goal From Baseline to 4, 8, 12, 16, 20 Weeks	8 weeks: <80 mm Hg, N=231	30.3 Percentage of Participants
Olmesartan Medoxomil/Amlodipine Tablets + Hydrochlorothiazide	Percentage of African American/Black Patients Achieving Seated Diastolic Blood Pressure Goal From Baseline to 4, 8, 12, 16, 20 Weeks	12 weeks: <90 mm Hg, N=232	82.3 Percentage of Participants
Olmesartan Medoxomil/Amlodipine Tablets + Hydrochlorothiazide	Percentage of African American/Black Patients Achieving Seated Diastolic Blood Pressure Goal From Baseline to 4, 8, 12, 16, 20 Weeks	12 weeks: <85 mm Hg, N=232	66.0 Percentage of Participants
Olmesartan Medoxomil/Amlodipine Tablets + Hydrochlorothiazide	Percentage of African American/Black Patients Achieving Seated Diastolic Blood Pressure Goal From Baseline to 4, 8, 12, 16, 20 Weeks	12 weeks: <80 mm Hg, N=232	45.3 Percentage of Participants
Olmesartan Medoxomil/Amlodipine Tablets + Hydrochlorothiazide	Percentage of African American/Black Patients Achieving Seated Diastolic Blood Pressure Goal From Baseline to 4, 8, 12, 16, 20 Weeks	16 weeks: <90 mm Hg, N=232	92.2 Percentage of Participants
Olmesartan Medoxomil/Amlodipine Tablets + Hydrochlorothiazide	Percentage of African American/Black Patients Achieving Seated Diastolic Blood Pressure Goal From Baseline to 4, 8, 12, 16, 20 Weeks	16 weeks: <85 mm Hg, N=232	76.3 Percentage of Participants
Olmesartan Medoxomil/Amlodipine Tablets + Hydrochlorothiazide	Percentage of African American/Black Patients Achieving Seated Diastolic Blood Pressure Goal From Baseline to 4, 8, 12, 16, 20 Weeks	16 weeks: <80 mm Hg, N=232	55.2 Percentage of Participants
Olmesartan Medoxomil/Amlodipine Tablets + Hydrochlorothiazide	Percentage of African American/Black Patients Achieving Seated Diastolic Blood Pressure Goal From Baseline to 4, 8, 12, 16, 20 Weeks	20 weeks: <90 mm Hg, N=232	94.8 Percentage of Participants
Olmesartan Medoxomil/Amlodipine Tablets + Hydrochlorothiazide	Percentage of African American/Black Patients Achieving Seated Diastolic Blood Pressure Goal From Baseline to 4, 8, 12, 16, 20 Weeks	20 weeks: <85 mm Hg, N=232	80.6 Percentage of Participants
Olmesartan Medoxomil/Amlodipine Tablets + Hydrochlorothiazide	Percentage of African American/Black Patients Achieving Seated Diastolic Blood Pressure Goal From Baseline to 4, 8, 12, 16, 20 Weeks	20 weeks: <80 mm Hg, N=232	61.2 Percentage of Participants

Secondary

Percentage of African American/Black Patients Achieving Seated Diastolic Blood Pressure Reduction Ranges From Baseline to 4, 8, 12, 16, 20 Weeks

Time frame: Baseline to 4, 8, 12, 16, 20 weeks

Arm	Measure	Group	Value (NUMBER)
Olmesartan Medoxomil/Amlodipine Tablets + Hydrochlorothiazide	Percentage of African American/Black Patients Achieving Seated Diastolic Blood Pressure Reduction Ranges From Baseline to 4, 8, 12, 16, 20 Weeks	4 weeks: ≤ 10 mm Hg, N=230	70.0 Percentage of Participants
Olmesartan Medoxomil/Amlodipine Tablets + Hydrochlorothiazide	Percentage of African American/Black Patients Achieving Seated Diastolic Blood Pressure Reduction Ranges From Baseline to 4, 8, 12, 16, 20 Weeks	4 weeks: >10 and ≤ 15 mm Hg, N=230	17.8 Percentage of Participants
Olmesartan Medoxomil/Amlodipine Tablets + Hydrochlorothiazide	Percentage of African American/Black Patients Achieving Seated Diastolic Blood Pressure Reduction Ranges From Baseline to 4, 8, 12, 16, 20 Weeks	4 weeks: >15 and ≤ 20 mm Hg, N=230	7.9 Percentage of Participants
Olmesartan Medoxomil/Amlodipine Tablets + Hydrochlorothiazide	Percentage of African American/Black Patients Achieving Seated Diastolic Blood Pressure Reduction Ranges From Baseline to 4, 8, 12, 16, 20 Weeks	4 weeks: >20 mm Hg, N=230	4.4 Percentage of Participants
Olmesartan Medoxomil/Amlodipine Tablets + Hydrochlorothiazide	Percentage of African American/Black Patients Achieving Seated Diastolic Blood Pressure Reduction Ranges From Baseline to 4, 8, 12, 16, 20 Weeks	8 weeks: ≤ 10 mm Hg, N=220	66.8 Percentage of Participants
Olmesartan Medoxomil/Amlodipine Tablets + Hydrochlorothiazide	Percentage of African American/Black Patients Achieving Seated Diastolic Blood Pressure Reduction Ranges From Baseline to 4, 8, 12, 16, 20 Weeks	8 weeks: >10 and ≤ 15 mm Hg, N=220	15.0 Percentage of Participants
Olmesartan Medoxomil/Amlodipine Tablets + Hydrochlorothiazide	Percentage of African American/Black Patients Achieving Seated Diastolic Blood Pressure Reduction Ranges From Baseline to 4, 8, 12, 16, 20 Weeks	8 weeks: >15 and ≤ 20 mm Hg, N=220	10.9 Percentage of Participants
Olmesartan Medoxomil/Amlodipine Tablets + Hydrochlorothiazide	Percentage of African American/Black Patients Achieving Seated Diastolic Blood Pressure Reduction Ranges From Baseline to 4, 8, 12, 16, 20 Weeks	8 weeks: >20 mm Hg, N=220	7.3 Percentage of Participants
Olmesartan Medoxomil/Amlodipine Tablets + Hydrochlorothiazide	Percentage of African American/Black Patients Achieving Seated Diastolic Blood Pressure Reduction Ranges From Baseline to 4, 8, 12, 16, 20 Weeks	12 weeks: ≤ 10 mm Hg, N=208	54.8 Percentage of Participants
Olmesartan Medoxomil/Amlodipine Tablets + Hydrochlorothiazide	Percentage of African American/Black Patients Achieving Seated Diastolic Blood Pressure Reduction Ranges From Baseline to 4, 8, 12, 16, 20 Weeks	12 weeks: >10 and ≤15 mm Hg, N=208	21.2 Percentage of Participants
Olmesartan Medoxomil/Amlodipine Tablets + Hydrochlorothiazide	Percentage of African American/Black Patients Achieving Seated Diastolic Blood Pressure Reduction Ranges From Baseline to 4, 8, 12, 16, 20 Weeks	12 weeks: >15 and ≤ 20 mm Hg, N=208	12.0 Percentage of Participants
Olmesartan Medoxomil/Amlodipine Tablets + Hydrochlorothiazide	Percentage of African American/Black Patients Achieving Seated Diastolic Blood Pressure Reduction Ranges From Baseline to 4, 8, 12, 16, 20 Weeks	12 weeks: >20 mm Hg, N=208	12.0 Percentage of Participants
Olmesartan Medoxomil/Amlodipine Tablets + Hydrochlorothiazide	Percentage of African American/Black Patients Achieving Seated Diastolic Blood Pressure Reduction Ranges From Baseline to 4, 8, 12, 16, 20 Weeks	16 weeks: ≤ 10 mm Hg, N=199	38.7 Percentage of Participants
Olmesartan Medoxomil/Amlodipine Tablets + Hydrochlorothiazide	Percentage of African American/Black Patients Achieving Seated Diastolic Blood Pressure Reduction Ranges From Baseline to 4, 8, 12, 16, 20 Weeks	16 weeks: >10 and ≤ 15 mm Hg, N=199	19.6 Percentage of Participants
Olmesartan Medoxomil/Amlodipine Tablets + Hydrochlorothiazide	Percentage of African American/Black Patients Achieving Seated Diastolic Blood Pressure Reduction Ranges From Baseline to 4, 8, 12, 16, 20 Weeks	16 weeks: >15 and ≤ 20 mm Hg, N=199	23.1 Percentage of Participants
Olmesartan Medoxomil/Amlodipine Tablets + Hydrochlorothiazide	Percentage of African American/Black Patients Achieving Seated Diastolic Blood Pressure Reduction Ranges From Baseline to 4, 8, 12, 16, 20 Weeks	16 weeks: >20 mm Hg, N=199	18.6 Percentage of Participants
Olmesartan Medoxomil/Amlodipine Tablets + Hydrochlorothiazide	Percentage of African American/Black Patients Achieving Seated Diastolic Blood Pressure Reduction Ranges From Baseline to 4, 8, 12, 16, 20 Weeks	20 weeks: ≤ 10 mm Hg, N=189	36.0 Percentage of Participants
Olmesartan Medoxomil/Amlodipine Tablets + Hydrochlorothiazide	Percentage of African American/Black Patients Achieving Seated Diastolic Blood Pressure Reduction Ranges From Baseline to 4, 8, 12, 16, 20 Weeks	20 weeks: >10 and ≤ 15 mm Hg, N=189	19.6 Percentage of Participants
Olmesartan Medoxomil/Amlodipine Tablets + Hydrochlorothiazide	Percentage of African American/Black Patients Achieving Seated Diastolic Blood Pressure Reduction Ranges From Baseline to 4, 8, 12, 16, 20 Weeks	20 weeks: >15 and ≤ 20 mm Hg, N=189	20.6 Percentage of Participants
Olmesartan Medoxomil/Amlodipine Tablets + Hydrochlorothiazide	Percentage of African American/Black Patients Achieving Seated Diastolic Blood Pressure Reduction Ranges From Baseline to 4, 8, 12, 16, 20 Weeks	20 weeks: >20 mm Hg, N=189	23.8 Percentage of Participants

Secondary

Percentage of African American/Black Patients Achieving Seated Systolic Blood Pressure Goal From Baseline to 4, 8, 12, 16, 20 Weeks

Time frame: Baseline to 4, 8, 12, 16, 20 weeks

Arm	Measure	Group	Value (NUMBER)
Olmesartan Medoxomil/Amlodipine Tablets + Hydrochlorothiazide	Percentage of African American/Black Patients Achieving Seated Systolic Blood Pressure Goal From Baseline to 4, 8, 12, 16, 20 Weeks	4 weeks: <140 mm Hg, N=230	51.7 Percentage of Participants
Olmesartan Medoxomil/Amlodipine Tablets + Hydrochlorothiazide	Percentage of African American/Black Patients Achieving Seated Systolic Blood Pressure Goal From Baseline to 4, 8, 12, 16, 20 Weeks	4 weeks: <135 mm Hg, N=230	34.4 Percentage of Participants
Olmesartan Medoxomil/Amlodipine Tablets + Hydrochlorothiazide	Percentage of African American/Black Patients Achieving Seated Systolic Blood Pressure Goal From Baseline to 4, 8, 12, 16, 20 Weeks	4 weeks: <130 mm Hg, N=230	19.6 Percentage of Participants
Olmesartan Medoxomil/Amlodipine Tablets + Hydrochlorothiazide	Percentage of African American/Black Patients Achieving Seated Systolic Blood Pressure Goal From Baseline to 4, 8, 12, 16, 20 Weeks	4 weeks: <120 mm Hg, N=230	5.7 Percentage of Participants
Olmesartan Medoxomil/Amlodipine Tablets + Hydrochlorothiazide	Percentage of African American/Black Patients Achieving Seated Systolic Blood Pressure Goal From Baseline to 4, 8, 12, 16, 20 Weeks	8 weeks: <140 mm Hg, N=231	62.3 Percentage of Participants
Olmesartan Medoxomil/Amlodipine Tablets + Hydrochlorothiazide	Percentage of African American/Black Patients Achieving Seated Systolic Blood Pressure Goal From Baseline to 4, 8, 12, 16, 20 Weeks	8 weeks: <135 mm Hg, N=231	44.6 Percentage of Participants
Olmesartan Medoxomil/Amlodipine Tablets + Hydrochlorothiazide	Percentage of African American/Black Patients Achieving Seated Systolic Blood Pressure Goal From Baseline to 4, 8, 12, 16, 20 Weeks	8 weeks: <130 mm Hg, N=231	33.8 Percentage of Participants
Olmesartan Medoxomil/Amlodipine Tablets + Hydrochlorothiazide	Percentage of African American/Black Patients Achieving Seated Systolic Blood Pressure Goal From Baseline to 4, 8, 12, 16, 20 Weeks	8 weeks: <120 mm Hg, N=231	13.0 Percentage of Participants
Olmesartan Medoxomil/Amlodipine Tablets + Hydrochlorothiazide	Percentage of African American/Black Patients Achieving Seated Systolic Blood Pressure Goal From Baseline to 4, 8, 12, 16, 20 Weeks	12 weeks: <140 mm Hg, N=232	76.3 Percentage of Participants
Olmesartan Medoxomil/Amlodipine Tablets + Hydrochlorothiazide	Percentage of African American/Black Patients Achieving Seated Systolic Blood Pressure Goal From Baseline to 4, 8, 12, 16, 20 Weeks	12 weeks: <135 mm Hg, N=232	59.1 Percentage of Participants
Olmesartan Medoxomil/Amlodipine Tablets + Hydrochlorothiazide	Percentage of African American/Black Patients Achieving Seated Systolic Blood Pressure Goal From Baseline to 4, 8, 12, 16, 20 Weeks	12 weeks: <130 mm Hg, N=232	47.0 Percentage of Participants
Olmesartan Medoxomil/Amlodipine Tablets + Hydrochlorothiazide	Percentage of African American/Black Patients Achieving Seated Systolic Blood Pressure Goal From Baseline to 4, 8, 12, 16, 20 Weeks	12 weeks: <120 mm Hg, N=232	19.8 Percentage of Participants
Olmesartan Medoxomil/Amlodipine Tablets + Hydrochlorothiazide	Percentage of African American/Black Patients Achieving Seated Systolic Blood Pressure Goal From Baseline to 4, 8, 12, 16, 20 Weeks	16 weeks: <140 mm Hg, N=232	84.9 Percentage of Participants
Olmesartan Medoxomil/Amlodipine Tablets + Hydrochlorothiazide	Percentage of African American/Black Patients Achieving Seated Systolic Blood Pressure Goal From Baseline to 4, 8, 12, 16, 20 Weeks	16 weeks: <135 mm Hg, N=232	71.1 Percentage of Participants
Olmesartan Medoxomil/Amlodipine Tablets + Hydrochlorothiazide	Percentage of African American/Black Patients Achieving Seated Systolic Blood Pressure Goal From Baseline to 4, 8, 12, 16, 20 Weeks	16 weeks: <130 mm Hg, N=232	61.2 Percentage of Participants
Olmesartan Medoxomil/Amlodipine Tablets + Hydrochlorothiazide	Percentage of African American/Black Patients Achieving Seated Systolic Blood Pressure Goal From Baseline to 4, 8, 12, 16, 20 Weeks	16 weeks: <120 mm Hg, N=232	34.1 Percentage of Participants
Olmesartan Medoxomil/Amlodipine Tablets + Hydrochlorothiazide	Percentage of African American/Black Patients Achieving Seated Systolic Blood Pressure Goal From Baseline to 4, 8, 12, 16, 20 Weeks	20 weeks: <140 mm Hg, N=232	91.0 Percentage of Participants
Olmesartan Medoxomil/Amlodipine Tablets + Hydrochlorothiazide	Percentage of African American/Black Patients Achieving Seated Systolic Blood Pressure Goal From Baseline to 4, 8, 12, 16, 20 Weeks	20 weeks: <135 mm Hg, N=232	80.6 Percentage of Participants
Olmesartan Medoxomil/Amlodipine Tablets + Hydrochlorothiazide	Percentage of African American/Black Patients Achieving Seated Systolic Blood Pressure Goal From Baseline to 4, 8, 12, 16, 20 Weeks	20 weeks: <130 mm Hg, N=232	71.1 Percentage of Participants
Olmesartan Medoxomil/Amlodipine Tablets + Hydrochlorothiazide	Percentage of African American/Black Patients Achieving Seated Systolic Blood Pressure Goal From Baseline to 4, 8, 12, 16, 20 Weeks	20 weeks: <120 mm Hg, N=232	44.4 Percentage of Participants

Secondary

Percentage of African American/Black Patients Achieving Seated Systolic Blood Pressure Reduction Ranges From Baseline to 4, 8, 12, 16, 20 Weeks

Time frame: Baseline to 4, 8, 12, 16, 20 weeks

Arm	Measure	Group	Value (NUMBER)
Olmesartan Medoxomil/Amlodipine Tablets + Hydrochlorothiazide	Percentage of African American/Black Patients Achieving Seated Systolic Blood Pressure Reduction Ranges From Baseline to 4, 8, 12, 16, 20 Weeks	4 weeks: ≤ 15 mm Hg, N=230	60.0 Percentage of Participants
Olmesartan Medoxomil/Amlodipine Tablets + Hydrochlorothiazide	Percentage of African American/Black Patients Achieving Seated Systolic Blood Pressure Reduction Ranges From Baseline to 4, 8, 12, 16, 20 Weeks	4 weeks: >15 and ≤ 30 mm Hg, N=230	32.2 Percentage of Participants
Olmesartan Medoxomil/Amlodipine Tablets + Hydrochlorothiazide	Percentage of African American/Black Patients Achieving Seated Systolic Blood Pressure Reduction Ranges From Baseline to 4, 8, 12, 16, 20 Weeks	4 weeks: >30 and ≤ 45 mm Hg, N=230	7.4 Percentage of Participants
Olmesartan Medoxomil/Amlodipine Tablets + Hydrochlorothiazide	Percentage of African American/Black Patients Achieving Seated Systolic Blood Pressure Reduction Ranges From Baseline to 4, 8, 12, 16, 20 Weeks	4 weeks: >45 mm Hg, N=230	0.4 Percentage of Participants
Olmesartan Medoxomil/Amlodipine Tablets + Hydrochlorothiazide	Percentage of African American/Black Patients Achieving Seated Systolic Blood Pressure Reduction Ranges From Baseline to 4, 8, 12, 16, 20 Weeks	8 weeks: ≤ 15 mm Hg, N=220	53.6 Percentage of Participants
Olmesartan Medoxomil/Amlodipine Tablets + Hydrochlorothiazide	Percentage of African American/Black Patients Achieving Seated Systolic Blood Pressure Reduction Ranges From Baseline to 4, 8, 12, 16, 20 Weeks	8 weeks: >15 and ≤ 30 mm Hg, N=220	38.2 Percentage of Participants
Olmesartan Medoxomil/Amlodipine Tablets + Hydrochlorothiazide	Percentage of African American/Black Patients Achieving Seated Systolic Blood Pressure Reduction Ranges From Baseline to 4, 8, 12, 16, 20 Weeks	8 weeks: >30 and ≤ 45 mm Hg, N=220	7.3 Percentage of Participants
Olmesartan Medoxomil/Amlodipine Tablets + Hydrochlorothiazide	Percentage of African American/Black Patients Achieving Seated Systolic Blood Pressure Reduction Ranges From Baseline to 4, 8, 12, 16, 20 Weeks	8 weeks: >45 mm Hg, N=220	0.9 Percentage of Participants
Olmesartan Medoxomil/Amlodipine Tablets + Hydrochlorothiazide	Percentage of African American/Black Patients Achieving Seated Systolic Blood Pressure Reduction Ranges From Baseline to 4, 8, 12, 16, 20 Weeks	12 weeks: ≤ 15 mm Hg, N=208	38.9 Percentage of Participants
Olmesartan Medoxomil/Amlodipine Tablets + Hydrochlorothiazide	Percentage of African American/Black Patients Achieving Seated Systolic Blood Pressure Reduction Ranges From Baseline to 4, 8, 12, 16, 20 Weeks	12 weeks: >15 and ≤ 30 mm Hg, N=208	41.8 Percentage of Participants
Olmesartan Medoxomil/Amlodipine Tablets + Hydrochlorothiazide	Percentage of African American/Black Patients Achieving Seated Systolic Blood Pressure Reduction Ranges From Baseline to 4, 8, 12, 16, 20 Weeks	12 weeks: >30 and ≤ 45 mm Hg, N=208	16.4 Percentage of Participants
Olmesartan Medoxomil/Amlodipine Tablets + Hydrochlorothiazide	Percentage of African American/Black Patients Achieving Seated Systolic Blood Pressure Reduction Ranges From Baseline to 4, 8, 12, 16, 20 Weeks	12 weeks: >45 mm Hg, N=208	2.9 Percentage of Participants
Olmesartan Medoxomil/Amlodipine Tablets + Hydrochlorothiazide	Percentage of African American/Black Patients Achieving Seated Systolic Blood Pressure Reduction Ranges From Baseline to 4, 8, 12, 16, 20 Weeks	16 weeks: ≤ 15 mm Hg, N=199	30.7 Percentage of Participants
Olmesartan Medoxomil/Amlodipine Tablets + Hydrochlorothiazide	Percentage of African American/Black Patients Achieving Seated Systolic Blood Pressure Reduction Ranges From Baseline to 4, 8, 12, 16, 20 Weeks	16 weeks: >15 and ≤ 30 mm Hg, N=199	37.2 Percentage of Participants
Olmesartan Medoxomil/Amlodipine Tablets + Hydrochlorothiazide	Percentage of African American/Black Patients Achieving Seated Systolic Blood Pressure Reduction Ranges From Baseline to 4, 8, 12, 16, 20 Weeks	16 weeks: >30 and ≤ 45 mm Hg, N=199	25.1 Percentage of Participants
Olmesartan Medoxomil/Amlodipine Tablets + Hydrochlorothiazide	Percentage of African American/Black Patients Achieving Seated Systolic Blood Pressure Reduction Ranges From Baseline to 4, 8, 12, 16, 20 Weeks	16 weeks: >45 mm Hg, N=199	7.0 Percentage of Participants
Olmesartan Medoxomil/Amlodipine Tablets + Hydrochlorothiazide	Percentage of African American/Black Patients Achieving Seated Systolic Blood Pressure Reduction Ranges From Baseline to 4, 8, 12, 16, 20 Weeks	20 weeks: ≤ 15 mm Hg, N=189	24.3 Percentage of Participants
Olmesartan Medoxomil/Amlodipine Tablets + Hydrochlorothiazide	Percentage of African American/Black Patients Achieving Seated Systolic Blood Pressure Reduction Ranges From Baseline to 4, 8, 12, 16, 20 Weeks	20 weeks: >15 and ≤ 30 mm Hg, N=189	37.6 Percentage of Participants
Olmesartan Medoxomil/Amlodipine Tablets + Hydrochlorothiazide	Percentage of African American/Black Patients Achieving Seated Systolic Blood Pressure Reduction Ranges From Baseline to 4, 8, 12, 16, 20 Weeks	20 weeks: >30 and ≤ 45 mm Hg, N=189	29.6 Percentage of Participants
Olmesartan Medoxomil/Amlodipine Tablets + Hydrochlorothiazide	Percentage of African American/Black Patients Achieving Seated Systolic Blood Pressure Reduction Ranges From Baseline to 4, 8, 12, 16, 20 Weeks	20 weeks: >45 mm Hg, N=189	8.5 Percentage of Participants

Secondary

Percentage of Asain Patients Achieving Seated Diastolic Blood Pressure Goal From Baseline to 4, 8, 12, 16, 20 Weeks

Time frame: Baseline to 4, 8, 12, 16, 20 weeks

Population: The analysis population consists of those Asian participants who have a baseline and at least 1 post-baseline measurement and who received at least one dose of study medication. However, the number of participants included will vary because of missing data and the number of dropouts.

Arm	Measure	Group	Value (NUMBER)
Olmesartan Medoxomil/Amlodipine Tablets + Hydrochlorothiazide	Percentage of Asain Patients Achieving Seated Diastolic Blood Pressure Goal From Baseline to 4, 8, 12, 16, 20 Weeks	4 weeks: <90 mm Hg, N=128	83.6 Percentage of Participants
Olmesartan Medoxomil/Amlodipine Tablets + Hydrochlorothiazide	Percentage of Asain Patients Achieving Seated Diastolic Blood Pressure Goal From Baseline to 4, 8, 12, 16, 20 Weeks	4 weeks: <85 mm Hg, N=128	69.5 Percentage of Participants
Olmesartan Medoxomil/Amlodipine Tablets + Hydrochlorothiazide	Percentage of Asain Patients Achieving Seated Diastolic Blood Pressure Goal From Baseline to 4, 8, 12, 16, 20 Weeks	4 weeks: <80 mm Hg, N=128	45.3 Percentage of Participants
Olmesartan Medoxomil/Amlodipine Tablets + Hydrochlorothiazide	Percentage of Asain Patients Achieving Seated Diastolic Blood Pressure Goal From Baseline to 4, 8, 12, 16, 20 Weeks	8 weeks: <90 mm Hg, N=128	89.1 Percentage of Participants
Olmesartan Medoxomil/Amlodipine Tablets + Hydrochlorothiazide	Percentage of Asain Patients Achieving Seated Diastolic Blood Pressure Goal From Baseline to 4, 8, 12, 16, 20 Weeks	8 weeks: <85 mm Hg, N=128	79.7 Percentage of Participants
Olmesartan Medoxomil/Amlodipine Tablets + Hydrochlorothiazide	Percentage of Asain Patients Achieving Seated Diastolic Blood Pressure Goal From Baseline to 4, 8, 12, 16, 20 Weeks	8 weeks: <80 mm Hg, N=128	60.2 Percentage of Participants
Olmesartan Medoxomil/Amlodipine Tablets + Hydrochlorothiazide	Percentage of Asain Patients Achieving Seated Diastolic Blood Pressure Goal From Baseline to 4, 8, 12, 16, 20 Weeks	12 weeks: <90 mm Hg, N=128	95.3 Percentage of Participants
Olmesartan Medoxomil/Amlodipine Tablets + Hydrochlorothiazide	Percentage of Asain Patients Achieving Seated Diastolic Blood Pressure Goal From Baseline to 4, 8, 12, 16, 20 Weeks	12 weeks: <85 mm Hg, N=128	87.5 Percentage of Participants
Olmesartan Medoxomil/Amlodipine Tablets + Hydrochlorothiazide	Percentage of Asain Patients Achieving Seated Diastolic Blood Pressure Goal From Baseline to 4, 8, 12, 16, 20 Weeks	12 weeks: <80 mm Hg, N=128	71.1 Percentage of Participants
Olmesartan Medoxomil/Amlodipine Tablets + Hydrochlorothiazide	Percentage of Asain Patients Achieving Seated Diastolic Blood Pressure Goal From Baseline to 4, 8, 12, 16, 20 Weeks	16 weeks: <90 mm Hg, N=128	96.9 Percentage of Participants
Olmesartan Medoxomil/Amlodipine Tablets + Hydrochlorothiazide	Percentage of Asain Patients Achieving Seated Diastolic Blood Pressure Goal From Baseline to 4, 8, 12, 16, 20 Weeks	16 weeks: <85 mm Hg, N=128	93.0 Percentage of Participants
Olmesartan Medoxomil/Amlodipine Tablets + Hydrochlorothiazide	Percentage of Asain Patients Achieving Seated Diastolic Blood Pressure Goal From Baseline to 4, 8, 12, 16, 20 Weeks	16 weeks: <80 mm Hg, N=128	82.0 Percentage of Participants
Olmesartan Medoxomil/Amlodipine Tablets + Hydrochlorothiazide	Percentage of Asain Patients Achieving Seated Diastolic Blood Pressure Goal From Baseline to 4, 8, 12, 16, 20 Weeks	20 weeks: <90 mm Hg, N=128	96.9 Percentage of Participants
Olmesartan Medoxomil/Amlodipine Tablets + Hydrochlorothiazide	Percentage of Asain Patients Achieving Seated Diastolic Blood Pressure Goal From Baseline to 4, 8, 12, 16, 20 Weeks	20 weeks: <85 mm Hg, N=128	93.0 Percentage of Participants
Olmesartan Medoxomil/Amlodipine Tablets + Hydrochlorothiazide	Percentage of Asain Patients Achieving Seated Diastolic Blood Pressure Goal From Baseline to 4, 8, 12, 16, 20 Weeks	20 weeks: <80 mm Hg, N=128	85.2 Percentage of Participants

Secondary

Percentage of Asian Patients Achieving Seated Diastolic Blood Pressure Reduction Ranges From Baseline to 4, 8, 12, 16, 20 Weeks

Time frame: Baseline to 4, 8, 12, 16, 20 weeks

Arm	Measure	Group	Value (NUMBER)
Olmesartan Medoxomil/Amlodipine Tablets + Hydrochlorothiazide	Percentage of Asian Patients Achieving Seated Diastolic Blood Pressure Reduction Ranges From Baseline to 4, 8, 12, 16, 20 Weeks	4 weeks: ≤ 10 mm Hg, N=126	47.6 Percentage of Participants
Olmesartan Medoxomil/Amlodipine Tablets + Hydrochlorothiazide	Percentage of Asian Patients Achieving Seated Diastolic Blood Pressure Reduction Ranges From Baseline to 4, 8, 12, 16, 20 Weeks	4 weeks: >10 and ≤ 15 mm Hg, N=126	26.2 Percentage of Participants
Olmesartan Medoxomil/Amlodipine Tablets + Hydrochlorothiazide	Percentage of Asian Patients Achieving Seated Diastolic Blood Pressure Reduction Ranges From Baseline to 4, 8, 12, 16, 20 Weeks	4 weeks: >15 and ≤ 20 mm Hg, N=126	13.5 Percentage of Participants
Olmesartan Medoxomil/Amlodipine Tablets + Hydrochlorothiazide	Percentage of Asian Patients Achieving Seated Diastolic Blood Pressure Reduction Ranges From Baseline to 4, 8, 12, 16, 20 Weeks	4 weeks: >20 mm Hg, N=126	12.7 Percentage of Participants
Olmesartan Medoxomil/Amlodipine Tablets + Hydrochlorothiazide	Percentage of Asian Patients Achieving Seated Diastolic Blood Pressure Reduction Ranges From Baseline to 4, 8, 12, 16, 20 Weeks	8 weeks: ≤ 10 mm Hg, N=123	38.2 Percentage of Participants
Olmesartan Medoxomil/Amlodipine Tablets + Hydrochlorothiazide	Percentage of Asian Patients Achieving Seated Diastolic Blood Pressure Reduction Ranges From Baseline to 4, 8, 12, 16, 20 Weeks	8 weeks: >10 and ≤ 15 mm Hg, N=123	24.4 Percentage of Participants
Olmesartan Medoxomil/Amlodipine Tablets + Hydrochlorothiazide	Percentage of Asian Patients Achieving Seated Diastolic Blood Pressure Reduction Ranges From Baseline to 4, 8, 12, 16, 20 Weeks	8 weeks: >15 and ≤ 20 mm Hg, N=123	22.0 Percentage of Participants
Olmesartan Medoxomil/Amlodipine Tablets + Hydrochlorothiazide	Percentage of Asian Patients Achieving Seated Diastolic Blood Pressure Reduction Ranges From Baseline to 4, 8, 12, 16, 20 Weeks	8 weeks: >20 mm Hg, N=123	15.5 Percentage of Participants
Olmesartan Medoxomil/Amlodipine Tablets + Hydrochlorothiazide	Percentage of Asian Patients Achieving Seated Diastolic Blood Pressure Reduction Ranges From Baseline to 4, 8, 12, 16, 20 Weeks	12 weeks: ≤ 10 mm Hg, N=120	33.3 Percentage of Participants
Olmesartan Medoxomil/Amlodipine Tablets + Hydrochlorothiazide	Percentage of Asian Patients Achieving Seated Diastolic Blood Pressure Reduction Ranges From Baseline to 4, 8, 12, 16, 20 Weeks	12 weeks: >10 and ≤15 mm Hg, N=120	25.8 Percentage of Participants
Olmesartan Medoxomil/Amlodipine Tablets + Hydrochlorothiazide	Percentage of Asian Patients Achieving Seated Diastolic Blood Pressure Reduction Ranges From Baseline to 4, 8, 12, 16, 20 Weeks	12 weeks: >15 and ≤ 20 mm Hg, N=120	19.2 Percentage of Participants
Olmesartan Medoxomil/Amlodipine Tablets + Hydrochlorothiazide	Percentage of Asian Patients Achieving Seated Diastolic Blood Pressure Reduction Ranges From Baseline to 4, 8, 12, 16, 20 Weeks	12 weeks: >20 mm Hg, N=120	21.7 Percentage of Participants
Olmesartan Medoxomil/Amlodipine Tablets + Hydrochlorothiazide	Percentage of Asian Patients Achieving Seated Diastolic Blood Pressure Reduction Ranges From Baseline to 4, 8, 12, 16, 20 Weeks	16 weeks: ≤ 10 mm Hg, N=112	27.7 Percentage of Participants
Olmesartan Medoxomil/Amlodipine Tablets + Hydrochlorothiazide	Percentage of Asian Patients Achieving Seated Diastolic Blood Pressure Reduction Ranges From Baseline to 4, 8, 12, 16, 20 Weeks	16 weeks: >10 and ≤ 15 mm Hg, N=112	17.0 Percentage of Participants
Olmesartan Medoxomil/Amlodipine Tablets + Hydrochlorothiazide	Percentage of Asian Patients Achieving Seated Diastolic Blood Pressure Reduction Ranges From Baseline to 4, 8, 12, 16, 20 Weeks	16 weeks: >15 and ≤ 20 mm Hg, N=112	20.5 Percentage of Participants
Olmesartan Medoxomil/Amlodipine Tablets + Hydrochlorothiazide	Percentage of Asian Patients Achieving Seated Diastolic Blood Pressure Reduction Ranges From Baseline to 4, 8, 12, 16, 20 Weeks	16 weeks: >20 mm Hg, N=112	34.8 Percentage of Participants
Olmesartan Medoxomil/Amlodipine Tablets + Hydrochlorothiazide	Percentage of Asian Patients Achieving Seated Diastolic Blood Pressure Reduction Ranges From Baseline to 4, 8, 12, 16, 20 Weeks	20 weeks: ≤ 10 mm Hg, N=105	36.2 Percentage of Participants
Olmesartan Medoxomil/Amlodipine Tablets + Hydrochlorothiazide	Percentage of Asian Patients Achieving Seated Diastolic Blood Pressure Reduction Ranges From Baseline to 4, 8, 12, 16, 20 Weeks	20 weeks: >10 and ≤ 15 mm Hg, N=105	16.2 Percentage of Participants
Olmesartan Medoxomil/Amlodipine Tablets + Hydrochlorothiazide	Percentage of Asian Patients Achieving Seated Diastolic Blood Pressure Reduction Ranges From Baseline to 4, 8, 12, 16, 20 Weeks	20 weeks: >15 and ≤ 20 mm Hg, N=105	18.1 Percentage of Participants
Olmesartan Medoxomil/Amlodipine Tablets + Hydrochlorothiazide	Percentage of Asian Patients Achieving Seated Diastolic Blood Pressure Reduction Ranges From Baseline to 4, 8, 12, 16, 20 Weeks	20 weeks: >20 mm Hg, N=105	29.5 Percentage of Participants

Secondary

Percentage of Asian Patients Achieving Seated Systolic Blood Pressure Goal From Baseline to 4, 8, 12, 16, 20 Weeks

Time frame: Baseline to 4, 8, 12, 16, 20 weeks

Population: The analysis population consists of those Asian participants who have a baseline and at least 1 post-baseline measurement and who received at least one dose of study medication. However, the number of participants included may vary because of missing data and the number of dropouts.

Arm	Measure	Group	Value (NUMBER)
Olmesartan Medoxomil/Amlodipine Tablets + Hydrochlorothiazide	Percentage of Asian Patients Achieving Seated Systolic Blood Pressure Goal From Baseline to 4, 8, 12, 16, 20 Weeks	4 weeks: <140 mm Hg, N=128	64.8 Percentage of Participants
Olmesartan Medoxomil/Amlodipine Tablets + Hydrochlorothiazide	Percentage of Asian Patients Achieving Seated Systolic Blood Pressure Goal From Baseline to 4, 8, 12, 16, 20 Weeks	4 weeks: <135 mm Hg, N=128	51.6 Percentage of Participants
Olmesartan Medoxomil/Amlodipine Tablets + Hydrochlorothiazide	Percentage of Asian Patients Achieving Seated Systolic Blood Pressure Goal From Baseline to 4, 8, 12, 16, 20 Weeks	4 weeks: <130 mm Hg, N=128	35.2 Percentage of Participants
Olmesartan Medoxomil/Amlodipine Tablets + Hydrochlorothiazide	Percentage of Asian Patients Achieving Seated Systolic Blood Pressure Goal From Baseline to 4, 8, 12, 16, 20 Weeks	4 weeks: <120 mm Hg, N=128	11.7 Percentage of Participants
Olmesartan Medoxomil/Amlodipine Tablets + Hydrochlorothiazide	Percentage of Asian Patients Achieving Seated Systolic Blood Pressure Goal From Baseline to 4, 8, 12, 16, 20 Weeks	8 weeks: <140 mm Hg, N=128	76.6 Percentage of Participants
Olmesartan Medoxomil/Amlodipine Tablets + Hydrochlorothiazide	Percentage of Asian Patients Achieving Seated Systolic Blood Pressure Goal From Baseline to 4, 8, 12, 16, 20 Weeks	8 weeks: <135 mm Hg, N=128	67.2 Percentage of Participants
Olmesartan Medoxomil/Amlodipine Tablets + Hydrochlorothiazide	Percentage of Asian Patients Achieving Seated Systolic Blood Pressure Goal From Baseline to 4, 8, 12, 16, 20 Weeks	8 weeks: <130 mm Hg, N=128	51.6 Percentage of Participants
Olmesartan Medoxomil/Amlodipine Tablets + Hydrochlorothiazide	Percentage of Asian Patients Achieving Seated Systolic Blood Pressure Goal From Baseline to 4, 8, 12, 16, 20 Weeks	8 weeks: <120 mm Hg, N=128	25.0 Percentage of Participants
Olmesartan Medoxomil/Amlodipine Tablets + Hydrochlorothiazide	Percentage of Asian Patients Achieving Seated Systolic Blood Pressure Goal From Baseline to 4, 8, 12, 16, 20 Weeks	12 weeks: <140 mm Hg, N=128	89.1 Percentage of Participants
Olmesartan Medoxomil/Amlodipine Tablets + Hydrochlorothiazide	Percentage of Asian Patients Achieving Seated Systolic Blood Pressure Goal From Baseline to 4, 8, 12, 16, 20 Weeks	12 weeks: <135 mm Hg, N=128	78.9 Percentage of Participants
Olmesartan Medoxomil/Amlodipine Tablets + Hydrochlorothiazide	Percentage of Asian Patients Achieving Seated Systolic Blood Pressure Goal From Baseline to 4, 8, 12, 16, 20 Weeks	12 weeks: <130 mm Hg, N=128	66.4 Percentage of Participants
Olmesartan Medoxomil/Amlodipine Tablets + Hydrochlorothiazide	Percentage of Asian Patients Achieving Seated Systolic Blood Pressure Goal From Baseline to 4, 8, 12, 16, 20 Weeks	12 weeks: <120 mm Hg, N=128	38.3 Percentage of Participants
Olmesartan Medoxomil/Amlodipine Tablets + Hydrochlorothiazide	Percentage of Asian Patients Achieving Seated Systolic Blood Pressure Goal From Baseline to 4, 8, 12, 16, 20 Weeks	16 weeks: <140 mm Hg, N=128	95.3 Percentage of Participants
Olmesartan Medoxomil/Amlodipine Tablets + Hydrochlorothiazide	Percentage of Asian Patients Achieving Seated Systolic Blood Pressure Goal From Baseline to 4, 8, 12, 16, 20 Weeks	16 weeks: <135 mm Hg, N=128	89.8 Percentage of Participants
Olmesartan Medoxomil/Amlodipine Tablets + Hydrochlorothiazide	Percentage of Asian Patients Achieving Seated Systolic Blood Pressure Goal From Baseline to 4, 8, 12, 16, 20 Weeks	16 weeks: <130 mm Hg, N=128	81.3 Percentage of Participants
Olmesartan Medoxomil/Amlodipine Tablets + Hydrochlorothiazide	Percentage of Asian Patients Achieving Seated Systolic Blood Pressure Goal From Baseline to 4, 8, 12, 16, 20 Weeks	16 weeks: <120 mm Hg, N=128	47.7 Percentage of Participants
Olmesartan Medoxomil/Amlodipine Tablets + Hydrochlorothiazide	Percentage of Asian Patients Achieving Seated Systolic Blood Pressure Goal From Baseline to 4, 8, 12, 16, 20 Weeks	20 weeks: <140 mm Hg, N=128	97.7 Percentage of Participants
Olmesartan Medoxomil/Amlodipine Tablets + Hydrochlorothiazide	Percentage of Asian Patients Achieving Seated Systolic Blood Pressure Goal From Baseline to 4, 8, 12, 16, 20 Weeks	20 weeks: <135 mm Hg, N=128	93.0 Percentage of Participants
Olmesartan Medoxomil/Amlodipine Tablets + Hydrochlorothiazide	Percentage of Asian Patients Achieving Seated Systolic Blood Pressure Goal From Baseline to 4, 8, 12, 16, 20 Weeks	20 weeks: <130 mm Hg, N=128	85.9 Percentage of Participants
Olmesartan Medoxomil/Amlodipine Tablets + Hydrochlorothiazide	Percentage of Asian Patients Achieving Seated Systolic Blood Pressure Goal From Baseline to 4, 8, 12, 16, 20 Weeks	20 weeks: <120 mm Hg, N=128	51.6 Percentage of Participants

Secondary

Percentage of Asian Patients Achieving Seated Systolic Blood Pressure Reduction Ranges From Baseline to 4, 8, 12, 16, 20 Weeks

Time frame: Baseline to 4, 8, 12, 16, 20 weeks

Arm	Measure	Group	Value (NUMBER)
Olmesartan Medoxomil/Amlodipine Tablets + Hydrochlorothiazide	Percentage of Asian Patients Achieving Seated Systolic Blood Pressure Reduction Ranges From Baseline to 4, 8, 12, 16, 20 Weeks	20 weeks: >30 and ≤ 45 mm Hg, N=105	33.3 Percentage of Participants
Olmesartan Medoxomil/Amlodipine Tablets + Hydrochlorothiazide	Percentage of Asian Patients Achieving Seated Systolic Blood Pressure Reduction Ranges From Baseline to 4, 8, 12, 16, 20 Weeks	4 weeks: ≤ 15 mm Hg, N=126	43.7 Percentage of Participants
Olmesartan Medoxomil/Amlodipine Tablets + Hydrochlorothiazide	Percentage of Asian Patients Achieving Seated Systolic Blood Pressure Reduction Ranges From Baseline to 4, 8, 12, 16, 20 Weeks	4 weeks: >15 and ≤ 30 mm Hg, N=126	38.1 Percentage of Participants
Olmesartan Medoxomil/Amlodipine Tablets + Hydrochlorothiazide	Percentage of Asian Patients Achieving Seated Systolic Blood Pressure Reduction Ranges From Baseline to 4, 8, 12, 16, 20 Weeks	4 weeks: >30 and ≤ 45 mm Hg, N=126	15.9 Percentage of Participants
Olmesartan Medoxomil/Amlodipine Tablets + Hydrochlorothiazide	Percentage of Asian Patients Achieving Seated Systolic Blood Pressure Reduction Ranges From Baseline to 4, 8, 12, 16, 20 Weeks	4 weeks: >45 mm Hg, N=126	2.4 Percentage of Participants
Olmesartan Medoxomil/Amlodipine Tablets + Hydrochlorothiazide	Percentage of Asian Patients Achieving Seated Systolic Blood Pressure Reduction Ranges From Baseline to 4, 8, 12, 16, 20 Weeks	8 weeks: ≤ 15 mm Hg, N=123	40.7 Percentage of Participants
Olmesartan Medoxomil/Amlodipine Tablets + Hydrochlorothiazide	Percentage of Asian Patients Achieving Seated Systolic Blood Pressure Reduction Ranges From Baseline to 4, 8, 12, 16, 20 Weeks	8 weeks: >15 and ≤ 30 mm Hg, N=123	35.8 Percentage of Participants
Olmesartan Medoxomil/Amlodipine Tablets + Hydrochlorothiazide	Percentage of Asian Patients Achieving Seated Systolic Blood Pressure Reduction Ranges From Baseline to 4, 8, 12, 16, 20 Weeks	8 weeks: >30 and ≤ 45 mm Hg, N=123	22.0 Percentage of Participants
Olmesartan Medoxomil/Amlodipine Tablets + Hydrochlorothiazide	Percentage of Asian Patients Achieving Seated Systolic Blood Pressure Reduction Ranges From Baseline to 4, 8, 12, 16, 20 Weeks	8 weeks: >45 mm Hg, N=123	1.6 Percentage of Participants
Olmesartan Medoxomil/Amlodipine Tablets + Hydrochlorothiazide	Percentage of Asian Patients Achieving Seated Systolic Blood Pressure Reduction Ranges From Baseline to 4, 8, 12, 16, 20 Weeks	12 weeks: ≤ 15 mm Hg, N=120	28.3 Percentage of Participants
Olmesartan Medoxomil/Amlodipine Tablets + Hydrochlorothiazide	Percentage of Asian Patients Achieving Seated Systolic Blood Pressure Reduction Ranges From Baseline to 4, 8, 12, 16, 20 Weeks	12 weeks: >15 and ≤ 30 mm Hg, N=120	39.2 Percentage of Participants
Olmesartan Medoxomil/Amlodipine Tablets + Hydrochlorothiazide	Percentage of Asian Patients Achieving Seated Systolic Blood Pressure Reduction Ranges From Baseline to 4, 8, 12, 16, 20 Weeks	12 weeks: >30 and ≤ 45 mm Hg, N=120	27.5 Percentage of Participants
Olmesartan Medoxomil/Amlodipine Tablets + Hydrochlorothiazide	Percentage of Asian Patients Achieving Seated Systolic Blood Pressure Reduction Ranges From Baseline to 4, 8, 12, 16, 20 Weeks	12 weeks: >45 mm Hg, N=120	5.0 Percentage of Participants
Olmesartan Medoxomil/Amlodipine Tablets + Hydrochlorothiazide	Percentage of Asian Patients Achieving Seated Systolic Blood Pressure Reduction Ranges From Baseline to 4, 8, 12, 16, 20 Weeks	16 weeks: ≤ 15 mm Hg, N=112	20.5 Percentage of Participants
Olmesartan Medoxomil/Amlodipine Tablets + Hydrochlorothiazide	Percentage of Asian Patients Achieving Seated Systolic Blood Pressure Reduction Ranges From Baseline to 4, 8, 12, 16, 20 Weeks	16 weeks: >15 and ≤ 30 mm Hg, N=112	36.6 Percentage of Participants
Olmesartan Medoxomil/Amlodipine Tablets + Hydrochlorothiazide	Percentage of Asian Patients Achieving Seated Systolic Blood Pressure Reduction Ranges From Baseline to 4, 8, 12, 16, 20 Weeks	16 weeks: >30 and ≤ 45 mm Hg, N=112	31.3 Percentage of Participants
Olmesartan Medoxomil/Amlodipine Tablets + Hydrochlorothiazide	Percentage of Asian Patients Achieving Seated Systolic Blood Pressure Reduction Ranges From Baseline to 4, 8, 12, 16, 20 Weeks	16 weeks: >45 mm Hg, N=112	11.6 Percentage of Participants
Olmesartan Medoxomil/Amlodipine Tablets + Hydrochlorothiazide	Percentage of Asian Patients Achieving Seated Systolic Blood Pressure Reduction Ranges From Baseline to 4, 8, 12, 16, 20 Weeks	20 weeks: ≤ 15 mm Hg, N=105	29.5 Percentage of Participants
Olmesartan Medoxomil/Amlodipine Tablets + Hydrochlorothiazide	Percentage of Asian Patients Achieving Seated Systolic Blood Pressure Reduction Ranges From Baseline to 4, 8, 12, 16, 20 Weeks	20 weeks: >15 and ≤ 30 mm Hg, N=105	28.6 Percentage of Participants
Olmesartan Medoxomil/Amlodipine Tablets + Hydrochlorothiazide	Percentage of Asian Patients Achieving Seated Systolic Blood Pressure Reduction Ranges From Baseline to 4, 8, 12, 16, 20 Weeks	20 weeks: >45 mm Hg, N=105	8.6 Percentage of Participants

Secondary

Percentage of Elderly Patients Achieving Seated Diastolic Blood Pressure Goal From Baseline to 4, 8, 12, 16, 20 Weeks

Time frame: Baseline to 4, 8, 12, 16, 20 weeks

Population: The analysis population consists of those elderly participants who have a baseline and at least 1 post-baseline measurement and who received at least one dose of study medication. However, the number of participants included will vary because of missing data and the number of dropouts. Elderly is defined as greater than or = to 65 years of age.

Arm	Measure	Group	Value (NUMBER)
Olmesartan Medoxomil/Amlodipine Tablets + Hydrochlorothiazide	Percentage of Elderly Patients Achieving Seated Diastolic Blood Pressure Goal From Baseline to 4, 8, 12, 16, 20 Weeks	4 weeks: <90 mm Hg, N=227	88.1 Percentage of Participants
Olmesartan Medoxomil/Amlodipine Tablets + Hydrochlorothiazide	Percentage of Elderly Patients Achieving Seated Diastolic Blood Pressure Goal From Baseline to 4, 8, 12, 16, 20 Weeks	4 weeks: <85 mm Hg, N=227	76.7 Percentage of Participants
Olmesartan Medoxomil/Amlodipine Tablets + Hydrochlorothiazide	Percentage of Elderly Patients Achieving Seated Diastolic Blood Pressure Goal From Baseline to 4, 8, 12, 16, 20 Weeks	4 weeks: <80 mm Hg, N=227	58.2 Percentage of Participants
Olmesartan Medoxomil/Amlodipine Tablets + Hydrochlorothiazide	Percentage of Elderly Patients Achieving Seated Diastolic Blood Pressure Goal From Baseline to 4, 8, 12, 16, 20 Weeks	8 weeks: <90 mm Hg, N=227	92.1 Percentage of Participants
Olmesartan Medoxomil/Amlodipine Tablets + Hydrochlorothiazide	Percentage of Elderly Patients Achieving Seated Diastolic Blood Pressure Goal From Baseline to 4, 8, 12, 16, 20 Weeks	8 weeks: <85 mm Hg, N=227	83.7 Percentage of Participants
Olmesartan Medoxomil/Amlodipine Tablets + Hydrochlorothiazide	Percentage of Elderly Patients Achieving Seated Diastolic Blood Pressure Goal From Baseline to 4, 8, 12, 16, 20 Weeks	8 weeks: <80 mm Hg, N=227	71.8 Percentage of Participants
Olmesartan Medoxomil/Amlodipine Tablets + Hydrochlorothiazide	Percentage of Elderly Patients Achieving Seated Diastolic Blood Pressure Goal From Baseline to 4, 8, 12, 16, 20 Weeks	12 weeks: <90 mm Hg, N=227	97.4 Percentage of Participants
Olmesartan Medoxomil/Amlodipine Tablets + Hydrochlorothiazide	Percentage of Elderly Patients Achieving Seated Diastolic Blood Pressure Goal From Baseline to 4, 8, 12, 16, 20 Weeks	12 weeks: <85 mm Hg, N=227	92.1 Percentage of Participants
Olmesartan Medoxomil/Amlodipine Tablets + Hydrochlorothiazide	Percentage of Elderly Patients Achieving Seated Diastolic Blood Pressure Goal From Baseline to 4, 8, 12, 16, 20 Weeks	12 weeks: <80 mm Hg, N=227	80.2 Percentage of Participants
Olmesartan Medoxomil/Amlodipine Tablets + Hydrochlorothiazide	Percentage of Elderly Patients Achieving Seated Diastolic Blood Pressure Goal From Baseline to 4, 8, 12, 16, 20 Weeks	16 weeks: <90 mm Hg, N=227	98.7 Percentage of Participants
Olmesartan Medoxomil/Amlodipine Tablets + Hydrochlorothiazide	Percentage of Elderly Patients Achieving Seated Diastolic Blood Pressure Goal From Baseline to 4, 8, 12, 16, 20 Weeks	16 weeks: <85 mm Hg, N=227	94.3 Percentage of Participants
Olmesartan Medoxomil/Amlodipine Tablets + Hydrochlorothiazide	Percentage of Elderly Patients Achieving Seated Diastolic Blood Pressure Goal From Baseline to 4, 8, 12, 16, 20 Weeks	16 weeks: <80 mm Hg, N=227	88.6 Percentage of Participants
Olmesartan Medoxomil/Amlodipine Tablets + Hydrochlorothiazide	Percentage of Elderly Patients Achieving Seated Diastolic Blood Pressure Goal From Baseline to 4, 8, 12, 16, 20 Weeks	20 weeks: <90 mm Hg, N=227	98.7 Percentage of Participants
Olmesartan Medoxomil/Amlodipine Tablets + Hydrochlorothiazide	Percentage of Elderly Patients Achieving Seated Diastolic Blood Pressure Goal From Baseline to 4, 8, 12, 16, 20 Weeks	20 weeks: <85 mm Hg, N=227	95.2 Percentage of Participants
Olmesartan Medoxomil/Amlodipine Tablets + Hydrochlorothiazide	Percentage of Elderly Patients Achieving Seated Diastolic Blood Pressure Goal From Baseline to 4, 8, 12, 16, 20 Weeks	20 weeks: <80 mm Hg, N=227	90.3 Percentage of Participants

Secondary

Percentage of Elderly Patients Achieving Seated Diastolic Blood Pressure Reduction Ranges From Baseline to 4, 8, 12, 16, 20 Weeks

Time frame: Baseline to 4, 8, 12, 16, 20 weeks

Arm	Measure	Group	Value (NUMBER)
Olmesartan Medoxomil/Amlodipine Tablets + Hydrochlorothiazide	Percentage of Elderly Patients Achieving Seated Diastolic Blood Pressure Reduction Ranges From Baseline to 4, 8, 12, 16, 20 Weeks	4 weeks: ≤ 10 mm Hg, N=224	63.8 Percentage of Participants
Olmesartan Medoxomil/Amlodipine Tablets + Hydrochlorothiazide	Percentage of Elderly Patients Achieving Seated Diastolic Blood Pressure Reduction Ranges From Baseline to 4, 8, 12, 16, 20 Weeks	4 weeks: >10 and ≤ 15 mm Hg, N=224	20.5 Percentage of Participants
Olmesartan Medoxomil/Amlodipine Tablets + Hydrochlorothiazide	Percentage of Elderly Patients Achieving Seated Diastolic Blood Pressure Reduction Ranges From Baseline to 4, 8, 12, 16, 20 Weeks	4 weeks: >15 and ≤ 20 mm Hg, N=224	9.4 Percentage of Participants
Olmesartan Medoxomil/Amlodipine Tablets + Hydrochlorothiazide	Percentage of Elderly Patients Achieving Seated Diastolic Blood Pressure Reduction Ranges From Baseline to 4, 8, 12, 16, 20 Weeks	4 weeks: >20 mm Hg, N=224	6.3 Percentage of Participants
Olmesartan Medoxomil/Amlodipine Tablets + Hydrochlorothiazide	Percentage of Elderly Patients Achieving Seated Diastolic Blood Pressure Reduction Ranges From Baseline to 4, 8, 12, 16, 20 Weeks	8 weeks: ≤ 10 mm Hg, N=217	57.1 Percentage of Participants
Olmesartan Medoxomil/Amlodipine Tablets + Hydrochlorothiazide	Percentage of Elderly Patients Achieving Seated Diastolic Blood Pressure Reduction Ranges From Baseline to 4, 8, 12, 16, 20 Weeks	8 weeks: >10 and ≤ 15 mm Hg, N=217	19.8 Percentage of Participants
Olmesartan Medoxomil/Amlodipine Tablets + Hydrochlorothiazide	Percentage of Elderly Patients Achieving Seated Diastolic Blood Pressure Reduction Ranges From Baseline to 4, 8, 12, 16, 20 Weeks	8 weeks: >15 and ≤ 20 mm Hg, N=217	14.3 Percentage of Participants
Olmesartan Medoxomil/Amlodipine Tablets + Hydrochlorothiazide	Percentage of Elderly Patients Achieving Seated Diastolic Blood Pressure Reduction Ranges From Baseline to 4, 8, 12, 16, 20 Weeks	8 weeks: >20 mm Hg, N=217	8.8 Percentage of Participants
Olmesartan Medoxomil/Amlodipine Tablets + Hydrochlorothiazide	Percentage of Elderly Patients Achieving Seated Diastolic Blood Pressure Reduction Ranges From Baseline to 4, 8, 12, 16, 20 Weeks	12 weeks: ≤ 10 mm Hg, N=199	45.2 Percentage of Participants
Olmesartan Medoxomil/Amlodipine Tablets + Hydrochlorothiazide	Percentage of Elderly Patients Achieving Seated Diastolic Blood Pressure Reduction Ranges From Baseline to 4, 8, 12, 16, 20 Weeks	12 weeks: >10 and ≤15 mm Hg, N=199	25.1 Percentage of Participants
Olmesartan Medoxomil/Amlodipine Tablets + Hydrochlorothiazide	Percentage of Elderly Patients Achieving Seated Diastolic Blood Pressure Reduction Ranges From Baseline to 4, 8, 12, 16, 20 Weeks	12 weeks: >15 and ≤ 20 mm Hg, N=199	15.6 Percentage of Participants
Olmesartan Medoxomil/Amlodipine Tablets + Hydrochlorothiazide	Percentage of Elderly Patients Achieving Seated Diastolic Blood Pressure Reduction Ranges From Baseline to 4, 8, 12, 16, 20 Weeks	12 weeks: >20 mm Hg, N=199	14.1 Percentage of Participants
Olmesartan Medoxomil/Amlodipine Tablets + Hydrochlorothiazide	Percentage of Elderly Patients Achieving Seated Diastolic Blood Pressure Reduction Ranges From Baseline to 4, 8, 12, 16, 20 Weeks	16 weeks: ≤ 10 mm Hg, N=179	27.4 Percentage of Participants
Olmesartan Medoxomil/Amlodipine Tablets + Hydrochlorothiazide	Percentage of Elderly Patients Achieving Seated Diastolic Blood Pressure Reduction Ranges From Baseline to 4, 8, 12, 16, 20 Weeks	16 weeks: >10 and ≤ 15 mm Hg, N=179	25.1 Percentage of Participants
Olmesartan Medoxomil/Amlodipine Tablets + Hydrochlorothiazide	Percentage of Elderly Patients Achieving Seated Diastolic Blood Pressure Reduction Ranges From Baseline to 4, 8, 12, 16, 20 Weeks	16 weeks: >15 and ≤ 20 mm Hg, N=179	22.9 Percentage of Participants
Olmesartan Medoxomil/Amlodipine Tablets + Hydrochlorothiazide	Percentage of Elderly Patients Achieving Seated Diastolic Blood Pressure Reduction Ranges From Baseline to 4, 8, 12, 16, 20 Weeks	16 weeks: >20 mm Hg, N=179	24.6 Percentage of Participants
Olmesartan Medoxomil/Amlodipine Tablets + Hydrochlorothiazide	Percentage of Elderly Patients Achieving Seated Diastolic Blood Pressure Reduction Ranges From Baseline to 4, 8, 12, 16, 20 Weeks	20 weeks: ≤ 10 mm Hg, N=166	34.9 Percentage of Participants
Olmesartan Medoxomil/Amlodipine Tablets + Hydrochlorothiazide	Percentage of Elderly Patients Achieving Seated Diastolic Blood Pressure Reduction Ranges From Baseline to 4, 8, 12, 16, 20 Weeks	20 weeks: >10 and ≤ 15 mm Hg, N=166	20.5 Percentage of Participants
Olmesartan Medoxomil/Amlodipine Tablets + Hydrochlorothiazide	Percentage of Elderly Patients Achieving Seated Diastolic Blood Pressure Reduction Ranges From Baseline to 4, 8, 12, 16, 20 Weeks	20 weeks: >15 and ≤ 20 mm Hg, N=166	24.1 Percentage of Participants
Olmesartan Medoxomil/Amlodipine Tablets + Hydrochlorothiazide	Percentage of Elderly Patients Achieving Seated Diastolic Blood Pressure Reduction Ranges From Baseline to 4, 8, 12, 16, 20 Weeks	20 weeks: >20 mm Hg, N=166	20.5 Percentage of Participants

Secondary

Percentage of Elderly Patients Achieving Seated Systolic Blood Pressure Goal From Baseline to 4, 8, 12, 16, 20 Weeks

Time frame: Baseline to 4, 8, 12, 16, 20 weeks

Population: The analysis population consists of those elderly participants who have a baseline and at least 1 post-baseline measurement and who received at least one dose of study medication. However, the number of participants included may vary because of missing data and the number of dropouts. Elderly is defined as greater than or = to 65 years of age.

Arm	Measure	Group	Value (NUMBER)
Olmesartan Medoxomil/Amlodipine Tablets + Hydrochlorothiazide	Percentage of Elderly Patients Achieving Seated Systolic Blood Pressure Goal From Baseline to 4, 8, 12, 16, 20 Weeks	4 weeks: <140 mm Hg, N=227	52.0 Percentage of Participants
Olmesartan Medoxomil/Amlodipine Tablets + Hydrochlorothiazide	Percentage of Elderly Patients Achieving Seated Systolic Blood Pressure Goal From Baseline to 4, 8, 12, 16, 20 Weeks	4 weeks: <135 mm Hg, N=227	37.9 Percentage of Participants
Olmesartan Medoxomil/Amlodipine Tablets + Hydrochlorothiazide	Percentage of Elderly Patients Achieving Seated Systolic Blood Pressure Goal From Baseline to 4, 8, 12, 16, 20 Weeks	4 weeks: <130 mm Hg, N=227	23.4 Percentage of Participants
Olmesartan Medoxomil/Amlodipine Tablets + Hydrochlorothiazide	Percentage of Elderly Patients Achieving Seated Systolic Blood Pressure Goal From Baseline to 4, 8, 12, 16, 20 Weeks	4 weeks: <120 mm Hg, N=227	9.7 Percentage of Participants
Olmesartan Medoxomil/Amlodipine Tablets + Hydrochlorothiazide	Percentage of Elderly Patients Achieving Seated Systolic Blood Pressure Goal From Baseline to 4, 8, 12, 16, 20 Weeks	8 weeks: <140 mm Hg, N=227	67.0 Percentage of Participants
Olmesartan Medoxomil/Amlodipine Tablets + Hydrochlorothiazide	Percentage of Elderly Patients Achieving Seated Systolic Blood Pressure Goal From Baseline to 4, 8, 12, 16, 20 Weeks	8 weeks: <135 mm Hg, N=227	57.7 Percentage of Participants
Olmesartan Medoxomil/Amlodipine Tablets + Hydrochlorothiazide	Percentage of Elderly Patients Achieving Seated Systolic Blood Pressure Goal From Baseline to 4, 8, 12, 16, 20 Weeks	8 weeks: <130 mm Hg, N=227	43.6 Percentage of Participants
Olmesartan Medoxomil/Amlodipine Tablets + Hydrochlorothiazide	Percentage of Elderly Patients Achieving Seated Systolic Blood Pressure Goal From Baseline to 4, 8, 12, 16, 20 Weeks	8 weeks: <120 mm Hg, N=227	18.1 Percentage of Participants
Olmesartan Medoxomil/Amlodipine Tablets + Hydrochlorothiazide	Percentage of Elderly Patients Achieving Seated Systolic Blood Pressure Goal From Baseline to 4, 8, 12, 16, 20 Weeks	12 weeks: <140 mm Hg, N=227	80.6 Percentage of Participants
Olmesartan Medoxomil/Amlodipine Tablets + Hydrochlorothiazide	Percentage of Elderly Patients Achieving Seated Systolic Blood Pressure Goal From Baseline to 4, 8, 12, 16, 20 Weeks	12 weeks: <135 mm Hg, N=227	70.0 Percentage of Participants
Olmesartan Medoxomil/Amlodipine Tablets + Hydrochlorothiazide	Percentage of Elderly Patients Achieving Seated Systolic Blood Pressure Goal From Baseline to 4, 8, 12, 16, 20 Weeks	12 weeks: <130 mm Hg, N=227	56.8 Percentage of Participants
Olmesartan Medoxomil/Amlodipine Tablets + Hydrochlorothiazide	Percentage of Elderly Patients Achieving Seated Systolic Blood Pressure Goal From Baseline to 4, 8, 12, 16, 20 Weeks	12 weeks: <120 mm Hg, N=227	28.6 Percentage of Participants
Olmesartan Medoxomil/Amlodipine Tablets + Hydrochlorothiazide	Percentage of Elderly Patients Achieving Seated Systolic Blood Pressure Goal From Baseline to 4, 8, 12, 16, 20 Weeks	16 weeks: <140 mm Hg, N=227	87.7 Percentage of Participants
Olmesartan Medoxomil/Amlodipine Tablets + Hydrochlorothiazide	Percentage of Elderly Patients Achieving Seated Systolic Blood Pressure Goal From Baseline to 4, 8, 12, 16, 20 Weeks	16 weeks: <135 mm Hg, N=227	79.7 Percentage of Participants
Olmesartan Medoxomil/Amlodipine Tablets + Hydrochlorothiazide	Percentage of Elderly Patients Achieving Seated Systolic Blood Pressure Goal From Baseline to 4, 8, 12, 16, 20 Weeks	16 weeks: <130 mm Hg, N=227	70.9 Percentage of Participants
Olmesartan Medoxomil/Amlodipine Tablets + Hydrochlorothiazide	Percentage of Elderly Patients Achieving Seated Systolic Blood Pressure Goal From Baseline to 4, 8, 12, 16, 20 Weeks	16 weeks: <120 mm Hg, N=227	43.6 Percentage of Participants
Olmesartan Medoxomil/Amlodipine Tablets + Hydrochlorothiazide	Percentage of Elderly Patients Achieving Seated Systolic Blood Pressure Goal From Baseline to 4, 8, 12, 16, 20 Weeks	20 weeks: <140 mm Hg, N=227	91.6 Percentage of Participants
Olmesartan Medoxomil/Amlodipine Tablets + Hydrochlorothiazide	Percentage of Elderly Patients Achieving Seated Systolic Blood Pressure Goal From Baseline to 4, 8, 12, 16, 20 Weeks	20 weeks: <135 mm Hg, N=227	85.9 Percentage of Participants
Olmesartan Medoxomil/Amlodipine Tablets + Hydrochlorothiazide	Percentage of Elderly Patients Achieving Seated Systolic Blood Pressure Goal From Baseline to 4, 8, 12, 16, 20 Weeks	20 weeks: <130 mm Hg, N=227	78.9 Percentage of Participants
Olmesartan Medoxomil/Amlodipine Tablets + Hydrochlorothiazide	Percentage of Elderly Patients Achieving Seated Systolic Blood Pressure Goal From Baseline to 4, 8, 12, 16, 20 Weeks	20 weeks: <120 mm Hg, N=227	50.7 Percentage of Participants

Secondary

Percentage of Elderly Patients Achieving Seated Systolic Blood Pressure Reduction Ranges From Baseline to 4, 8, 12, 16, 20 Weeks

Time frame: Baseline to 4, 8, 12, 16, 20 weeks

Arm	Measure	Group	Value (NUMBER)
Olmesartan Medoxomil/Amlodipine Tablets + Hydrochlorothiazide	Percentage of Elderly Patients Achieving Seated Systolic Blood Pressure Reduction Ranges From Baseline to 4, 8, 12, 16, 20 Weeks	4 weeks: ≤ 15 mm Hg, N=224	47.3 Percentage of Participants
Olmesartan Medoxomil/Amlodipine Tablets + Hydrochlorothiazide	Percentage of Elderly Patients Achieving Seated Systolic Blood Pressure Reduction Ranges From Baseline to 4, 8, 12, 16, 20 Weeks	4 weeks: >15 and ≤ 30 mm Hg, N=224	40.2 Percentage of Participants
Olmesartan Medoxomil/Amlodipine Tablets + Hydrochlorothiazide	Percentage of Elderly Patients Achieving Seated Systolic Blood Pressure Reduction Ranges From Baseline to 4, 8, 12, 16, 20 Weeks	4 weeks: >30 and ≤ 45 mm Hg, N=224	11.2 Percentage of Participants
Olmesartan Medoxomil/Amlodipine Tablets + Hydrochlorothiazide	Percentage of Elderly Patients Achieving Seated Systolic Blood Pressure Reduction Ranges From Baseline to 4, 8, 12, 16, 20 Weeks	4 weeks: >45 mm Hg, N=224	1.3 Percentage of Participants
Olmesartan Medoxomil/Amlodipine Tablets + Hydrochlorothiazide	Percentage of Elderly Patients Achieving Seated Systolic Blood Pressure Reduction Ranges From Baseline to 4, 8, 12, 16, 20 Weeks	8 weeks: ≤ 15 mm Hg, N=217	42.9 Percentage of Participants
Olmesartan Medoxomil/Amlodipine Tablets + Hydrochlorothiazide	Percentage of Elderly Patients Achieving Seated Systolic Blood Pressure Reduction Ranges From Baseline to 4, 8, 12, 16, 20 Weeks	8 weeks: >15 and ≤ 30 mm Hg, N=217	37.8 Percentage of Participants
Olmesartan Medoxomil/Amlodipine Tablets + Hydrochlorothiazide	Percentage of Elderly Patients Achieving Seated Systolic Blood Pressure Reduction Ranges From Baseline to 4, 8, 12, 16, 20 Weeks	8 weeks: >30 and ≤ 45 mm Hg, N=217	16.6 Percentage of Participants
Olmesartan Medoxomil/Amlodipine Tablets + Hydrochlorothiazide	Percentage of Elderly Patients Achieving Seated Systolic Blood Pressure Reduction Ranges From Baseline to 4, 8, 12, 16, 20 Weeks	8 weeks: >45 mm Hg, N=217	2.8 Percentage of Participants
Olmesartan Medoxomil/Amlodipine Tablets + Hydrochlorothiazide	Percentage of Elderly Patients Achieving Seated Systolic Blood Pressure Reduction Ranges From Baseline to 4, 8, 12, 16, 20 Weeks	12 weeks: ≤ 15 mm Hg, N=199	26.6 Percentage of Participants
Olmesartan Medoxomil/Amlodipine Tablets + Hydrochlorothiazide	Percentage of Elderly Patients Achieving Seated Systolic Blood Pressure Reduction Ranges From Baseline to 4, 8, 12, 16, 20 Weeks	12 weeks: >15 and ≤ 30 mm Hg, N=199	46.7 Percentage of Participants
Olmesartan Medoxomil/Amlodipine Tablets + Hydrochlorothiazide	Percentage of Elderly Patients Achieving Seated Systolic Blood Pressure Reduction Ranges From Baseline to 4, 8, 12, 16, 20 Weeks	12 weeks: >30 and ≤ 45 mm Hg, N=199	24.6 Percentage of Participants
Olmesartan Medoxomil/Amlodipine Tablets + Hydrochlorothiazide	Percentage of Elderly Patients Achieving Seated Systolic Blood Pressure Reduction Ranges From Baseline to 4, 8, 12, 16, 20 Weeks	12 weeks: >45 mm Hg, N=199	2.0 Percentage of Participants
Olmesartan Medoxomil/Amlodipine Tablets + Hydrochlorothiazide	Percentage of Elderly Patients Achieving Seated Systolic Blood Pressure Reduction Ranges From Baseline to 4, 8, 12, 16, 20 Weeks	16 weeks: ≤ 15 mm Hg, N=179	17.9 Percentage of Participants
Olmesartan Medoxomil/Amlodipine Tablets + Hydrochlorothiazide	Percentage of Elderly Patients Achieving Seated Systolic Blood Pressure Reduction Ranges From Baseline to 4, 8, 12, 16, 20 Weeks	16 weeks: >15 and ≤ 30 mm Hg, N=179	32.4 Percentage of Participants
Olmesartan Medoxomil/Amlodipine Tablets + Hydrochlorothiazide	Percentage of Elderly Patients Achieving Seated Systolic Blood Pressure Reduction Ranges From Baseline to 4, 8, 12, 16, 20 Weeks	16 weeks: >30 and ≤ 45 mm Hg, N=179	39.7 Percentage of Participants
Olmesartan Medoxomil/Amlodipine Tablets + Hydrochlorothiazide	Percentage of Elderly Patients Achieving Seated Systolic Blood Pressure Reduction Ranges From Baseline to 4, 8, 12, 16, 20 Weeks	16 weeks: >45 mm Hg, N=179	10.1 Percentage of Participants
Olmesartan Medoxomil/Amlodipine Tablets + Hydrochlorothiazide	Percentage of Elderly Patients Achieving Seated Systolic Blood Pressure Reduction Ranges From Baseline to 4, 8, 12, 16, 20 Weeks	20 weeks: ≤ 15 mm Hg, N=166	14.5 Percentage of Participants
Olmesartan Medoxomil/Amlodipine Tablets + Hydrochlorothiazide	Percentage of Elderly Patients Achieving Seated Systolic Blood Pressure Reduction Ranges From Baseline to 4, 8, 12, 16, 20 Weeks	20 weeks: >15 and ≤ 30 mm Hg, N=166	37.4 Percentage of Participants
Olmesartan Medoxomil/Amlodipine Tablets + Hydrochlorothiazide	Percentage of Elderly Patients Achieving Seated Systolic Blood Pressure Reduction Ranges From Baseline to 4, 8, 12, 16, 20 Weeks	20 weeks: >30 and ≤ 45 mm Hg, N=166	38.0 Percentage of Participants
Olmesartan Medoxomil/Amlodipine Tablets + Hydrochlorothiazide	Percentage of Elderly Patients Achieving Seated Systolic Blood Pressure Reduction Ranges From Baseline to 4, 8, 12, 16, 20 Weeks	20 weeks: >45 mm Hg, N=166	10.2 Percentage of Participants

Secondary

Percentage of Hispanic Patients Achieving Seated Diastolic Blood Pressure Goal From Baseline to 4, 8, 12, 16, 20 Weeks

Time frame: Baseline to 4, 8, 12, 16, 20 weeks

Population: The analysis population consists of those Hispanic participants who have a baseline and at least 1 post-baseline measurement and who received at least one dose of study medication. However, the number of participants included will vary because of missing data and the number of dropouts.

Arm	Measure	Group	Value (NUMBER)
Olmesartan Medoxomil/Amlodipine Tablets + Hydrochlorothiazide	Percentage of Hispanic Patients Achieving Seated Diastolic Blood Pressure Goal From Baseline to 4, 8, 12, 16, 20 Weeks	4 weeks: <90 mm Hg, N=98	66.3 Percentage of Participants
Olmesartan Medoxomil/Amlodipine Tablets + Hydrochlorothiazide	Percentage of Hispanic Patients Achieving Seated Diastolic Blood Pressure Goal From Baseline to 4, 8, 12, 16, 20 Weeks	4 weeks: <85 mm Hg, N=98	53.1 Percentage of Participants
Olmesartan Medoxomil/Amlodipine Tablets + Hydrochlorothiazide	Percentage of Hispanic Patients Achieving Seated Diastolic Blood Pressure Goal From Baseline to 4, 8, 12, 16, 20 Weeks	4 weeks: <80 mm Hg, N=98	34.7 Percentage of Participants
Olmesartan Medoxomil/Amlodipine Tablets + Hydrochlorothiazide	Percentage of Hispanic Patients Achieving Seated Diastolic Blood Pressure Goal From Baseline to 4, 8, 12, 16, 20 Weeks	8 weeks: <90 mm Hg, N=100	85.0 Percentage of Participants
Olmesartan Medoxomil/Amlodipine Tablets + Hydrochlorothiazide	Percentage of Hispanic Patients Achieving Seated Diastolic Blood Pressure Goal From Baseline to 4, 8, 12, 16, 20 Weeks	8 weeks: <85 mm Hg, N=100	70.0 Percentage of Participants
Olmesartan Medoxomil/Amlodipine Tablets + Hydrochlorothiazide	Percentage of Hispanic Patients Achieving Seated Diastolic Blood Pressure Goal From Baseline to 4, 8, 12, 16, 20 Weeks	8 weeks: <80 mm Hg, N=100	48.0 Percentage of Participants
Olmesartan Medoxomil/Amlodipine Tablets + Hydrochlorothiazide	Percentage of Hispanic Patients Achieving Seated Diastolic Blood Pressure Goal From Baseline to 4, 8, 12, 16, 20 Weeks	12 weeks: <90 mm Hg, N=100	92.0 Percentage of Participants
Olmesartan Medoxomil/Amlodipine Tablets + Hydrochlorothiazide	Percentage of Hispanic Patients Achieving Seated Diastolic Blood Pressure Goal From Baseline to 4, 8, 12, 16, 20 Weeks	12 weeks: <85 mm Hg, N=100	78.0 Percentage of Participants
Olmesartan Medoxomil/Amlodipine Tablets + Hydrochlorothiazide	Percentage of Hispanic Patients Achieving Seated Diastolic Blood Pressure Goal From Baseline to 4, 8, 12, 16, 20 Weeks	12 weeks: <80 mm Hg, N=100	62.0 Percentage of Participants
Olmesartan Medoxomil/Amlodipine Tablets + Hydrochlorothiazide	Percentage of Hispanic Patients Achieving Seated Diastolic Blood Pressure Goal From Baseline to 4, 8, 12, 16, 20 Weeks	16 weeks: <90 mm Hg, N=100	96.0 Percentage of Participants
Olmesartan Medoxomil/Amlodipine Tablets + Hydrochlorothiazide	Percentage of Hispanic Patients Achieving Seated Diastolic Blood Pressure Goal From Baseline to 4, 8, 12, 16, 20 Weeks	16 weeks: <85 mm Hg, N=100	90.0 Percentage of Participants
Olmesartan Medoxomil/Amlodipine Tablets + Hydrochlorothiazide	Percentage of Hispanic Patients Achieving Seated Diastolic Blood Pressure Goal From Baseline to 4, 8, 12, 16, 20 Weeks	16 weeks: <80 mm Hg, N=100	75.0 Percentage of Participants
Olmesartan Medoxomil/Amlodipine Tablets + Hydrochlorothiazide	Percentage of Hispanic Patients Achieving Seated Diastolic Blood Pressure Goal From Baseline to 4, 8, 12, 16, 20 Weeks	20 weeks: <90 mm Hg, N=100	96.0 Percentage of Participants
Olmesartan Medoxomil/Amlodipine Tablets + Hydrochlorothiazide	Percentage of Hispanic Patients Achieving Seated Diastolic Blood Pressure Goal From Baseline to 4, 8, 12, 16, 20 Weeks	20 weeks: <85 mm Hg, N=100	90.0 Percentage of Participants
Olmesartan Medoxomil/Amlodipine Tablets + Hydrochlorothiazide	Percentage of Hispanic Patients Achieving Seated Diastolic Blood Pressure Goal From Baseline to 4, 8, 12, 16, 20 Weeks	20 weeks: <80 mm Hg, N=100	75.0 Percentage of Participants

Secondary

Percentage of Hispanic Patients Achieving Seated Diastolic Blood Pressure Reduction Ranges From Baseline to 4, 8, 12, 16, 20 Weeks

Time frame: Baseline to 4, 8, 12, 16, 20 weeks

Arm	Measure	Group	Value (NUMBER)
Olmesartan Medoxomil/Amlodipine Tablets + Hydrochlorothiazide	Percentage of Hispanic Patients Achieving Seated Diastolic Blood Pressure Reduction Ranges From Baseline to 4, 8, 12, 16, 20 Weeks	4 weeks: ≤ 10 mm Hg, N=98	65.3 Percentage of Participants
Olmesartan Medoxomil/Amlodipine Tablets + Hydrochlorothiazide	Percentage of Hispanic Patients Achieving Seated Diastolic Blood Pressure Reduction Ranges From Baseline to 4, 8, 12, 16, 20 Weeks	4 weeks: >10 and ≤ 15 mm Hg, N=98	16.3 Percentage of Participants
Olmesartan Medoxomil/Amlodipine Tablets + Hydrochlorothiazide	Percentage of Hispanic Patients Achieving Seated Diastolic Blood Pressure Reduction Ranges From Baseline to 4, 8, 12, 16, 20 Weeks	4 weeks: >15 and ≤ 20 mm Hg, N=98	8.2 Percentage of Participants
Olmesartan Medoxomil/Amlodipine Tablets + Hydrochlorothiazide	Percentage of Hispanic Patients Achieving Seated Diastolic Blood Pressure Reduction Ranges From Baseline to 4, 8, 12, 16, 20 Weeks	4 weeks: >20 mm Hg, N=98	10.2 Percentage of Participants
Olmesartan Medoxomil/Amlodipine Tablets + Hydrochlorothiazide	Percentage of Hispanic Patients Achieving Seated Diastolic Blood Pressure Reduction Ranges From Baseline to 4, 8, 12, 16, 20 Weeks	8 weeks: ≤ 10 mm Hg, N=91	52.8 Percentage of Participants
Olmesartan Medoxomil/Amlodipine Tablets + Hydrochlorothiazide	Percentage of Hispanic Patients Achieving Seated Diastolic Blood Pressure Reduction Ranges From Baseline to 4, 8, 12, 16, 20 Weeks	8 weeks: >10 and ≤ 15 mm Hg, N=91	18.7 Percentage of Participants
Olmesartan Medoxomil/Amlodipine Tablets + Hydrochlorothiazide	Percentage of Hispanic Patients Achieving Seated Diastolic Blood Pressure Reduction Ranges From Baseline to 4, 8, 12, 16, 20 Weeks	8 weeks: >15 and ≤ 20 mm Hg, N=91	14.3 Percentage of Participants
Olmesartan Medoxomil/Amlodipine Tablets + Hydrochlorothiazide	Percentage of Hispanic Patients Achieving Seated Diastolic Blood Pressure Reduction Ranges From Baseline to 4, 8, 12, 16, 20 Weeks	8 weeks: >20 mm Hg, N=91	14.3 Percentage of Participants
Olmesartan Medoxomil/Amlodipine Tablets + Hydrochlorothiazide	Percentage of Hispanic Patients Achieving Seated Diastolic Blood Pressure Reduction Ranges From Baseline to 4, 8, 12, 16, 20 Weeks	12 weeks: ≤ 10 mm Hg, N=83	41.0 Percentage of Participants
Olmesartan Medoxomil/Amlodipine Tablets + Hydrochlorothiazide	Percentage of Hispanic Patients Achieving Seated Diastolic Blood Pressure Reduction Ranges From Baseline to 4, 8, 12, 16, 20 Weeks	12 weeks: >10 and ≤15 mm Hg, N=83	20.5 Percentage of Participants
Olmesartan Medoxomil/Amlodipine Tablets + Hydrochlorothiazide	Percentage of Hispanic Patients Achieving Seated Diastolic Blood Pressure Reduction Ranges From Baseline to 4, 8, 12, 16, 20 Weeks	12 weeks: >15 and ≤ 20 mm Hg, N=83	14.5 Percentage of Participants
Olmesartan Medoxomil/Amlodipine Tablets + Hydrochlorothiazide	Percentage of Hispanic Patients Achieving Seated Diastolic Blood Pressure Reduction Ranges From Baseline to 4, 8, 12, 16, 20 Weeks	12 weeks: >20 mm Hg, N=83	24.1 Percentage of Participants
Olmesartan Medoxomil/Amlodipine Tablets + Hydrochlorothiazide	Percentage of Hispanic Patients Achieving Seated Diastolic Blood Pressure Reduction Ranges From Baseline to 4, 8, 12, 16, 20 Weeks	16 weeks: ≤ 10 mm Hg, N=75	30.7 Percentage of Participants
Olmesartan Medoxomil/Amlodipine Tablets + Hydrochlorothiazide	Percentage of Hispanic Patients Achieving Seated Diastolic Blood Pressure Reduction Ranges From Baseline to 4, 8, 12, 16, 20 Weeks	16 weeks: >10 and ≤ 15 mm Hg, N=75	25.3 Percentage of Participants
Olmesartan Medoxomil/Amlodipine Tablets + Hydrochlorothiazide	Percentage of Hispanic Patients Achieving Seated Diastolic Blood Pressure Reduction Ranges From Baseline to 4, 8, 12, 16, 20 Weeks	16 weeks: >15 and ≤ 20 mm Hg, N=75	16.0 Percentage of Participants
Olmesartan Medoxomil/Amlodipine Tablets + Hydrochlorothiazide	Percentage of Hispanic Patients Achieving Seated Diastolic Blood Pressure Reduction Ranges From Baseline to 4, 8, 12, 16, 20 Weeks	16 weeks: >20 mm Hg, N=75	28.0 Percentage of Participants
Olmesartan Medoxomil/Amlodipine Tablets + Hydrochlorothiazide	Percentage of Hispanic Patients Achieving Seated Diastolic Blood Pressure Reduction Ranges From Baseline to 4, 8, 12, 16, 20 Weeks	20 weeks: ≤ 10 mm Hg, N=71	31.0 Percentage of Participants
Olmesartan Medoxomil/Amlodipine Tablets + Hydrochlorothiazide	Percentage of Hispanic Patients Achieving Seated Diastolic Blood Pressure Reduction Ranges From Baseline to 4, 8, 12, 16, 20 Weeks	20 weeks: >10 and ≤ 15 mm Hg, N=71	12.7 Percentage of Participants
Olmesartan Medoxomil/Amlodipine Tablets + Hydrochlorothiazide	Percentage of Hispanic Patients Achieving Seated Diastolic Blood Pressure Reduction Ranges From Baseline to 4, 8, 12, 16, 20 Weeks	20 weeks: >15 and ≤ 20 mm Hg, N=71	26.8 Percentage of Participants
Olmesartan Medoxomil/Amlodipine Tablets + Hydrochlorothiazide	Percentage of Hispanic Patients Achieving Seated Diastolic Blood Pressure Reduction Ranges From Baseline to 4, 8, 12, 16, 20 Weeks	20 weeks: >20 mm Hg, N=71	29.6 Percentage of Participants

Secondary

Percentage of Hispanic Patients Achieving Seated Systolic Blood Pressure Goal From Baseline to 4, 8, 12, 16, 20 Weeks

Time frame: Baseline to 4, 8, 12, 16, 20 weeks

Population: The analysis population consists of those Hispanic participants who have a baseline and at least 1 post-baseline measurement and who received at least one dose of study medication. However, the number of participants included may vary because of missing data and the number of dropouts.

Arm	Measure	Group	Value (NUMBER)
Olmesartan Medoxomil/Amlodipine Tablets + Hydrochlorothiazide	Percentage of Hispanic Patients Achieving Seated Systolic Blood Pressure Goal From Baseline to 4, 8, 12, 16, 20 Weeks	4 weeks: <140 mm Hg, N=98	55.1 Percentage of Participants
Olmesartan Medoxomil/Amlodipine Tablets + Hydrochlorothiazide	Percentage of Hispanic Patients Achieving Seated Systolic Blood Pressure Goal From Baseline to 4, 8, 12, 16, 20 Weeks	4 weeks: <135 mm Hg, N=98	39.8 Percentage of Participants
Olmesartan Medoxomil/Amlodipine Tablets + Hydrochlorothiazide	Percentage of Hispanic Patients Achieving Seated Systolic Blood Pressure Goal From Baseline to 4, 8, 12, 16, 20 Weeks	4 weeks: <130 mm Hg, N=98	31.6 Percentage of Participants
Olmesartan Medoxomil/Amlodipine Tablets + Hydrochlorothiazide	Percentage of Hispanic Patients Achieving Seated Systolic Blood Pressure Goal From Baseline to 4, 8, 12, 16, 20 Weeks	4 weeks: <120 mm Hg, N=98	10.2 Percentage of Participants
Olmesartan Medoxomil/Amlodipine Tablets + Hydrochlorothiazide	Percentage of Hispanic Patients Achieving Seated Systolic Blood Pressure Goal From Baseline to 4, 8, 12, 16, 20 Weeks	8 weeks: <140 mm Hg, N=100	64.0 Percentage of Participants
Olmesartan Medoxomil/Amlodipine Tablets + Hydrochlorothiazide	Percentage of Hispanic Patients Achieving Seated Systolic Blood Pressure Goal From Baseline to 4, 8, 12, 16, 20 Weeks	8 weeks: <135 mm Hg, N=100	51.0 Percentage of Participants
Olmesartan Medoxomil/Amlodipine Tablets + Hydrochlorothiazide	Percentage of Hispanic Patients Achieving Seated Systolic Blood Pressure Goal From Baseline to 4, 8, 12, 16, 20 Weeks	8 weeks: <130 mm Hg, N=100	41.0 Percentage of Participants
Olmesartan Medoxomil/Amlodipine Tablets + Hydrochlorothiazide	Percentage of Hispanic Patients Achieving Seated Systolic Blood Pressure Goal From Baseline to 4, 8, 12, 16, 20 Weeks	8 weeks: <120 mm Hg, N=100	15.0 Percentage of Participants
Olmesartan Medoxomil/Amlodipine Tablets + Hydrochlorothiazide	Percentage of Hispanic Patients Achieving Seated Systolic Blood Pressure Goal From Baseline to 4, 8, 12, 16, 20 Weeks	12 weeks: <140 mm Hg, N=100	77.0 Percentage of Participants
Olmesartan Medoxomil/Amlodipine Tablets + Hydrochlorothiazide	Percentage of Hispanic Patients Achieving Seated Systolic Blood Pressure Goal From Baseline to 4, 8, 12, 16, 20 Weeks	12 weeks: <135 mm Hg, N=100	67.0 Percentage of Participants
Olmesartan Medoxomil/Amlodipine Tablets + Hydrochlorothiazide	Percentage of Hispanic Patients Achieving Seated Systolic Blood Pressure Goal From Baseline to 4, 8, 12, 16, 20 Weeks	12 weeks: <130 mm Hg, N=100	54.0 Percentage of Participants
Olmesartan Medoxomil/Amlodipine Tablets + Hydrochlorothiazide	Percentage of Hispanic Patients Achieving Seated Systolic Blood Pressure Goal From Baseline to 4, 8, 12, 16, 20 Weeks	12 weeks: <120 mm Hg, N=100	30.0 Percentage of Participants
Olmesartan Medoxomil/Amlodipine Tablets + Hydrochlorothiazide	Percentage of Hispanic Patients Achieving Seated Systolic Blood Pressure Goal From Baseline to 4, 8, 12, 16, 20 Weeks	16 weeks: <140 mm Hg, N=100	84.0 Percentage of Participants
Olmesartan Medoxomil/Amlodipine Tablets + Hydrochlorothiazide	Percentage of Hispanic Patients Achieving Seated Systolic Blood Pressure Goal From Baseline to 4, 8, 12, 16, 20 Weeks	16 weeks: <135 mm Hg, N=100	77.0 Percentage of Participants
Olmesartan Medoxomil/Amlodipine Tablets + Hydrochlorothiazide	Percentage of Hispanic Patients Achieving Seated Systolic Blood Pressure Goal From Baseline to 4, 8, 12, 16, 20 Weeks	16 weeks: <130 mm Hg, N=100	66.0 Percentage of Participants
Olmesartan Medoxomil/Amlodipine Tablets + Hydrochlorothiazide	Percentage of Hispanic Patients Achieving Seated Systolic Blood Pressure Goal From Baseline to 4, 8, 12, 16, 20 Weeks	16 weeks: <120 mm Hg, N=100	37.0 Percentage of Participants
Olmesartan Medoxomil/Amlodipine Tablets + Hydrochlorothiazide	Percentage of Hispanic Patients Achieving Seated Systolic Blood Pressure Goal From Baseline to 4, 8, 12, 16, 20 Weeks	20 weeks: <140 mm Hg, N=100	88.0 Percentage of Participants
Olmesartan Medoxomil/Amlodipine Tablets + Hydrochlorothiazide	Percentage of Hispanic Patients Achieving Seated Systolic Blood Pressure Goal From Baseline to 4, 8, 12, 16, 20 Weeks	20 weeks: <135 mm Hg, N=100	83.0 Percentage of Participants
Olmesartan Medoxomil/Amlodipine Tablets + Hydrochlorothiazide	Percentage of Hispanic Patients Achieving Seated Systolic Blood Pressure Goal From Baseline to 4, 8, 12, 16, 20 Weeks	20 weeks: <130 mm Hg, N=100	72.0 Percentage of Participants
Olmesartan Medoxomil/Amlodipine Tablets + Hydrochlorothiazide	Percentage of Hispanic Patients Achieving Seated Systolic Blood Pressure Goal From Baseline to 4, 8, 12, 16, 20 Weeks	20 weeks: <120 mm Hg, N=100	41.0 Percentage of Participants

Secondary

Percentage of Hispanic Patients Achieving Seated Systolic Blood Pressure Reduction Ranges From Baseline to 4, 8, 12, 16, 20 Weeks

Time frame: Baseline to 4, 8, 12, 16, 20 weeks

Arm	Measure	Group	Value (NUMBER)
Olmesartan Medoxomil/Amlodipine Tablets + Hydrochlorothiazide	Percentage of Hispanic Patients Achieving Seated Systolic Blood Pressure Reduction Ranges From Baseline to 4, 8, 12, 16, 20 Weeks	4 weeks: ≤ 15 mm Hg, N=98	50.0 Percentage of Participants
Olmesartan Medoxomil/Amlodipine Tablets + Hydrochlorothiazide	Percentage of Hispanic Patients Achieving Seated Systolic Blood Pressure Reduction Ranges From Baseline to 4, 8, 12, 16, 20 Weeks	4 weeks: >15 and ≤ 30 mm Hg, N=98	37.8 Percentage of Participants
Olmesartan Medoxomil/Amlodipine Tablets + Hydrochlorothiazide	Percentage of Hispanic Patients Achieving Seated Systolic Blood Pressure Reduction Ranges From Baseline to 4, 8, 12, 16, 20 Weeks	4 weeks: >30 and ≤ 45 mm Hg, N=98	7.1 Percentage of Participants
Olmesartan Medoxomil/Amlodipine Tablets + Hydrochlorothiazide	Percentage of Hispanic Patients Achieving Seated Systolic Blood Pressure Reduction Ranges From Baseline to 4, 8, 12, 16, 20 Weeks	4 weeks: >45 mm Hg, N=98	5.1 Percentage of Participants
Olmesartan Medoxomil/Amlodipine Tablets + Hydrochlorothiazide	Percentage of Hispanic Patients Achieving Seated Systolic Blood Pressure Reduction Ranges From Baseline to 4, 8, 12, 16, 20 Weeks	8 weeks: ≤ 15 mm Hg, N=91	42.9 Percentage of Participants
Olmesartan Medoxomil/Amlodipine Tablets + Hydrochlorothiazide	Percentage of Hispanic Patients Achieving Seated Systolic Blood Pressure Reduction Ranges From Baseline to 4, 8, 12, 16, 20 Weeks	8 weeks: >15 and ≤ 30 mm Hg, N=91	44.0 Percentage of Participants
Olmesartan Medoxomil/Amlodipine Tablets + Hydrochlorothiazide	Percentage of Hispanic Patients Achieving Seated Systolic Blood Pressure Reduction Ranges From Baseline to 4, 8, 12, 16, 20 Weeks	8 weeks: >30 and ≤ 45 mm Hg, N=91	9.9 Percentage of Participants
Olmesartan Medoxomil/Amlodipine Tablets + Hydrochlorothiazide	Percentage of Hispanic Patients Achieving Seated Systolic Blood Pressure Reduction Ranges From Baseline to 4, 8, 12, 16, 20 Weeks	8 weeks: >45 mm Hg, N=91	3.3 Percentage of Participants
Olmesartan Medoxomil/Amlodipine Tablets + Hydrochlorothiazide	Percentage of Hispanic Patients Achieving Seated Systolic Blood Pressure Reduction Ranges From Baseline to 4, 8, 12, 16, 20 Weeks	12 weeks: ≤ 15 mm Hg, N=83	31.3 Percentage of Participants
Olmesartan Medoxomil/Amlodipine Tablets + Hydrochlorothiazide	Percentage of Hispanic Patients Achieving Seated Systolic Blood Pressure Reduction Ranges From Baseline to 4, 8, 12, 16, 20 Weeks	12 weeks: >15 and ≤ 30 mm Hg, N=83	36.1 Percentage of Participants
Olmesartan Medoxomil/Amlodipine Tablets + Hydrochlorothiazide	Percentage of Hispanic Patients Achieving Seated Systolic Blood Pressure Reduction Ranges From Baseline to 4, 8, 12, 16, 20 Weeks	12 weeks: >30 and ≤ 45 mm Hg, N=83	25.3 Percentage of Participants
Olmesartan Medoxomil/Amlodipine Tablets + Hydrochlorothiazide	Percentage of Hispanic Patients Achieving Seated Systolic Blood Pressure Reduction Ranges From Baseline to 4, 8, 12, 16, 20 Weeks	12 weeks: >45 mm Hg, N=83	7.2 Percentage of Participants
Olmesartan Medoxomil/Amlodipine Tablets + Hydrochlorothiazide	Percentage of Hispanic Patients Achieving Seated Systolic Blood Pressure Reduction Ranges From Baseline to 4, 8, 12, 16, 20 Weeks	16 weeks: ≤ 15 mm Hg, N=75	22.7 Percentage of Participants
Olmesartan Medoxomil/Amlodipine Tablets + Hydrochlorothiazide	Percentage of Hispanic Patients Achieving Seated Systolic Blood Pressure Reduction Ranges From Baseline to 4, 8, 12, 16, 20 Weeks	16 weeks: >15 and ≤ 30 mm Hg, N=75	36.0 Percentage of Participants
Olmesartan Medoxomil/Amlodipine Tablets + Hydrochlorothiazide	Percentage of Hispanic Patients Achieving Seated Systolic Blood Pressure Reduction Ranges From Baseline to 4, 8, 12, 16, 20 Weeks	16 weeks: >30 and ≤ 45 mm Hg, N=75	34.7 Percentage of Participants
Olmesartan Medoxomil/Amlodipine Tablets + Hydrochlorothiazide	Percentage of Hispanic Patients Achieving Seated Systolic Blood Pressure Reduction Ranges From Baseline to 4, 8, 12, 16, 20 Weeks	16 weeks: >45 mm Hg, N=75	6.7 Percentage of Participants
Olmesartan Medoxomil/Amlodipine Tablets + Hydrochlorothiazide	Percentage of Hispanic Patients Achieving Seated Systolic Blood Pressure Reduction Ranges From Baseline to 4, 8, 12, 16, 20 Weeks	20 weeks: ≤ 15 mm Hg, N=71	23.9 Percentage of Participants
Olmesartan Medoxomil/Amlodipine Tablets + Hydrochlorothiazide	Percentage of Hispanic Patients Achieving Seated Systolic Blood Pressure Reduction Ranges From Baseline to 4, 8, 12, 16, 20 Weeks	20 weeks: >15 and ≤ 30 mm Hg, N=71	33.8 Percentage of Participants
Olmesartan Medoxomil/Amlodipine Tablets + Hydrochlorothiazide	Percentage of Hispanic Patients Achieving Seated Systolic Blood Pressure Reduction Ranges From Baseline to 4, 8, 12, 16, 20 Weeks	20 weeks: >30 and ≤ 45 mm Hg, N=71	33.8 Percentage of Participants
Olmesartan Medoxomil/Amlodipine Tablets + Hydrochlorothiazide	Percentage of Hispanic Patients Achieving Seated Systolic Blood Pressure Reduction Ranges From Baseline to 4, 8, 12, 16, 20 Weeks	20 weeks: >45 mm Hg, N=71	8.5 Percentage of Participants

Secondary

Percentage of Obese Patients Achieving Seated Diastolic Blood Pressure Goal From Baseline to 4, 8, 12, 16, 20 Weeks

Time frame: Baseline to 4, 8, 12, 16, 20 weeks

Population: The analysis population consists of those obese participants who have a baseline and at least 1 post-baseline measurement and who received at least one dose of study medication. However, the number of participants included may vary because of missing data and the number of dropouts. Obesity is defined as Body Mass Index ≥30 kg/m2

Arm	Measure	Group	Value (NUMBER)
Olmesartan Medoxomil/Amlodipine Tablets + Hydrochlorothiazide	Percentage of Obese Patients Achieving Seated Diastolic Blood Pressure Goal From Baseline to 4, 8, 12, 16, 20 Weeks	4 weeks: <90 mm Hg, N=497	63.2 Percentage of Participants
Olmesartan Medoxomil/Amlodipine Tablets + Hydrochlorothiazide	Percentage of Obese Patients Achieving Seated Diastolic Blood Pressure Goal From Baseline to 4, 8, 12, 16, 20 Weeks	4 weeks: <85 mm Hg, N=497	46.3 Percentage of Participants
Olmesartan Medoxomil/Amlodipine Tablets + Hydrochlorothiazide	Percentage of Obese Patients Achieving Seated Diastolic Blood Pressure Goal From Baseline to 4, 8, 12, 16, 20 Weeks	4 weeks: <80 mm Hg, N=497	26.0 Percentage of Participants
Olmesartan Medoxomil/Amlodipine Tablets + Hydrochlorothiazide	Percentage of Obese Patients Achieving Seated Diastolic Blood Pressure Goal From Baseline to 4, 8, 12, 16, 20 Weeks	8 weeks: <90 mm Hg, N=497	77.2 Percentage of Participants
Olmesartan Medoxomil/Amlodipine Tablets + Hydrochlorothiazide	Percentage of Obese Patients Achieving Seated Diastolic Blood Pressure Goal From Baseline to 4, 8, 12, 16, 20 Weeks	8 weeks: <85 mm Hg, N=500	59.4 Percentage of Participants
Olmesartan Medoxomil/Amlodipine Tablets + Hydrochlorothiazide	Percentage of Obese Patients Achieving Seated Diastolic Blood Pressure Goal From Baseline to 4, 8, 12, 16, 20 Weeks	8 weeks: <80 mm Hg, N=500	38.8 Percentage of Participants
Olmesartan Medoxomil/Amlodipine Tablets + Hydrochlorothiazide	Percentage of Obese Patients Achieving Seated Diastolic Blood Pressure Goal From Baseline to 4, 8, 12, 16, 20 Weeks	12 weeks: <90 mm Hg, N=500	86.6 Percentage of Participants
Olmesartan Medoxomil/Amlodipine Tablets + Hydrochlorothiazide	Percentage of Obese Patients Achieving Seated Diastolic Blood Pressure Goal From Baseline to 4, 8, 12, 16, 20 Weeks	12 weeks: <85 mm Hg, N=500	69.8 Percentage of Participants
Olmesartan Medoxomil/Amlodipine Tablets + Hydrochlorothiazide	Percentage of Obese Patients Achieving Seated Diastolic Blood Pressure Goal From Baseline to 4, 8, 12, 16, 20 Weeks	12 weeks: <80 mm Hg, N=500	48.4 Percentage of Participants
Olmesartan Medoxomil/Amlodipine Tablets + Hydrochlorothiazide	Percentage of Obese Patients Achieving Seated Diastolic Blood Pressure Goal From Baseline to 4, 8, 12, 16, 20 Weeks	16 weeks: <90 mm Hg, N=500	93.2 Percentage of Participants
Olmesartan Medoxomil/Amlodipine Tablets + Hydrochlorothiazide	Percentage of Obese Patients Achieving Seated Diastolic Blood Pressure Goal From Baseline to 4, 8, 12, 16, 20 Weeks	16 weeks: <85 mm Hg, N=500	80.4 Percentage of Participants
Olmesartan Medoxomil/Amlodipine Tablets + Hydrochlorothiazide	Percentage of Obese Patients Achieving Seated Diastolic Blood Pressure Goal From Baseline to 4, 8, 12, 16, 20 Weeks	16 weeks: <80 mm Hg, N=500	60.4 Percentage of Participants
Olmesartan Medoxomil/Amlodipine Tablets + Hydrochlorothiazide	Percentage of Obese Patients Achieving Seated Diastolic Blood Pressure Goal From Baseline to 4, 8, 12, 16, 20 Weeks	20 weeks: <90 mm Hg, N=500	94.6 Percentage of Participants
Olmesartan Medoxomil/Amlodipine Tablets + Hydrochlorothiazide	Percentage of Obese Patients Achieving Seated Diastolic Blood Pressure Goal From Baseline to 4, 8, 12, 16, 20 Weeks	20 weeks: <85 mm Hg, N=500	83.8 Percentage of Participants
Olmesartan Medoxomil/Amlodipine Tablets + Hydrochlorothiazide	Percentage of Obese Patients Achieving Seated Diastolic Blood Pressure Goal From Baseline to 4, 8, 12, 16, 20 Weeks	20 weeks: <80 mm Hg, N=500	67.6 Percentage of Participants

Secondary

Percentage of Obese Patients Achieving Seated Diastolic Blood Pressure Reduction Ranges From Baseline to 4, 8, 12, 16, 20 Weeks

Time frame: Baseline to 4, 8, 12, 16, 20 weeks

Population: The analysis population consists of those obese participants who have a baseline and at least 1 post-baseline measurement and who received at least one dose of study medication. However, the number of participants included will vary because of missing data and the number of dropouts. Obesity is defined as Body Mass Index ≥30 kg/m2

Arm	Measure	Group	Value (NUMBER)
Olmesartan Medoxomil/Amlodipine Tablets + Hydrochlorothiazide	Percentage of Obese Patients Achieving Seated Diastolic Blood Pressure Reduction Ranges From Baseline to 4, 8, 12, 16, 20 Weeks	4 weeks: ≤ 10 mm Hg, N=495	67.5 Percentage of Participants
Olmesartan Medoxomil/Amlodipine Tablets + Hydrochlorothiazide	Percentage of Obese Patients Achieving Seated Diastolic Blood Pressure Reduction Ranges From Baseline to 4, 8, 12, 16, 20 Weeks	4 weeks: >10 and ≤ 15 mm Hg, N=495	17.8 Percentage of Participants
Olmesartan Medoxomil/Amlodipine Tablets + Hydrochlorothiazide	Percentage of Obese Patients Achieving Seated Diastolic Blood Pressure Reduction Ranges From Baseline to 4, 8, 12, 16, 20 Weeks	4 weeks: >15 and ≤ 20 mm Hg, N=495	8.5 Percentage of Participants
Olmesartan Medoxomil/Amlodipine Tablets + Hydrochlorothiazide	Percentage of Obese Patients Achieving Seated Diastolic Blood Pressure Reduction Ranges From Baseline to 4, 8, 12, 16, 20 Weeks	4 weeks: >20 mm Hg, N=495	6.3 Percentage of Participants
Olmesartan Medoxomil/Amlodipine Tablets + Hydrochlorothiazide	Percentage of Obese Patients Achieving Seated Diastolic Blood Pressure Reduction Ranges From Baseline to 4, 8, 12, 16, 20 Weeks	8 weeks: ≤ 10 mm Hg, N=468	59.4 Percentage of Participants
Olmesartan Medoxomil/Amlodipine Tablets + Hydrochlorothiazide	Percentage of Obese Patients Achieving Seated Diastolic Blood Pressure Reduction Ranges From Baseline to 4, 8, 12, 16, 20 Weeks	8 weeks: >10 and ≤ 15 mm Hg, N=468	19.9 Percentage of Participants
Olmesartan Medoxomil/Amlodipine Tablets + Hydrochlorothiazide	Percentage of Obese Patients Achieving Seated Diastolic Blood Pressure Reduction Ranges From Baseline to 4, 8, 12, 16, 20 Weeks	8 weeks: >15 and ≤ 20 mm Hg, N=468	13.0 Percentage of Participants
Olmesartan Medoxomil/Amlodipine Tablets + Hydrochlorothiazide	Percentage of Obese Patients Achieving Seated Diastolic Blood Pressure Reduction Ranges From Baseline to 4, 8, 12, 16, 20 Weeks	8 weeks: >20 mm Hg, N=468	7.7 Percentage of Participants
Olmesartan Medoxomil/Amlodipine Tablets + Hydrochlorothiazide	Percentage of Obese Patients Achieving Seated Diastolic Blood Pressure Reduction Ranges From Baseline to 4, 8, 12, 16, 20 Weeks	12 weeks: ≤ 10 mm Hg, N=436	48.9 Percentage of Participants
Olmesartan Medoxomil/Amlodipine Tablets + Hydrochlorothiazide	Percentage of Obese Patients Achieving Seated Diastolic Blood Pressure Reduction Ranges From Baseline to 4, 8, 12, 16, 20 Weeks	12 weeks: >10 and ≤15 mm Hg, N=436	22.5 Percentage of Participants
Olmesartan Medoxomil/Amlodipine Tablets + Hydrochlorothiazide	Percentage of Obese Patients Achieving Seated Diastolic Blood Pressure Reduction Ranges From Baseline to 4, 8, 12, 16, 20 Weeks	12 weeks: >15 and ≤ 20 mm Hg, N=436	16.1 Percentage of Participants
Olmesartan Medoxomil/Amlodipine Tablets + Hydrochlorothiazide	Percentage of Obese Patients Achieving Seated Diastolic Blood Pressure Reduction Ranges From Baseline to 4, 8, 12, 16, 20 Weeks	12 weeks: >20 mm Hg, N=436	12.6 Percentage of Participants
Olmesartan Medoxomil/Amlodipine Tablets + Hydrochlorothiazide	Percentage of Obese Patients Achieving Seated Diastolic Blood Pressure Reduction Ranges From Baseline to 4, 8, 12, 16, 20 Weeks	16 weeks: ≤ 10 mm Hg, N=400	33.3 Percentage of Participants
Olmesartan Medoxomil/Amlodipine Tablets + Hydrochlorothiazide	Percentage of Obese Patients Achieving Seated Diastolic Blood Pressure Reduction Ranges From Baseline to 4, 8, 12, 16, 20 Weeks	16 weeks: >10 and ≤ 15 mm Hg, N=400	23.0 Percentage of Participants
Olmesartan Medoxomil/Amlodipine Tablets + Hydrochlorothiazide	Percentage of Obese Patients Achieving Seated Diastolic Blood Pressure Reduction Ranges From Baseline to 4, 8, 12, 16, 20 Weeks	16 weeks: >15 and ≤ 20 mm Hg, N=400	19.0 Percentage of Participants
Olmesartan Medoxomil/Amlodipine Tablets + Hydrochlorothiazide	Percentage of Obese Patients Achieving Seated Diastolic Blood Pressure Reduction Ranges From Baseline to 4, 8, 12, 16, 20 Weeks	16 weeks: >20 mm Hg, N=400	24.8 Percentage of Participants
Olmesartan Medoxomil/Amlodipine Tablets + Hydrochlorothiazide	Percentage of Obese Patients Achieving Seated Diastolic Blood Pressure Reduction Ranges From Baseline to 4, 8, 12, 16, 20 Weeks	20 weeks: ≤ 10 mm Hg, N=379	31.9 Percentage of Participants
Olmesartan Medoxomil/Amlodipine Tablets + Hydrochlorothiazide	Percentage of Obese Patients Achieving Seated Diastolic Blood Pressure Reduction Ranges From Baseline to 4, 8, 12, 16, 20 Weeks	20 weeks: >10 and ≤ 15 mm Hg, N=379	18.7 Percentage of Participants
Olmesartan Medoxomil/Amlodipine Tablets + Hydrochlorothiazide	Percentage of Obese Patients Achieving Seated Diastolic Blood Pressure Reduction Ranges From Baseline to 4, 8, 12, 16, 20 Weeks	20 weeks: >15 and ≤ 20 mm Hg, N=379	22.4 Percentage of Participants
Olmesartan Medoxomil/Amlodipine Tablets + Hydrochlorothiazide	Percentage of Obese Patients Achieving Seated Diastolic Blood Pressure Reduction Ranges From Baseline to 4, 8, 12, 16, 20 Weeks	20 weeks: >20 mm Hg, N=379	26.9 Percentage of Participants

Secondary

Percentage of Obese Patients Achieving Seated Systolic Blood Pressure Goal From Baseline to 4, 8, 12, 16, 20 Weeks

Time frame: Baseline to 4, 8, 12, 16, 20 weeks

Arm	Measure	Group	Value (NUMBER)
Olmesartan Medoxomil/Amlodipine Tablets + Hydrochlorothiazide	Percentage of Obese Patients Achieving Seated Systolic Blood Pressure Goal From Baseline to 4, 8, 12, 16, 20 Weeks	4 weeks: <140 mm Hg, N=497	51.3 Percentage of Participants
Olmesartan Medoxomil/Amlodipine Tablets + Hydrochlorothiazide	Percentage of Obese Patients Achieving Seated Systolic Blood Pressure Goal From Baseline to 4, 8, 12, 16, 20 Weeks	4 weeks: <135 mm Hg, N=497	37.2 Percentage of Participants
Olmesartan Medoxomil/Amlodipine Tablets + Hydrochlorothiazide	Percentage of Obese Patients Achieving Seated Systolic Blood Pressure Goal From Baseline to 4, 8, 12, 16, 20 Weeks	4 weeks: <130 mm Hg, N=497	23.3 Percentage of Participants
Olmesartan Medoxomil/Amlodipine Tablets + Hydrochlorothiazide	Percentage of Obese Patients Achieving Seated Systolic Blood Pressure Goal From Baseline to 4, 8, 12, 16, 20 Weeks	4 weeks: <120 mm Hg, N=497	7.9 Percentage of Participants
Olmesartan Medoxomil/Amlodipine Tablets + Hydrochlorothiazide	Percentage of Obese Patients Achieving Seated Systolic Blood Pressure Goal From Baseline to 4, 8, 12, 16, 20 Weeks	8 weeks: <140 mm Hg, N=500	63.2 Percentage of Participants
Olmesartan Medoxomil/Amlodipine Tablets + Hydrochlorothiazide	Percentage of Obese Patients Achieving Seated Systolic Blood Pressure Goal From Baseline to 4, 8, 12, 16, 20 Weeks	8 weeks: <135 mm Hg, N=500	49.2 Percentage of Participants
Olmesartan Medoxomil/Amlodipine Tablets + Hydrochlorothiazide	Percentage of Obese Patients Achieving Seated Systolic Blood Pressure Goal From Baseline to 4, 8, 12, 16, 20 Weeks	8 weeks: <130 mm Hg, N=500	37.0 Percentage of Participants
Olmesartan Medoxomil/Amlodipine Tablets + Hydrochlorothiazide	Percentage of Obese Patients Achieving Seated Systolic Blood Pressure Goal From Baseline to 4, 8, 12, 16, 20 Weeks	8 weeks: <120 mm Hg, N=500	13.8 Percentage of Participants
Olmesartan Medoxomil/Amlodipine Tablets + Hydrochlorothiazide	Percentage of Obese Patients Achieving Seated Systolic Blood Pressure Goal From Baseline to 4, 8, 12, 16, 20 Weeks	12 weeks: <140 mm Hg, N=500	76.6 Percentage of Participants
Olmesartan Medoxomil/Amlodipine Tablets + Hydrochlorothiazide	Percentage of Obese Patients Achieving Seated Systolic Blood Pressure Goal From Baseline to 4, 8, 12, 16, 20 Weeks	12 weeks: <135 mm Hg, N=500	61.6 Percentage of Participants
Olmesartan Medoxomil/Amlodipine Tablets + Hydrochlorothiazide	Percentage of Obese Patients Achieving Seated Systolic Blood Pressure Goal From Baseline to 4, 8, 12, 16, 20 Weeks	12 weeks: <130 mm Hg, N=500	49.2 Percentage of Participants
Olmesartan Medoxomil/Amlodipine Tablets + Hydrochlorothiazide	Percentage of Obese Patients Achieving Seated Systolic Blood Pressure Goal From Baseline to 4, 8, 12, 16, 20 Weeks	12 weeks: <120 mm Hg, N=500	23.2 Percentage of Participants
Olmesartan Medoxomil/Amlodipine Tablets + Hydrochlorothiazide	Percentage of Obese Patients Achieving Seated Systolic Blood Pressure Goal From Baseline to 4, 8, 12, 16, 20 Weeks	16 weeks: <140 mm Hg, N=500	85.8 Percentage of Participants
Olmesartan Medoxomil/Amlodipine Tablets + Hydrochlorothiazide	Percentage of Obese Patients Achieving Seated Systolic Blood Pressure Goal From Baseline to 4, 8, 12, 16, 20 Weeks	16 weeks: <135 mm Hg, N=500	75.6 Percentage of Participants
Olmesartan Medoxomil/Amlodipine Tablets + Hydrochlorothiazide	Percentage of Obese Patients Achieving Seated Systolic Blood Pressure Goal From Baseline to 4, 8, 12, 16, 20 Weeks	16 weeks: <130 mm Hg, N=500	63.6 Percentage of Participants
Olmesartan Medoxomil/Amlodipine Tablets + Hydrochlorothiazide	Percentage of Obese Patients Achieving Seated Systolic Blood Pressure Goal From Baseline to 4, 8, 12, 16, 20 Weeks	16 weeks: <120 mm Hg, N=500	34.6 Percentage of Participants
Olmesartan Medoxomil/Amlodipine Tablets + Hydrochlorothiazide	Percentage of Obese Patients Achieving Seated Systolic Blood Pressure Goal From Baseline to 4, 8, 12, 16, 20 Weeks	20 weeks: <140 mm Hg, N=500	90.2 Percentage of Participants
Olmesartan Medoxomil/Amlodipine Tablets + Hydrochlorothiazide	Percentage of Obese Patients Achieving Seated Systolic Blood Pressure Goal From Baseline to 4, 8, 12, 16, 20 Weeks	20 weeks: <135 mm Hg, N=500	82.6 Percentage of Participants
Olmesartan Medoxomil/Amlodipine Tablets + Hydrochlorothiazide	Percentage of Obese Patients Achieving Seated Systolic Blood Pressure Goal From Baseline to 4, 8, 12, 16, 20 Weeks	20 weeks: <130 mm Hg, N=500	72.2 Percentage of Participants
Olmesartan Medoxomil/Amlodipine Tablets + Hydrochlorothiazide	Percentage of Obese Patients Achieving Seated Systolic Blood Pressure Goal From Baseline to 4, 8, 12, 16, 20 Weeks	20 weeks: <120 mm Hg, N=500	43.0 Percentage of Participants

Secondary

Percentage of Obese Patients Achieving Seated Systolic Blood Pressure Reduction Ranges From Baseline to 4, 8, 12, 16, 20 Weeks

Time frame: Baseline to 4, 8, 12, 16, 20 weeks

Arm	Measure	Group	Value (NUMBER)
Olmesartan Medoxomil/Amlodipine Tablets + Hydrochlorothiazide	Percentage of Obese Patients Achieving Seated Systolic Blood Pressure Reduction Ranges From Baseline to 4, 8, 12, 16, 20 Weeks	4 weeks: ≤ 15 mm Hg, N=495	56.0 Percentage of Participants
Olmesartan Medoxomil/Amlodipine Tablets + Hydrochlorothiazide	Percentage of Obese Patients Achieving Seated Systolic Blood Pressure Reduction Ranges From Baseline to 4, 8, 12, 16, 20 Weeks	4 weeks: >15 and ≤ 30 mm Hg, N=495	35.2 Percentage of Participants
Olmesartan Medoxomil/Amlodipine Tablets + Hydrochlorothiazide	Percentage of Obese Patients Achieving Seated Systolic Blood Pressure Reduction Ranges From Baseline to 4, 8, 12, 16, 20 Weeks	4 weeks: >30 and ≤ 45 mm Hg, N=495	8.5 Percentage of Participants
Olmesartan Medoxomil/Amlodipine Tablets + Hydrochlorothiazide	Percentage of Obese Patients Achieving Seated Systolic Blood Pressure Reduction Ranges From Baseline to 4, 8, 12, 16, 20 Weeks	4 weeks: >45 mm Hg, N=495	0.4 Percentage of Participants
Olmesartan Medoxomil/Amlodipine Tablets + Hydrochlorothiazide	Percentage of Obese Patients Achieving Seated Systolic Blood Pressure Reduction Ranges From Baseline to 4, 8, 12, 16, 20 Weeks	8 weeks: ≤ 15 mm Hg, N=468	52.4 Percentage of Participants
Olmesartan Medoxomil/Amlodipine Tablets + Hydrochlorothiazide	Percentage of Obese Patients Achieving Seated Systolic Blood Pressure Reduction Ranges From Baseline to 4, 8, 12, 16, 20 Weeks	8 weeks: >15 and ≤ 30 mm Hg, N=468	35.9 Percentage of Participants
Olmesartan Medoxomil/Amlodipine Tablets + Hydrochlorothiazide	Percentage of Obese Patients Achieving Seated Systolic Blood Pressure Reduction Ranges From Baseline to 4, 8, 12, 16, 20 Weeks	8 weeks: >30 and ≤ 45 mm Hg, N=468	10.3 Percentage of Participants
Olmesartan Medoxomil/Amlodipine Tablets + Hydrochlorothiazide	Percentage of Obese Patients Achieving Seated Systolic Blood Pressure Reduction Ranges From Baseline to 4, 8, 12, 16, 20 Weeks	8 weeks: >45 mm Hg, N=468	1.5 Percentage of Participants
Olmesartan Medoxomil/Amlodipine Tablets + Hydrochlorothiazide	Percentage of Obese Patients Achieving Seated Systolic Blood Pressure Reduction Ranges From Baseline to 4, 8, 12, 16, 20 Weeks	12 weeks: ≤ 15 mm Hg, N=436	37.8 Percentage of Participants
Olmesartan Medoxomil/Amlodipine Tablets + Hydrochlorothiazide	Percentage of Obese Patients Achieving Seated Systolic Blood Pressure Reduction Ranges From Baseline to 4, 8, 12, 16, 20 Weeks	12 weeks: >15 and ≤ 30 mm Hg, N=436	42.4 Percentage of Participants
Olmesartan Medoxomil/Amlodipine Tablets + Hydrochlorothiazide	Percentage of Obese Patients Achieving Seated Systolic Blood Pressure Reduction Ranges From Baseline to 4, 8, 12, 16, 20 Weeks	12 weeks: >30 and ≤ 45 mm Hg, N=436	17.4 Percentage of Participants
Olmesartan Medoxomil/Amlodipine Tablets + Hydrochlorothiazide	Percentage of Obese Patients Achieving Seated Systolic Blood Pressure Reduction Ranges From Baseline to 4, 8, 12, 16, 20 Weeks	12 weeks: >45 mm Hg, N=436	2.5 Percentage of Participants
Olmesartan Medoxomil/Amlodipine Tablets + Hydrochlorothiazide	Percentage of Obese Patients Achieving Seated Systolic Blood Pressure Reduction Ranges From Baseline to 4, 8, 12, 16, 20 Weeks	16 weeks: ≤ 15 mm Hg, N=400	27.8 Percentage of Participants
Olmesartan Medoxomil/Amlodipine Tablets + Hydrochlorothiazide	Percentage of Obese Patients Achieving Seated Systolic Blood Pressure Reduction Ranges From Baseline to 4, 8, 12, 16, 20 Weeks	16 weeks: >15 and ≤ 30 mm Hg, N=400	36.0 Percentage of Participants
Olmesartan Medoxomil/Amlodipine Tablets + Hydrochlorothiazide	Percentage of Obese Patients Achieving Seated Systolic Blood Pressure Reduction Ranges From Baseline to 4, 8, 12, 16, 20 Weeks	16 weeks: >30 and ≤ 45 mm Hg, N=400	27.5 Percentage of Participants
Olmesartan Medoxomil/Amlodipine Tablets + Hydrochlorothiazide	Percentage of Obese Patients Achieving Seated Systolic Blood Pressure Reduction Ranges From Baseline to 4, 8, 12, 16, 20 Weeks	16 weeks: >45 mm Hg, N=400	8.8 Percentage of Participants
Olmesartan Medoxomil/Amlodipine Tablets + Hydrochlorothiazide	Percentage of Obese Patients Achieving Seated Systolic Blood Pressure Reduction Ranges From Baseline to 4, 8, 12, 16, 20 Weeks	20 weeks: ≤ 15 mm Hg, N=379	20.6 Percentage of Participants
Olmesartan Medoxomil/Amlodipine Tablets + Hydrochlorothiazide	Percentage of Obese Patients Achieving Seated Systolic Blood Pressure Reduction Ranges From Baseline to 4, 8, 12, 16, 20 Weeks	20 weeks: >15 and ≤ 30 mm Hg, N=379	37.5 Percentage of Participants
Olmesartan Medoxomil/Amlodipine Tablets + Hydrochlorothiazide	Percentage of Obese Patients Achieving Seated Systolic Blood Pressure Reduction Ranges From Baseline to 4, 8, 12, 16, 20 Weeks	20 weeks: >30 and ≤ 45 mm Hg, N=379	33.3 Percentage of Participants
Olmesartan Medoxomil/Amlodipine Tablets + Hydrochlorothiazide	Percentage of Obese Patients Achieving Seated Systolic Blood Pressure Reduction Ranges From Baseline to 4, 8, 12, 16, 20 Weeks	20 weeks: >45 mm Hg, N=379	8.7 Percentage of Participants

Secondary

Percentage of Participants Achieving the Mean 24-hour Blood Pressure Goals, as Measured by Ambulatory Blood Pressure Monitor, From Baseline to 12 Weeks

Once the Ambulatory Blood Pressure Monitor (ABPM) has been applied, the dose of medication was taken and the subject wore the ABPM for a period of 24 hours.

Time frame: Baseline to 12 weeks

Population: Ambulatory blood pressure (ABPM) subset of participants who have both technically successful baseline and 12 week ABPM data.

Arm	Measure	Group	Value (NUMBER)
Olmesartan Medoxomil/Amlodipine Tablets + Hydrochlorothiazide	Percentage of Participants Achieving the Mean 24-hour Blood Pressure Goals, as Measured by Ambulatory Blood Pressure Monitor, From Baseline to 12 Weeks	24-hour mean systolic blood pressure <140 mmHg	95.6 Percentage of participants
Olmesartan Medoxomil/Amlodipine Tablets + Hydrochlorothiazide	Percentage of Participants Achieving the Mean 24-hour Blood Pressure Goals, as Measured by Ambulatory Blood Pressure Monitor, From Baseline to 12 Weeks	24-hour mean systolic blood pressure <135 mmHg	90.4 Percentage of participants
Olmesartan Medoxomil/Amlodipine Tablets + Hydrochlorothiazide	Percentage of Participants Achieving the Mean 24-hour Blood Pressure Goals, as Measured by Ambulatory Blood Pressure Monitor, From Baseline to 12 Weeks	24-hour mean systolic blood pressure <130 mmHg	79.9 Percentage of participants
Olmesartan Medoxomil/Amlodipine Tablets + Hydrochlorothiazide	Percentage of Participants Achieving the Mean 24-hour Blood Pressure Goals, as Measured by Ambulatory Blood Pressure Monitor, From Baseline to 12 Weeks	24-hour mean systolic blood pressure <120 mmHg	47.2 Percentage of participants
Olmesartan Medoxomil/Amlodipine Tablets + Hydrochlorothiazide	Percentage of Participants Achieving the Mean 24-hour Blood Pressure Goals, as Measured by Ambulatory Blood Pressure Monitor, From Baseline to 12 Weeks	24-hour mean diastolic blood pressure <90 mmHg	98.7 Percentage of participants
Olmesartan Medoxomil/Amlodipine Tablets + Hydrochlorothiazide	Percentage of Participants Achieving the Mean 24-hour Blood Pressure Goals, as Measured by Ambulatory Blood Pressure Monitor, From Baseline to 12 Weeks	24-hour mean diastolic blood pressure <85 mmHg	96.1 Percentage of participants
Olmesartan Medoxomil/Amlodipine Tablets + Hydrochlorothiazide	Percentage of Participants Achieving the Mean 24-hour Blood Pressure Goals, as Measured by Ambulatory Blood Pressure Monitor, From Baseline to 12 Weeks	24-hour mean diastolic blood pressure <80 mmHg	84.7 Percentage of participants
Olmesartan Medoxomil/Amlodipine Tablets + Hydrochlorothiazide	Percentage of Participants Achieving the Mean 24-hour Blood Pressure Goals, as Measured by Ambulatory Blood Pressure Monitor, From Baseline to 12 Weeks	24-hour mean blood pressure <140/90 mmHg	94.3 Percentage of participants
Olmesartan Medoxomil/Amlodipine Tablets + Hydrochlorothiazide	Percentage of Participants Achieving the Mean 24-hour Blood Pressure Goals, as Measured by Ambulatory Blood Pressure Monitor, From Baseline to 12 Weeks	24-hour mean blood pressure <135/95 mmHg	89.1 Percentage of participants
Olmesartan Medoxomil/Amlodipine Tablets + Hydrochlorothiazide	Percentage of Participants Achieving the Mean 24-hour Blood Pressure Goals, as Measured by Ambulatory Blood Pressure Monitor, From Baseline to 12 Weeks	24-hour mean blood pressure <135/80 mmHg	80.3 Percentage of participants
Olmesartan Medoxomil/Amlodipine Tablets + Hydrochlorothiazide	Percentage of Participants Achieving the Mean 24-hour Blood Pressure Goals, as Measured by Ambulatory Blood Pressure Monitor, From Baseline to 12 Weeks	24-hour mean blood pressure <130/80 mmHg	73.4 Percentage of participants
Olmesartan Medoxomil/Amlodipine Tablets + Hydrochlorothiazide	Percentage of Participants Achieving the Mean 24-hour Blood Pressure Goals, as Measured by Ambulatory Blood Pressure Monitor, From Baseline to 12 Weeks	24-hour mean blood pressure <125/75 mmHg	52.4 Percentage of participants
Olmesartan Medoxomil/Amlodipine Tablets + Hydrochlorothiazide	Percentage of Participants Achieving the Mean 24-hour Blood Pressure Goals, as Measured by Ambulatory Blood Pressure Monitor, From Baseline to 12 Weeks	24-hour mean blood pressure <120/80 mmHg	45.9 Percentage of participants
Olmesartan Medoxomil/Amlodipine Tablets + Hydrochlorothiazide	Percentage of Participants Achieving the Mean 24-hour Blood Pressure Goals, as Measured by Ambulatory Blood Pressure Monitor, From Baseline to 12 Weeks	24-hour mean blood pressure <120/70 mmHg	27.5 Percentage of participants

Secondary

Percentage of Participants Achieving the Mean 24-hour Blood Pressure Goals, as Measured by Ambulatory Blood Pressure Monitor, From Baseline to 20 Weeks

Once the Ambulatory Blood Pressure Monitor (ABPM) has been applied, the dose of medication was taken and the subject wore the ABPM for a period of 24 hours.

Time frame: Baseline to 20 weeks

Population: Ambulatory blood pressure (ABPM) subset of participants who have both technically successful baseline and 20 week ABPM data.

Arm	Measure	Group	Value (NUMBER)
Olmesartan Medoxomil/Amlodipine Tablets + Hydrochlorothiazide	Percentage of Participants Achieving the Mean 24-hour Blood Pressure Goals, as Measured by Ambulatory Blood Pressure Monitor, From Baseline to 20 Weeks	24-hour mean systolic blood pressure <140 mmHg	99.5 Percentage of participants
Olmesartan Medoxomil/Amlodipine Tablets + Hydrochlorothiazide	Percentage of Participants Achieving the Mean 24-hour Blood Pressure Goals, as Measured by Ambulatory Blood Pressure Monitor, From Baseline to 20 Weeks	24-hour mean systolic blood pressure <135 mmHg	97.5 Percentage of participants
Olmesartan Medoxomil/Amlodipine Tablets + Hydrochlorothiazide	Percentage of Participants Achieving the Mean 24-hour Blood Pressure Goals, as Measured by Ambulatory Blood Pressure Monitor, From Baseline to 20 Weeks	24-hour mean systolic blood pressure <130 mmHg	94.5 Percentage of participants
Olmesartan Medoxomil/Amlodipine Tablets + Hydrochlorothiazide	Percentage of Participants Achieving the Mean 24-hour Blood Pressure Goals, as Measured by Ambulatory Blood Pressure Monitor, From Baseline to 20 Weeks	24-hour mean systolic blood pressure <120 mmHg	70.4 Percentage of participants
Olmesartan Medoxomil/Amlodipine Tablets + Hydrochlorothiazide	Percentage of Participants Achieving the Mean 24-hour Blood Pressure Goals, as Measured by Ambulatory Blood Pressure Monitor, From Baseline to 20 Weeks	24-hour mean diastolic blood pressure <90 mmHg	100.0 Percentage of participants
Olmesartan Medoxomil/Amlodipine Tablets + Hydrochlorothiazide	Percentage of Participants Achieving the Mean 24-hour Blood Pressure Goals, as Measured by Ambulatory Blood Pressure Monitor, From Baseline to 20 Weeks	24-hour mean diastolic blood pressure <85 mmHg	97.5 Percentage of participants
Olmesartan Medoxomil/Amlodipine Tablets + Hydrochlorothiazide	Percentage of Participants Achieving the Mean 24-hour Blood Pressure Goals, as Measured by Ambulatory Blood Pressure Monitor, From Baseline to 20 Weeks	24-hour mean diastolic blood pressure <80 mmHg	93.0 Percentage of participants
Olmesartan Medoxomil/Amlodipine Tablets + Hydrochlorothiazide	Percentage of Participants Achieving the Mean 24-hour Blood Pressure Goals, as Measured by Ambulatory Blood Pressure Monitor, From Baseline to 20 Weeks	24-hour mean blood pressure <140/90 mmHg	99.5 Percentage of participants
Olmesartan Medoxomil/Amlodipine Tablets + Hydrochlorothiazide	Percentage of Participants Achieving the Mean 24-hour Blood Pressure Goals, as Measured by Ambulatory Blood Pressure Monitor, From Baseline to 20 Weeks	24-hour mean blood pressure <135/95 mmHg	96.0 Percentage of participants
Olmesartan Medoxomil/Amlodipine Tablets + Hydrochlorothiazide	Percentage of Participants Achieving the Mean 24-hour Blood Pressure Goals, as Measured by Ambulatory Blood Pressure Monitor, From Baseline to 20 Weeks	24-hour mean blood pressure <135/80 mmHg	92.5 Percentage of participants
Olmesartan Medoxomil/Amlodipine Tablets + Hydrochlorothiazide	Percentage of Participants Achieving the Mean 24-hour Blood Pressure Goals, as Measured by Ambulatory Blood Pressure Monitor, From Baseline to 20 Weeks	24-hour mean blood pressure <130/80 mmHg	90.5 Percentage of participants
Olmesartan Medoxomil/Amlodipine Tablets + Hydrochlorothiazide	Percentage of Participants Achieving the Mean 24-hour Blood Pressure Goals, as Measured by Ambulatory Blood Pressure Monitor, From Baseline to 20 Weeks	24-hour mean blood pressure <125/75 mmHg	75.4 Percentage of participants
Olmesartan Medoxomil/Amlodipine Tablets + Hydrochlorothiazide	Percentage of Participants Achieving the Mean 24-hour Blood Pressure Goals, as Measured by Ambulatory Blood Pressure Monitor, From Baseline to 20 Weeks	24-hour mean blood pressure <120/80 mmHg	70.4 Percentage of participants
Olmesartan Medoxomil/Amlodipine Tablets + Hydrochlorothiazide	Percentage of Participants Achieving the Mean 24-hour Blood Pressure Goals, as Measured by Ambulatory Blood Pressure Monitor, From Baseline to 20 Weeks	24-hour mean blood pressure <120/70 mmHg	55.3 Percentage of participants

Secondary

Percentage of Participants Achieving the Mean Daytime Blood Pressure Goals, as Measured by Ambulatory Blood Pressure Monitor, From Baseline to 12 Weeks

Once the Ambulatory Blood Pressure Monitor (ABPM) has been applied, the dose of medication was taken and the subject wore the ABPM for a period of 24 hours. Daytime is defined as 8AM - 4PM.

Time frame: Baseline to 12 weeks

Population: Ambulatory blood pressure (ABPM) subset of participants who have both technically successful baseline and 12 week ABPM data.

Arm	Measure	Group	Value (NUMBER)
Olmesartan Medoxomil/Amlodipine Tablets + Hydrochlorothiazide	Percentage of Participants Achieving the Mean Daytime Blood Pressure Goals, as Measured by Ambulatory Blood Pressure Monitor, From Baseline to 12 Weeks	Daytime mean systolic blood pressure <140 mmHg	88.2 Percentage of participants
Olmesartan Medoxomil/Amlodipine Tablets + Hydrochlorothiazide	Percentage of Participants Achieving the Mean Daytime Blood Pressure Goals, as Measured by Ambulatory Blood Pressure Monitor, From Baseline to 12 Weeks	Daytime mean systolic blood pressure <135 mmHg	79.9 Percentage of participants
Olmesartan Medoxomil/Amlodipine Tablets + Hydrochlorothiazide	Percentage of Participants Achieving the Mean Daytime Blood Pressure Goals, as Measured by Ambulatory Blood Pressure Monitor, From Baseline to 12 Weeks	Daytime mean systolic blood pressure <130 mmHg	66.4 Percentage of participants
Olmesartan Medoxomil/Amlodipine Tablets + Hydrochlorothiazide	Percentage of Participants Achieving the Mean Daytime Blood Pressure Goals, as Measured by Ambulatory Blood Pressure Monitor, From Baseline to 12 Weeks	Daytime mean systolic blood pressure <120 mmHg	28.8 Percentage of participants
Olmesartan Medoxomil/Amlodipine Tablets + Hydrochlorothiazide	Percentage of Participants Achieving the Mean Daytime Blood Pressure Goals, as Measured by Ambulatory Blood Pressure Monitor, From Baseline to 12 Weeks	Daytime mean diastolic blood pressure <90 mmHg	95.6 Percentage of participants
Olmesartan Medoxomil/Amlodipine Tablets + Hydrochlorothiazide	Percentage of Participants Achieving the Mean Daytime Blood Pressure Goals, as Measured by Ambulatory Blood Pressure Monitor, From Baseline to 12 Weeks	Daytime mean diastolic blood pressure <85 mmHg	83.0 Percentage of participants
Olmesartan Medoxomil/Amlodipine Tablets + Hydrochlorothiazide	Percentage of Participants Achieving the Mean Daytime Blood Pressure Goals, as Measured by Ambulatory Blood Pressure Monitor, From Baseline to 12 Weeks	Daytime mean diastolic blood pressure <80 mmHg	65.5 Percentage of participants
Olmesartan Medoxomil/Amlodipine Tablets + Hydrochlorothiazide	Percentage of Participants Achieving the Mean Daytime Blood Pressure Goals, as Measured by Ambulatory Blood Pressure Monitor, From Baseline to 12 Weeks	Daytime mean blood pressure <140/90 mmHg	86.9 Percentage of participants
Olmesartan Medoxomil/Amlodipine Tablets + Hydrochlorothiazide	Percentage of Participants Achieving the Mean Daytime Blood Pressure Goals, as Measured by Ambulatory Blood Pressure Monitor, From Baseline to 12 Weeks	Daytime mean blood pressure <135/95 mmHg	72.9 Percentage of participants
Olmesartan Medoxomil/Amlodipine Tablets + Hydrochlorothiazide	Percentage of Participants Achieving the Mean Daytime Blood Pressure Goals, as Measured by Ambulatory Blood Pressure Monitor, From Baseline to 12 Weeks	Daytime mean blood pressure <135/80 mmHg	61.1 Percentage of participants
Olmesartan Medoxomil/Amlodipine Tablets + Hydrochlorothiazide	Percentage of Participants Achieving the Mean Daytime Blood Pressure Goals, as Measured by Ambulatory Blood Pressure Monitor, From Baseline to 12 Weeks	Daytime mean blood pressure <130/80 mmHg	53.3 Percentage of participants
Olmesartan Medoxomil/Amlodipine Tablets + Hydrochlorothiazide	Percentage of Participants Achieving the Mean Daytime Blood Pressure Goals, as Measured by Ambulatory Blood Pressure Monitor, From Baseline to 12 Weeks	Daytime mean blood pressure <125/75 mmHg	31.9 Percentage of participants
Olmesartan Medoxomil/Amlodipine Tablets + Hydrochlorothiazide	Percentage of Participants Achieving the Mean Daytime Blood Pressure Goals, as Measured by Ambulatory Blood Pressure Monitor, From Baseline to 12 Weeks	Daytime mean blood pressure <120/80 mmHg	27.9 Percentage of participants
Olmesartan Medoxomil/Amlodipine Tablets + Hydrochlorothiazide	Percentage of Participants Achieving the Mean Daytime Blood Pressure Goals, as Measured by Ambulatory Blood Pressure Monitor, From Baseline to 12 Weeks	Daytime mean blood pressure <120/70 mmHg	13.1 Percentage of participants

Secondary

Percentage of Participants Achieving the Mean Daytime Blood Pressure Goals, as Measured by Ambulatory Blood Pressure Monitor, From Baseline to 20 Weeks

Once the Ambulatory Blood Pressure Monitor (ABPM) has been applied, the dose of medication was taken and the subject wore the ABPM for a period of 24 hours. Daytime is defined as 8AM - 4PM.

Time frame: Baseline to 20 weeks

Population: Ambulatory blood pressure (ABPM) subset of participants who have both technically successful baseline and 20 week ABPM data.

Arm	Measure	Group	Value (NUMBER)
Olmesartan Medoxomil/Amlodipine Tablets + Hydrochlorothiazide	Percentage of Participants Achieving the Mean Daytime Blood Pressure Goals, as Measured by Ambulatory Blood Pressure Monitor, From Baseline to 20 Weeks	Daytime mean systolic blood pressure <140 mmHg	96.5 Percentage of participants
Olmesartan Medoxomil/Amlodipine Tablets + Hydrochlorothiazide	Percentage of Participants Achieving the Mean Daytime Blood Pressure Goals, as Measured by Ambulatory Blood Pressure Monitor, From Baseline to 20 Weeks	Daytime mean systolic blood pressure <135 mmHg	93.5 Percentage of participants
Olmesartan Medoxomil/Amlodipine Tablets + Hydrochlorothiazide	Percentage of Participants Achieving the Mean Daytime Blood Pressure Goals, as Measured by Ambulatory Blood Pressure Monitor, From Baseline to 20 Weeks	Daytime mean systolic blood pressure <130 mmHg	83.9 Percentage of participants
Olmesartan Medoxomil/Amlodipine Tablets + Hydrochlorothiazide	Percentage of Participants Achieving the Mean Daytime Blood Pressure Goals, as Measured by Ambulatory Blood Pressure Monitor, From Baseline to 20 Weeks	Daytime mean systolic blood pressure <120 mmHg	51.8 Percentage of participants
Olmesartan Medoxomil/Amlodipine Tablets + Hydrochlorothiazide	Percentage of Participants Achieving the Mean Daytime Blood Pressure Goals, as Measured by Ambulatory Blood Pressure Monitor, From Baseline to 20 Weeks	Daytime mean diastolic blood pressure <90 mmHg	98.5 Percentage of participants
Olmesartan Medoxomil/Amlodipine Tablets + Hydrochlorothiazide	Percentage of Participants Achieving the Mean Daytime Blood Pressure Goals, as Measured by Ambulatory Blood Pressure Monitor, From Baseline to 20 Weeks	Daytime mean diastolic blood pressure <85 mmHg	92.5 Percentage of participants
Olmesartan Medoxomil/Amlodipine Tablets + Hydrochlorothiazide	Percentage of Participants Achieving the Mean Daytime Blood Pressure Goals, as Measured by Ambulatory Blood Pressure Monitor, From Baseline to 20 Weeks	Daytime mean diastolic blood pressure <80 mmHg	83.9 Percentage of participants
Olmesartan Medoxomil/Amlodipine Tablets + Hydrochlorothiazide	Percentage of Participants Achieving the Mean Daytime Blood Pressure Goals, as Measured by Ambulatory Blood Pressure Monitor, From Baseline to 20 Weeks	Daytime mean blood pressure <140/90 mmHg	95.0 Percentage of participants
Olmesartan Medoxomil/Amlodipine Tablets + Hydrochlorothiazide	Percentage of Participants Achieving the Mean Daytime Blood Pressure Goals, as Measured by Ambulatory Blood Pressure Monitor, From Baseline to 20 Weeks	Daytime mean blood pressure <135/95 mmHg	88.4 Percentage of participants
Olmesartan Medoxomil/Amlodipine Tablets + Hydrochlorothiazide	Percentage of Participants Achieving the Mean Daytime Blood Pressure Goals, as Measured by Ambulatory Blood Pressure Monitor, From Baseline to 20 Weeks	Daytime mean blood pressure <135/80 mmHg	81.9 Percentage of participants
Olmesartan Medoxomil/Amlodipine Tablets + Hydrochlorothiazide	Percentage of Participants Achieving the Mean Daytime Blood Pressure Goals, as Measured by Ambulatory Blood Pressure Monitor, From Baseline to 20 Weeks	Daytime mean blood pressure <130/80 mmHg	77.4 Percentage of participants
Olmesartan Medoxomil/Amlodipine Tablets + Hydrochlorothiazide	Percentage of Participants Achieving the Mean Daytime Blood Pressure Goals, as Measured by Ambulatory Blood Pressure Monitor, From Baseline to 20 Weeks	Daytime mean blood pressure <125/75 mmHg	56.8 Percentage of participants
Olmesartan Medoxomil/Amlodipine Tablets + Hydrochlorothiazide	Percentage of Participants Achieving the Mean Daytime Blood Pressure Goals, as Measured by Ambulatory Blood Pressure Monitor, From Baseline to 20 Weeks	Daytime mean blood pressure <120/80 mmHg	51.3 Percentage of participants
Olmesartan Medoxomil/Amlodipine Tablets + Hydrochlorothiazide	Percentage of Participants Achieving the Mean Daytime Blood Pressure Goals, as Measured by Ambulatory Blood Pressure Monitor, From Baseline to 20 Weeks	Daytime mean blood pressure <120/70 mmHg	33.2 Percentage of participants

Secondary

Percentage of Participants Achieving the Mean Nighttime Blood Pressure Goals, as Measured by Ambulatory Blood Pressure Monitor, From Baseline to 12 Weeks

Once the Ambulatory Blood Pressure Monitor (ABPM) has been applied, the dose of medication was taken and the subject wore the ABPM for a period of 24 hours. Nighttime is defined as 10p.m. - 6 a.m.

Time frame: Baseline to 12 weeks

Population: Ambulatory blood pressure (ABPM) subset of participants who have both technically successful baseline and 12 week ABPM data.

Arm	Measure	Group	Value (NUMBER)
Olmesartan Medoxomil/Amlodipine Tablets + Hydrochlorothiazide	Percentage of Participants Achieving the Mean Nighttime Blood Pressure Goals, as Measured by Ambulatory Blood Pressure Monitor, From Baseline to 12 Weeks	Nighttime mean systolic blood pressure <140 mmHg	97.8 Percentage of participants
Olmesartan Medoxomil/Amlodipine Tablets + Hydrochlorothiazide	Percentage of Participants Achieving the Mean Nighttime Blood Pressure Goals, as Measured by Ambulatory Blood Pressure Monitor, From Baseline to 12 Weeks	Nighttime mean systolic blood pressure <135 mmHg	94.3 Percentage of participants
Olmesartan Medoxomil/Amlodipine Tablets + Hydrochlorothiazide	Percentage of Participants Achieving the Mean Nighttime Blood Pressure Goals, as Measured by Ambulatory Blood Pressure Monitor, From Baseline to 12 Weeks	Nighttime mean systolic blood pressure <130 mmHg	92.6 Percentage of participants
Olmesartan Medoxomil/Amlodipine Tablets + Hydrochlorothiazide	Percentage of Participants Achieving the Mean Nighttime Blood Pressure Goals, as Measured by Ambulatory Blood Pressure Monitor, From Baseline to 12 Weeks	Nighttime mean systolic blood pressure <120 mmHg	74.7 Percentage of participants
Olmesartan Medoxomil/Amlodipine Tablets + Hydrochlorothiazide	Percentage of Participants Achieving the Mean Nighttime Blood Pressure Goals, as Measured by Ambulatory Blood Pressure Monitor, From Baseline to 12 Weeks	Nighttime mean diastolic blood pressure <90 mmHg	99.6 Percentage of participants
Olmesartan Medoxomil/Amlodipine Tablets + Hydrochlorothiazide	Percentage of Participants Achieving the Mean Nighttime Blood Pressure Goals, as Measured by Ambulatory Blood Pressure Monitor, From Baseline to 12 Weeks	Nighttime mean diastolic blood pressure <85 mmHg	98.3 Percentage of participants
Olmesartan Medoxomil/Amlodipine Tablets + Hydrochlorothiazide	Percentage of Participants Achieving the Mean Nighttime Blood Pressure Goals, as Measured by Ambulatory Blood Pressure Monitor, From Baseline to 12 Weeks	Nighttime mean diastolic blood pressure <80 mmHg	94.8 Percentage of participants
Olmesartan Medoxomil/Amlodipine Tablets + Hydrochlorothiazide	Percentage of Participants Achieving the Mean Nighttime Blood Pressure Goals, as Measured by Ambulatory Blood Pressure Monitor, From Baseline to 12 Weeks	Nighttime mean blood pressure <140/90 mmHg	97.4 Percentage of participants
Olmesartan Medoxomil/Amlodipine Tablets + Hydrochlorothiazide	Percentage of Participants Achieving the Mean Nighttime Blood Pressure Goals, as Measured by Ambulatory Blood Pressure Monitor, From Baseline to 12 Weeks	Nighttime mean blood pressure <135/95 mmHg	93.4 Percentage of participants
Olmesartan Medoxomil/Amlodipine Tablets + Hydrochlorothiazide	Percentage of Participants Achieving the Mean Nighttime Blood Pressure Goals, as Measured by Ambulatory Blood Pressure Monitor, From Baseline to 12 Weeks	Nighttime mean blood pressure <135/80 mmHg	90.8 Percentage of participants
Olmesartan Medoxomil/Amlodipine Tablets + Hydrochlorothiazide	Percentage of Participants Achieving the Mean Nighttime Blood Pressure Goals, as Measured by Ambulatory Blood Pressure Monitor, From Baseline to 12 Weeks	Nighttime mean blood pressure <130/80 mmHg	89.1 Percentage of participants
Olmesartan Medoxomil/Amlodipine Tablets + Hydrochlorothiazide	Percentage of Participants Achieving the Mean Nighttime Blood Pressure Goals, as Measured by Ambulatory Blood Pressure Monitor, From Baseline to 12 Weeks	Nighttime mean blood pressure <125/75 mmHg	77.7 Percentage of participants
Olmesartan Medoxomil/Amlodipine Tablets + Hydrochlorothiazide	Percentage of Participants Achieving the Mean Nighttime Blood Pressure Goals, as Measured by Ambulatory Blood Pressure Monitor, From Baseline to 12 Weeks	Nighttime mean blood pressure <120/80 mmHg	74.2 Percentage of participants
Olmesartan Medoxomil/Amlodipine Tablets + Hydrochlorothiazide	Percentage of Participants Achieving the Mean Nighttime Blood Pressure Goals, as Measured by Ambulatory Blood Pressure Monitor, From Baseline to 12 Weeks	Nighttime mean blood pressure <120/70 mmHg	62.0 Percentage of participants

Secondary

Percentage of Participants Achieving the Mean Nighttime Blood Pressure Goals, as Measured by Ambulatory Blood Pressure Monitor, From Baseline to 20 Weeks

Once the Ambulatory Blood Pressure Monitor (ABPM) has been applied, the dose of medication was taken and the subject wore the ABPM for a period of 24 hours. Nighttime is defined as 10 p.m. - 6 a.m.

Time frame: Baseline to 20 weeks

Population: Ambulatory blood pressure (ABPM) subset of participants who have both technically successful baseline and 20 week ABPM data.

Arm	Measure	Group	Value (NUMBER)
Olmesartan Medoxomil/Amlodipine Tablets + Hydrochlorothiazide	Percentage of Participants Achieving the Mean Nighttime Blood Pressure Goals, as Measured by Ambulatory Blood Pressure Monitor, From Baseline to 20 Weeks	Nighttime mean systolic blood pressure <140 mmHg	99.5 Percentage of participants
Olmesartan Medoxomil/Amlodipine Tablets + Hydrochlorothiazide	Percentage of Participants Achieving the Mean Nighttime Blood Pressure Goals, as Measured by Ambulatory Blood Pressure Monitor, From Baseline to 20 Weeks	Nighttime mean systolic blood pressure <135 mmHg	99.5 Percentage of participants
Olmesartan Medoxomil/Amlodipine Tablets + Hydrochlorothiazide	Percentage of Participants Achieving the Mean Nighttime Blood Pressure Goals, as Measured by Ambulatory Blood Pressure Monitor, From Baseline to 20 Weeks	Nighttime mean systolic blood pressure <130 mmHg	97.5 Percentage of participants
Olmesartan Medoxomil/Amlodipine Tablets + Hydrochlorothiazide	Percentage of Participants Achieving the Mean Nighttime Blood Pressure Goals, as Measured by Ambulatory Blood Pressure Monitor, From Baseline to 20 Weeks	Nighttime mean systolic blood pressure <120 mmHg	86.4 Percentage of participants
Olmesartan Medoxomil/Amlodipine Tablets + Hydrochlorothiazide	Percentage of Participants Achieving the Mean Nighttime Blood Pressure Goals, as Measured by Ambulatory Blood Pressure Monitor, From Baseline to 20 Weeks	Nighttime mean diastolic blood pressure <90 mmHg	99.5 Percentage of participants
Olmesartan Medoxomil/Amlodipine Tablets + Hydrochlorothiazide	Percentage of Participants Achieving the Mean Nighttime Blood Pressure Goals, as Measured by Ambulatory Blood Pressure Monitor, From Baseline to 20 Weeks	Nighttime mean diastolic blood pressure <85 mmHg	98.5 Percentage of participants
Olmesartan Medoxomil/Amlodipine Tablets + Hydrochlorothiazide	Percentage of Participants Achieving the Mean Nighttime Blood Pressure Goals, as Measured by Ambulatory Blood Pressure Monitor, From Baseline to 20 Weeks	Nighttime mean diastolic blood pressure <80 mmHg	96.0 Percentage of participants
Olmesartan Medoxomil/Amlodipine Tablets + Hydrochlorothiazide	Percentage of Participants Achieving the Mean Nighttime Blood Pressure Goals, as Measured by Ambulatory Blood Pressure Monitor, From Baseline to 20 Weeks	Nighttime mean blood pressure <140/90 mmHg	99.0 Percentage of participants
Olmesartan Medoxomil/Amlodipine Tablets + Hydrochlorothiazide	Percentage of Participants Achieving the Mean Nighttime Blood Pressure Goals, as Measured by Ambulatory Blood Pressure Monitor, From Baseline to 20 Weeks	Nighttime mean blood pressure <135/95 mmHg	98.5 Percentage of participants
Olmesartan Medoxomil/Amlodipine Tablets + Hydrochlorothiazide	Percentage of Participants Achieving the Mean Nighttime Blood Pressure Goals, as Measured by Ambulatory Blood Pressure Monitor, From Baseline to 20 Weeks	Nighttime mean blood pressure <135/80 mmHg	96.0 Percentage of participants
Olmesartan Medoxomil/Amlodipine Tablets + Hydrochlorothiazide	Percentage of Participants Achieving the Mean Nighttime Blood Pressure Goals, as Measured by Ambulatory Blood Pressure Monitor, From Baseline to 20 Weeks	Nighttime mean blood pressure <130/80 mmHg	95.0 Percentage of participants
Olmesartan Medoxomil/Amlodipine Tablets + Hydrochlorothiazide	Percentage of Participants Achieving the Mean Nighttime Blood Pressure Goals, as Measured by Ambulatory Blood Pressure Monitor, From Baseline to 20 Weeks	Nighttime mean blood pressure <125/75 mmHg	88.9 Percentage of participants
Olmesartan Medoxomil/Amlodipine Tablets + Hydrochlorothiazide	Percentage of Participants Achieving the Mean Nighttime Blood Pressure Goals, as Measured by Ambulatory Blood Pressure Monitor, From Baseline to 20 Weeks	Nighttime mean blood pressure <120/80 mmHg	85.9 Percentage of participants
Olmesartan Medoxomil/Amlodipine Tablets + Hydrochlorothiazide	Percentage of Participants Achieving the Mean Nighttime Blood Pressure Goals, as Measured by Ambulatory Blood Pressure Monitor, From Baseline to 20 Weeks	Nighttime mean blood pressure <120/70 mmHg	78.9 Percentage of participants

Secondary

Percentage of Participants Previously on a Beta Blocker Achieving the Blood Pressure Goals From Baseline to 12 Weeks

Time frame: Baseline to 12 weeks

Population: Participants previously on an beta blocker who have received at least one dose of study medication and who have a baseline value.

Arm	Measure	Group	Value (NUMBER)
Olmesartan Medoxomil/Amlodipine Tablets + Hydrochlorothiazide	Percentage of Participants Previously on a Beta Blocker Achieving the Blood Pressure Goals From Baseline to 12 Weeks	Blood pressure <120/80 mmHg	29.2 Percentage of participants
Olmesartan Medoxomil/Amlodipine Tablets + Hydrochlorothiazide	Percentage of Participants Previously on a Beta Blocker Achieving the Blood Pressure Goals From Baseline to 12 Weeks	Systolic blood pressure <140 mmHg	88.5 Percentage of participants
Olmesartan Medoxomil/Amlodipine Tablets + Hydrochlorothiazide	Percentage of Participants Previously on a Beta Blocker Achieving the Blood Pressure Goals From Baseline to 12 Weeks	Systolic blood pressure <135 mmHg	75.2 Percentage of participants
Olmesartan Medoxomil/Amlodipine Tablets + Hydrochlorothiazide	Percentage of Participants Previously on a Beta Blocker Achieving the Blood Pressure Goals From Baseline to 12 Weeks	Systolic blood pressure <130 mmHg	62.0 Percentage of participants
Olmesartan Medoxomil/Amlodipine Tablets + Hydrochlorothiazide	Percentage of Participants Previously on a Beta Blocker Achieving the Blood Pressure Goals From Baseline to 12 Weeks	Systolic blood pressure <120 mmHg	33.6 Percentage of participants
Olmesartan Medoxomil/Amlodipine Tablets + Hydrochlorothiazide	Percentage of Participants Previously on a Beta Blocker Achieving the Blood Pressure Goals From Baseline to 12 Weeks	Diastolic blood pressure <90 mmHg	94.7 Percentage of participants
Olmesartan Medoxomil/Amlodipine Tablets + Hydrochlorothiazide	Percentage of Participants Previously on a Beta Blocker Achieving the Blood Pressure Goals From Baseline to 12 Weeks	Diastolic blood pressure <85 mmHg	83.2 Percentage of participants
Olmesartan Medoxomil/Amlodipine Tablets + Hydrochlorothiazide	Percentage of Participants Previously on a Beta Blocker Achieving the Blood Pressure Goals From Baseline to 12 Weeks	Diastolic blood pressure <80 mmHg	61.1 Percentage of participants
Olmesartan Medoxomil/Amlodipine Tablets + Hydrochlorothiazide	Percentage of Participants Previously on a Beta Blocker Achieving the Blood Pressure Goals From Baseline to 12 Weeks	Blood pressure <140/90 mmHg	86.7 Percentage of participants
Olmesartan Medoxomil/Amlodipine Tablets + Hydrochlorothiazide	Percentage of Participants Previously on a Beta Blocker Achieving the Blood Pressure Goals From Baseline to 12 Weeks	Blood pressure <135/80 mmHg	55.8 Percentage of participants
Olmesartan Medoxomil/Amlodipine Tablets + Hydrochlorothiazide	Percentage of Participants Previously on a Beta Blocker Achieving the Blood Pressure Goals From Baseline to 12 Weeks	Blood pressure <130/80 mmHg	49.6 Percentage of participants

Secondary

Percentage of Participants Previously on a Beta Blocker Achieving the Blood Pressure Goals From Baseline to 20 Weeks

Time frame: Baseline to 20 weeks

Population: Participants previously on an beta blocker who have received at least one dose of study medication and who have a baseline value.

Arm	Measure	Group	Value (NUMBER)
Olmesartan Medoxomil/Amlodipine Tablets + Hydrochlorothiazide	Percentage of Participants Previously on a Beta Blocker Achieving the Blood Pressure Goals From Baseline to 20 Weeks	Systolic blood pressure <140 mmHg	93.8 Percentage of participants
Olmesartan Medoxomil/Amlodipine Tablets + Hydrochlorothiazide	Percentage of Participants Previously on a Beta Blocker Achieving the Blood Pressure Goals From Baseline to 20 Weeks	Systolic blood pressure <135 mmHg	87.6 Percentage of participants
Olmesartan Medoxomil/Amlodipine Tablets + Hydrochlorothiazide	Percentage of Participants Previously on a Beta Blocker Achieving the Blood Pressure Goals From Baseline to 20 Weeks	Systolic blood pressure <130 mmHg	79.7 Percentage of participants
Olmesartan Medoxomil/Amlodipine Tablets + Hydrochlorothiazide	Percentage of Participants Previously on a Beta Blocker Achieving the Blood Pressure Goals From Baseline to 20 Weeks	Systolic blood pressure <120 mmHg	47.8 Percentage of participants
Olmesartan Medoxomil/Amlodipine Tablets + Hydrochlorothiazide	Percentage of Participants Previously on a Beta Blocker Achieving the Blood Pressure Goals From Baseline to 20 Weeks	Diastolic blood pressure <90 mmHg	98.2 Percentage of participants
Olmesartan Medoxomil/Amlodipine Tablets + Hydrochlorothiazide	Percentage of Participants Previously on a Beta Blocker Achieving the Blood Pressure Goals From Baseline to 20 Weeks	Diastolic blood pressure <85 mmHg	89.4 Percentage of participants
Olmesartan Medoxomil/Amlodipine Tablets + Hydrochlorothiazide	Percentage of Participants Previously on a Beta Blocker Achieving the Blood Pressure Goals From Baseline to 20 Weeks	Diastolic blood pressure <80 mmHg	77.0 Percentage of participants
Olmesartan Medoxomil/Amlodipine Tablets + Hydrochlorothiazide	Percentage of Participants Previously on a Beta Blocker Achieving the Blood Pressure Goals From Baseline to 20 Weeks	Blood pressure <140/90 mmHg	92.9 Percentage of participants
Olmesartan Medoxomil/Amlodipine Tablets + Hydrochlorothiazide	Percentage of Participants Previously on a Beta Blocker Achieving the Blood Pressure Goals From Baseline to 20 Weeks	Blood pressure <135/80 mmHg	74.3 Percentage of participants
Olmesartan Medoxomil/Amlodipine Tablets + Hydrochlorothiazide	Percentage of Participants Previously on a Beta Blocker Achieving the Blood Pressure Goals From Baseline to 20 Weeks	Blood pressure <130/80 mmHg	69.9 Percentage of participants
Olmesartan Medoxomil/Amlodipine Tablets + Hydrochlorothiazide	Percentage of Participants Previously on a Beta Blocker Achieving the Blood Pressure Goals From Baseline to 20 Weeks	Blood pressure <120/80 mmHg	43.4 Percentage of participants

Secondary

Percentage of Participants Previously on a Dihydropyridine Calcium Channel Blocker Achieving the Blood Pressure Goals From Baseline to 12 Weeks

Time frame: Baseline to 12 weeks

Population: Participants previously on a Dihydropyridine Calcium Channel Blocker who have received at least one dose of study medication and who have a baseline value.

Arm	Measure	Group	Value (NUMBER)
Olmesartan Medoxomil/Amlodipine Tablets + Hydrochlorothiazide	Percentage of Participants Previously on a Dihydropyridine Calcium Channel Blocker Achieving the Blood Pressure Goals From Baseline to 12 Weeks	Systolic blood pressure <140 mmHg	73.5 Percentage of participants
Olmesartan Medoxomil/Amlodipine Tablets + Hydrochlorothiazide	Percentage of Participants Previously on a Dihydropyridine Calcium Channel Blocker Achieving the Blood Pressure Goals From Baseline to 12 Weeks	Systolic blood pressure <135 mmHg	59.0 Percentage of participants
Olmesartan Medoxomil/Amlodipine Tablets + Hydrochlorothiazide	Percentage of Participants Previously on a Dihydropyridine Calcium Channel Blocker Achieving the Blood Pressure Goals From Baseline to 12 Weeks	Systolic blood pressure <130 mmHg	47.9 Percentage of participants
Olmesartan Medoxomil/Amlodipine Tablets + Hydrochlorothiazide	Percentage of Participants Previously on a Dihydropyridine Calcium Channel Blocker Achieving the Blood Pressure Goals From Baseline to 12 Weeks	Systolic blood pressure <120 mmHg	18.8 Percentage of participants
Olmesartan Medoxomil/Amlodipine Tablets + Hydrochlorothiazide	Percentage of Participants Previously on a Dihydropyridine Calcium Channel Blocker Achieving the Blood Pressure Goals From Baseline to 12 Weeks	Diastolic blood pressure <90 mmHg	86.3 Percentage of participants
Olmesartan Medoxomil/Amlodipine Tablets + Hydrochlorothiazide	Percentage of Participants Previously on a Dihydropyridine Calcium Channel Blocker Achieving the Blood Pressure Goals From Baseline to 12 Weeks	Diastolic blood pressure <85 mmHg	72.7 Percentage of participants
Olmesartan Medoxomil/Amlodipine Tablets + Hydrochlorothiazide	Percentage of Participants Previously on a Dihydropyridine Calcium Channel Blocker Achieving the Blood Pressure Goals From Baseline to 12 Weeks	Diastolic blood pressure <80 mmHg	48.7 Percentage of participants
Olmesartan Medoxomil/Amlodipine Tablets + Hydrochlorothiazide	Percentage of Participants Previously on a Dihydropyridine Calcium Channel Blocker Achieving the Blood Pressure Goals From Baseline to 12 Weeks	Blood pressure <140/90 mmHg	68.4 Percentage of participants
Olmesartan Medoxomil/Amlodipine Tablets + Hydrochlorothiazide	Percentage of Participants Previously on a Dihydropyridine Calcium Channel Blocker Achieving the Blood Pressure Goals From Baseline to 12 Weeks	Blood pressure <135/80 mmHg	40.2 Percentage of participants
Olmesartan Medoxomil/Amlodipine Tablets + Hydrochlorothiazide	Percentage of Participants Previously on a Dihydropyridine Calcium Channel Blocker Achieving the Blood Pressure Goals From Baseline to 12 Weeks	Blood pressure <130/80 mmHg	34.2 Percentage of participants
Olmesartan Medoxomil/Amlodipine Tablets + Hydrochlorothiazide	Percentage of Participants Previously on a Dihydropyridine Calcium Channel Blocker Achieving the Blood Pressure Goals From Baseline to 12 Weeks	Blood pressure <120/80 mmHg	16.2 Percentage of participants

Secondary

Percentage of Participants Previously on a Dihydropyridine Calcium Channel Blocker Achieving the Blood Pressure Goals From Baseline to 20 Weeks

Time frame: Baseline to 20 weeks

Population: Participants previously on a Dihydropyridine Calcium Channel Blocker who have received at least one dose of study medication and who have a baseline value.

Arm	Measure	Group	Value (NUMBER)
Olmesartan Medoxomil/Amlodipine Tablets + Hydrochlorothiazide	Percentage of Participants Previously on a Dihydropyridine Calcium Channel Blocker Achieving the Blood Pressure Goals From Baseline to 20 Weeks	Blood pressure <120/80 mmHg	36.8 Percentage of participants
Olmesartan Medoxomil/Amlodipine Tablets + Hydrochlorothiazide	Percentage of Participants Previously on a Dihydropyridine Calcium Channel Blocker Achieving the Blood Pressure Goals From Baseline to 20 Weeks	Systolic blood pressure <140 mmHg	89.7 Percentage of participants
Olmesartan Medoxomil/Amlodipine Tablets + Hydrochlorothiazide	Percentage of Participants Previously on a Dihydropyridine Calcium Channel Blocker Achieving the Blood Pressure Goals From Baseline to 20 Weeks	Systolic blood pressure <135 mmHg	83.8 Percentage of participants
Olmesartan Medoxomil/Amlodipine Tablets + Hydrochlorothiazide	Percentage of Participants Previously on a Dihydropyridine Calcium Channel Blocker Achieving the Blood Pressure Goals From Baseline to 20 Weeks	Systolic blood pressure <130 mmHg	69.2 Percentage of participants
Olmesartan Medoxomil/Amlodipine Tablets + Hydrochlorothiazide	Percentage of Participants Previously on a Dihydropyridine Calcium Channel Blocker Achieving the Blood Pressure Goals From Baseline to 20 Weeks	Systolic blood pressure <120 mmHg	41.0 Percentage of participants
Olmesartan Medoxomil/Amlodipine Tablets + Hydrochlorothiazide	Percentage of Participants Previously on a Dihydropyridine Calcium Channel Blocker Achieving the Blood Pressure Goals From Baseline to 20 Weeks	Diastolic blood pressure <90 mmHg	91.5 Percentage of participants
Olmesartan Medoxomil/Amlodipine Tablets + Hydrochlorothiazide	Percentage of Participants Previously on a Dihydropyridine Calcium Channel Blocker Achieving the Blood Pressure Goals From Baseline to 20 Weeks	Diastolic blood pressure <85 mmHg	85.5 Percentage of participants
Olmesartan Medoxomil/Amlodipine Tablets + Hydrochlorothiazide	Percentage of Participants Previously on a Dihydropyridine Calcium Channel Blocker Achieving the Blood Pressure Goals From Baseline to 20 Weeks	Diastolic blood pressure <80 mmHg	69.2 Percentage of participants
Olmesartan Medoxomil/Amlodipine Tablets + Hydrochlorothiazide	Percentage of Participants Previously on a Dihydropyridine Calcium Channel Blocker Achieving the Blood Pressure Goals From Baseline to 20 Weeks	Blood pressure <140/90 mmHg	85.5 Percentage of participants
Olmesartan Medoxomil/Amlodipine Tablets + Hydrochlorothiazide	Percentage of Participants Previously on a Dihydropyridine Calcium Channel Blocker Achieving the Blood Pressure Goals From Baseline to 20 Weeks	Blood pressure <135/80 mmHg	64.1 Percentage of participants
Olmesartan Medoxomil/Amlodipine Tablets + Hydrochlorothiazide	Percentage of Participants Previously on a Dihydropyridine Calcium Channel Blocker Achieving the Blood Pressure Goals From Baseline to 20 Weeks	Blood pressure <130/80 mmHg	59.8 Percentage of participants

Secondary

Percentage of Participants Previously on a Diuretic Achieving the Blood Pressure Goals From Baseline to 12 Weeks

Time frame: Baseline to 12 weeks

Population: Participants previously on a diuretic who have received at least one dose of study medication and who have a baseline value.

Arm	Measure	Group	Value (NUMBER)
Olmesartan Medoxomil/Amlodipine Tablets + Hydrochlorothiazide	Percentage of Participants Previously on a Diuretic Achieving the Blood Pressure Goals From Baseline to 12 Weeks	Systolic blood pressure <140 mmHg	92.8 Percentage of participants
Olmesartan Medoxomil/Amlodipine Tablets + Hydrochlorothiazide	Percentage of Participants Previously on a Diuretic Achieving the Blood Pressure Goals From Baseline to 12 Weeks	Systolic blood pressure <135 mmHg	82.5 Percentage of participants
Olmesartan Medoxomil/Amlodipine Tablets + Hydrochlorothiazide	Percentage of Participants Previously on a Diuretic Achieving the Blood Pressure Goals From Baseline to 12 Weeks	Systolic blood pressure <130 mmHg	78.3 Percentage of participants
Olmesartan Medoxomil/Amlodipine Tablets + Hydrochlorothiazide	Percentage of Participants Previously on a Diuretic Achieving the Blood Pressure Goals From Baseline to 12 Weeks	Systolic blood pressure <120 mmHg	51.2 Percentage of participants
Olmesartan Medoxomil/Amlodipine Tablets + Hydrochlorothiazide	Percentage of Participants Previously on a Diuretic Achieving the Blood Pressure Goals From Baseline to 12 Weeks	Diastolic blood pressure <90 mmHg	94.6 Percentage of participants
Olmesartan Medoxomil/Amlodipine Tablets + Hydrochlorothiazide	Percentage of Participants Previously on a Diuretic Achieving the Blood Pressure Goals From Baseline to 12 Weeks	Diastolic blood pressure <85 mmHg	86.8 Percentage of participants
Olmesartan Medoxomil/Amlodipine Tablets + Hydrochlorothiazide	Percentage of Participants Previously on a Diuretic Achieving the Blood Pressure Goals From Baseline to 12 Weeks	Diastolic blood pressure <80 mmHg	71.7 Percentage of participants
Olmesartan Medoxomil/Amlodipine Tablets + Hydrochlorothiazide	Percentage of Participants Previously on a Diuretic Achieving the Blood Pressure Goals From Baseline to 12 Weeks	Blood pressure <140/90 mmHg	88.6 Percentage of participants
Olmesartan Medoxomil/Amlodipine Tablets + Hydrochlorothiazide	Percentage of Participants Previously on a Diuretic Achieving the Blood Pressure Goals From Baseline to 12 Weeks	Blood pressure <135/80 mmHg	67.5 Percentage of participants
Olmesartan Medoxomil/Amlodipine Tablets + Hydrochlorothiazide	Percentage of Participants Previously on a Diuretic Achieving the Blood Pressure Goals From Baseline to 12 Weeks	Blood pressure <130/80 mmHg	65.1 Percentage of participants
Olmesartan Medoxomil/Amlodipine Tablets + Hydrochlorothiazide	Percentage of Participants Previously on a Diuretic Achieving the Blood Pressure Goals From Baseline to 12 Weeks	Blood pressure <120/80 mmHg	48.2 Percentage of participants

Secondary

Percentage of Participants Previously on a Diuretic Achieving the Blood Pressure Goals From Baseline to 20 Weeks

Time frame: Baseline to 20 weeks

Population: Participants previously on a diuretic who have received at least one dose of study medication and who have a baseline value.

Arm	Measure	Group	Value (NUMBER)
Olmesartan Medoxomil/Amlodipine Tablets + Hydrochlorothiazide	Percentage of Participants Previously on a Diuretic Achieving the Blood Pressure Goals From Baseline to 20 Weeks	Systolic blood pressure <140 mmHg	92.8 Percentage of participants
Olmesartan Medoxomil/Amlodipine Tablets + Hydrochlorothiazide	Percentage of Participants Previously on a Diuretic Achieving the Blood Pressure Goals From Baseline to 20 Weeks	Systolic blood pressure <135 mmHg	82.5 Percentage of participants
Olmesartan Medoxomil/Amlodipine Tablets + Hydrochlorothiazide	Percentage of Participants Previously on a Diuretic Achieving the Blood Pressure Goals From Baseline to 20 Weeks	Systolic blood pressure <130 mmHg	78.3 Percentage of participants
Olmesartan Medoxomil/Amlodipine Tablets + Hydrochlorothiazide	Percentage of Participants Previously on a Diuretic Achieving the Blood Pressure Goals From Baseline to 20 Weeks	Systolic blood pressure <120 mmHg	51.2 Percentage of participants
Olmesartan Medoxomil/Amlodipine Tablets + Hydrochlorothiazide	Percentage of Participants Previously on a Diuretic Achieving the Blood Pressure Goals From Baseline to 20 Weeks	Diastolic blood pressure <90 mmHg	94.6 Percentage of participants
Olmesartan Medoxomil/Amlodipine Tablets + Hydrochlorothiazide	Percentage of Participants Previously on a Diuretic Achieving the Blood Pressure Goals From Baseline to 20 Weeks	Diastolic blood pressure <85 mmHg	86.8 Percentage of participants
Olmesartan Medoxomil/Amlodipine Tablets + Hydrochlorothiazide	Percentage of Participants Previously on a Diuretic Achieving the Blood Pressure Goals From Baseline to 20 Weeks	Diastolic blood pressure <80 mmHg	71.7 Percentage of participants
Olmesartan Medoxomil/Amlodipine Tablets + Hydrochlorothiazide	Percentage of Participants Previously on a Diuretic Achieving the Blood Pressure Goals From Baseline to 20 Weeks	Blood pressure <140/90 mmHg	88.6 Percentage of participants
Olmesartan Medoxomil/Amlodipine Tablets + Hydrochlorothiazide	Percentage of Participants Previously on a Diuretic Achieving the Blood Pressure Goals From Baseline to 20 Weeks	Blood pressure <135/80 mmHg	67.5 Percentage of participants
Olmesartan Medoxomil/Amlodipine Tablets + Hydrochlorothiazide	Percentage of Participants Previously on a Diuretic Achieving the Blood Pressure Goals From Baseline to 20 Weeks	Blood pressure <130/80 mmHg	65.1 Percentage of participants
Olmesartan Medoxomil/Amlodipine Tablets + Hydrochlorothiazide	Percentage of Participants Previously on a Diuretic Achieving the Blood Pressure Goals From Baseline to 20 Weeks	Blood pressure <120/80 mmHg	48.2 Percentage of participants

Secondary

Percentage of Participants Previously on an Angiotensin Converting Enzyme Inhibitor Achieving the Blood Pressure Goals From Baseline to 12 Weeks

Time frame: Baseline to 12 weeks

Population: Participants previously on an angiotensin converting enzyme inhibitor who have received at least one dose of study medication and who have a baseline value.

Arm	Measure	Group	Value (NUMBER)
Olmesartan Medoxomil/Amlodipine Tablets + Hydrochlorothiazide	Percentage of Participants Previously on an Angiotensin Converting Enzyme Inhibitor Achieving the Blood Pressure Goals From Baseline to 12 Weeks	Systolic blood pressure <140 mmHg	81.3 Percentage of participants
Olmesartan Medoxomil/Amlodipine Tablets + Hydrochlorothiazide	Percentage of Participants Previously on an Angiotensin Converting Enzyme Inhibitor Achieving the Blood Pressure Goals From Baseline to 12 Weeks	Systolic blood pressure <135 mmHg	69.3 Percentage of participants
Olmesartan Medoxomil/Amlodipine Tablets + Hydrochlorothiazide	Percentage of Participants Previously on an Angiotensin Converting Enzyme Inhibitor Achieving the Blood Pressure Goals From Baseline to 12 Weeks	Systolic blood pressure <130 mmHg	53.0 Percentage of participants
Olmesartan Medoxomil/Amlodipine Tablets + Hydrochlorothiazide	Percentage of Participants Previously on an Angiotensin Converting Enzyme Inhibitor Achieving the Blood Pressure Goals From Baseline to 12 Weeks	Systolic blood pressure <120 mmHg	31.5 Percentage of participants
Olmesartan Medoxomil/Amlodipine Tablets + Hydrochlorothiazide	Percentage of Participants Previously on an Angiotensin Converting Enzyme Inhibitor Achieving the Blood Pressure Goals From Baseline to 12 Weeks	Diastolic blood pressure <90 mmHg	94.4 Percentage of participants
Olmesartan Medoxomil/Amlodipine Tablets + Hydrochlorothiazide	Percentage of Participants Previously on an Angiotensin Converting Enzyme Inhibitor Achieving the Blood Pressure Goals From Baseline to 12 Weeks	Diastolic blood pressure <85 mmHg	80.6 Percentage of participants
Olmesartan Medoxomil/Amlodipine Tablets + Hydrochlorothiazide	Percentage of Participants Previously on an Angiotensin Converting Enzyme Inhibitor Achieving the Blood Pressure Goals From Baseline to 12 Weeks	Diastolic blood pressure <80 mmHg	64.3 Percentage of participants
Olmesartan Medoxomil/Amlodipine Tablets + Hydrochlorothiazide	Percentage of Participants Previously on an Angiotensin Converting Enzyme Inhibitor Achieving the Blood Pressure Goals From Baseline to 12 Weeks	Blood pressure <140/90 mmHg	78.5 Percentage of participants
Olmesartan Medoxomil/Amlodipine Tablets + Hydrochlorothiazide	Percentage of Participants Previously on an Angiotensin Converting Enzyme Inhibitor Achieving the Blood Pressure Goals From Baseline to 12 Weeks	Blood pressure <135/80 mmHg	52.7 Percentage of participants
Olmesartan Medoxomil/Amlodipine Tablets + Hydrochlorothiazide	Percentage of Participants Previously on an Angiotensin Converting Enzyme Inhibitor Achieving the Blood Pressure Goals From Baseline to 12 Weeks	Blood pressure <130/80 mmHg	43.5 Percentage of participants
Olmesartan Medoxomil/Amlodipine Tablets + Hydrochlorothiazide	Percentage of Participants Previously on an Angiotensin Converting Enzyme Inhibitor Achieving the Blood Pressure Goals From Baseline to 12 Weeks	Blood pressure <120/80 mmHg	27.9 Percentage of participants

Secondary

Percentage of Participants Previously on an Angiotensin Converting Enzyme Inhibitor Achieving the Blood Pressure Goals From Baseline to 20 Weeks

Time frame: Baseline to 20 weeks

Population: Participants previously on an angiotensin converting enzyme inhibitor who have received at least one dose of study medication and who have a baseline value.

Arm	Measure	Group	Value (NUMBER)
Olmesartan Medoxomil/Amlodipine Tablets + Hydrochlorothiazide	Percentage of Participants Previously on an Angiotensin Converting Enzyme Inhibitor Achieving the Blood Pressure Goals From Baseline to 20 Weeks	Blood pressure <140/90 mmHg	90.5 Percentage of participants
Olmesartan Medoxomil/Amlodipine Tablets + Hydrochlorothiazide	Percentage of Participants Previously on an Angiotensin Converting Enzyme Inhibitor Achieving the Blood Pressure Goals From Baseline to 20 Weeks	Blood pressure <135/80 mmHg	71.0 Percentage of participants
Olmesartan Medoxomil/Amlodipine Tablets + Hydrochlorothiazide	Percentage of Participants Previously on an Angiotensin Converting Enzyme Inhibitor Achieving the Blood Pressure Goals From Baseline to 20 Weeks	Blood pressure <130/80 mmHg	61.5 Percentage of participants
Olmesartan Medoxomil/Amlodipine Tablets + Hydrochlorothiazide	Percentage of Participants Previously on an Angiotensin Converting Enzyme Inhibitor Achieving the Blood Pressure Goals From Baseline to 20 Weeks	Systolic blood pressure <140 mmHg	91.5 Percentage of participants
Olmesartan Medoxomil/Amlodipine Tablets + Hydrochlorothiazide	Percentage of Participants Previously on an Angiotensin Converting Enzyme Inhibitor Achieving the Blood Pressure Goals From Baseline to 20 Weeks	Systolic blood pressure <135 mmHg	84.5 Percentage of participants
Olmesartan Medoxomil/Amlodipine Tablets + Hydrochlorothiazide	Percentage of Participants Previously on an Angiotensin Converting Enzyme Inhibitor Achieving the Blood Pressure Goals From Baseline to 20 Weeks	Systolic blood pressure <130 mmHg	71.4 Percentage of participants
Olmesartan Medoxomil/Amlodipine Tablets + Hydrochlorothiazide	Percentage of Participants Previously on an Angiotensin Converting Enzyme Inhibitor Achieving the Blood Pressure Goals From Baseline to 20 Weeks	Systolic blood pressure <120 mmHg	47.4 Percentage of participants
Olmesartan Medoxomil/Amlodipine Tablets + Hydrochlorothiazide	Percentage of Participants Previously on an Angiotensin Converting Enzyme Inhibitor Achieving the Blood Pressure Goals From Baseline to 20 Weeks	Diastolic blood pressure <90 mmHg	98.2 Percentage of participants
Olmesartan Medoxomil/Amlodipine Tablets + Hydrochlorothiazide	Percentage of Participants Previously on an Angiotensin Converting Enzyme Inhibitor Achieving the Blood Pressure Goals From Baseline to 20 Weeks	Diastolic blood pressure <85 mmHg	89.8 Percentage of participants
Olmesartan Medoxomil/Amlodipine Tablets + Hydrochlorothiazide	Percentage of Participants Previously on an Angiotensin Converting Enzyme Inhibitor Achieving the Blood Pressure Goals From Baseline to 20 Weeks	Diastolic blood pressure <80 mmHg	78.5 Percentage of participants
Olmesartan Medoxomil/Amlodipine Tablets + Hydrochlorothiazide	Percentage of Participants Previously on an Angiotensin Converting Enzyme Inhibitor Achieving the Blood Pressure Goals From Baseline to 20 Weeks	Blood pressure <120/80 mmHg	44.5 Percentage of participants

Secondary

Percentage of Participants Previously on an Angiotensin II Receptor Blocker Achieving the Blood Pressure Goals From Baseline to 12 Weeks

Time frame: Baseline to 12 weeks

Population: Participants previously on an angiotensin II receptor blocker who have received at least one dose of study medication and who have a baseline value.

Arm	Measure	Group	Value (NUMBER)
Olmesartan Medoxomil/Amlodipine Tablets + Hydrochlorothiazide	Percentage of Participants Previously on an Angiotensin II Receptor Blocker Achieving the Blood Pressure Goals From Baseline to 12 Weeks	Systolic blood pressure <140 mmHg	80.8 Percentage of participants
Olmesartan Medoxomil/Amlodipine Tablets + Hydrochlorothiazide	Percentage of Participants Previously on an Angiotensin II Receptor Blocker Achieving the Blood Pressure Goals From Baseline to 12 Weeks	Systolic blood pressure <135 mmHg	69.2 Percentage of participants
Olmesartan Medoxomil/Amlodipine Tablets + Hydrochlorothiazide	Percentage of Participants Previously on an Angiotensin II Receptor Blocker Achieving the Blood Pressure Goals From Baseline to 12 Weeks	Systolic blood pressure <130 mmHg	56.0 Percentage of participants
Olmesartan Medoxomil/Amlodipine Tablets + Hydrochlorothiazide	Percentage of Participants Previously on an Angiotensin II Receptor Blocker Achieving the Blood Pressure Goals From Baseline to 12 Weeks	Systolic blood pressure <120 mmHg	26.1 Percentage of participants
Olmesartan Medoxomil/Amlodipine Tablets + Hydrochlorothiazide	Percentage of Participants Previously on an Angiotensin II Receptor Blocker Achieving the Blood Pressure Goals From Baseline to 12 Weeks	Diastolic blood pressure <90 mmHg	89.7 Percentage of participants
Olmesartan Medoxomil/Amlodipine Tablets + Hydrochlorothiazide	Percentage of Participants Previously on an Angiotensin II Receptor Blocker Achieving the Blood Pressure Goals From Baseline to 12 Weeks	Diastolic blood pressure <85 mmHg	76.9 Percentage of participants
Olmesartan Medoxomil/Amlodipine Tablets + Hydrochlorothiazide	Percentage of Participants Previously on an Angiotensin II Receptor Blocker Achieving the Blood Pressure Goals From Baseline to 12 Weeks	Diastolic blood pressure <80 mmHg	59.0 Percentage of participants
Olmesartan Medoxomil/Amlodipine Tablets + Hydrochlorothiazide	Percentage of Participants Previously on an Angiotensin II Receptor Blocker Achieving the Blood Pressure Goals From Baseline to 12 Weeks	Blood pressure <140/90 mmHg	76.1 Percentage of participants
Olmesartan Medoxomil/Amlodipine Tablets + Hydrochlorothiazide	Percentage of Participants Previously on an Angiotensin II Receptor Blocker Achieving the Blood Pressure Goals From Baseline to 12 Weeks	Blood pressure <135/80 mmHg	52.6 Percentage of participants
Olmesartan Medoxomil/Amlodipine Tablets + Hydrochlorothiazide	Percentage of Participants Previously on an Angiotensin II Receptor Blocker Achieving the Blood Pressure Goals From Baseline to 12 Weeks	Blood pressure <130/80 mmHg	46.2 Percentage of participants
Olmesartan Medoxomil/Amlodipine Tablets + Hydrochlorothiazide	Percentage of Participants Previously on an Angiotensin II Receptor Blocker Achieving the Blood Pressure Goals From Baseline to 12 Weeks	Blood pressure <120/80 mmHg	23.1 Percentage of participants

Secondary

Percentage of Participants Previously on an Angiotensin II Receptor Blocker Achieving the Blood Pressure Goals From Baseline to 20 Weeks

Time frame: Baseline to 20 weeks

Population: Participants previously on an angiotensin II receptor blocker who have received at least one dose of study medication and who have a baseline value.

Arm	Measure	Group	Value (NUMBER)
Olmesartan Medoxomil/Amlodipine Tablets + Hydrochlorothiazide	Percentage of Participants Previously on an Angiotensin II Receptor Blocker Achieving the Blood Pressure Goals From Baseline to 20 Weeks	Systolic blood pressure <140 mmHg	92.3 Percentage of participants
Olmesartan Medoxomil/Amlodipine Tablets + Hydrochlorothiazide	Percentage of Participants Previously on an Angiotensin II Receptor Blocker Achieving the Blood Pressure Goals From Baseline to 20 Weeks	Systolic blood pressure <135 mmHg	87.2 Percentage of participants
Olmesartan Medoxomil/Amlodipine Tablets + Hydrochlorothiazide	Percentage of Participants Previously on an Angiotensin II Receptor Blocker Achieving the Blood Pressure Goals From Baseline to 20 Weeks	Systolic blood pressure <130 mmHg	79.5 Percentage of participants
Olmesartan Medoxomil/Amlodipine Tablets + Hydrochlorothiazide	Percentage of Participants Previously on an Angiotensin II Receptor Blocker Achieving the Blood Pressure Goals From Baseline to 20 Weeks	Systolic blood pressure <120 mmHg	47.4 Percentage of participants
Olmesartan Medoxomil/Amlodipine Tablets + Hydrochlorothiazide	Percentage of Participants Previously on an Angiotensin II Receptor Blocker Achieving the Blood Pressure Goals From Baseline to 20 Weeks	Diastolic blood pressure <90 mmHg	96.6 Percentage of participants
Olmesartan Medoxomil/Amlodipine Tablets + Hydrochlorothiazide	Percentage of Participants Previously on an Angiotensin II Receptor Blocker Achieving the Blood Pressure Goals From Baseline to 20 Weeks	Diastolic blood pressure <85 mmHg	89.3 Percentage of participants
Olmesartan Medoxomil/Amlodipine Tablets + Hydrochlorothiazide	Percentage of Participants Previously on an Angiotensin II Receptor Blocker Achieving the Blood Pressure Goals From Baseline to 20 Weeks	Diastolic blood pressure <80 mmHg	74.8 Percentage of participants
Olmesartan Medoxomil/Amlodipine Tablets + Hydrochlorothiazide	Percentage of Participants Previously on an Angiotensin II Receptor Blocker Achieving the Blood Pressure Goals From Baseline to 20 Weeks	Blood pressure <140/90 mmHg	90.6 Percentage of participants
Olmesartan Medoxomil/Amlodipine Tablets + Hydrochlorothiazide	Percentage of Participants Previously on an Angiotensin II Receptor Blocker Achieving the Blood Pressure Goals From Baseline to 20 Weeks	Blood pressure <135/80 mmHg	70.1 Percentage of participants
Olmesartan Medoxomil/Amlodipine Tablets + Hydrochlorothiazide	Percentage of Participants Previously on an Angiotensin II Receptor Blocker Achieving the Blood Pressure Goals From Baseline to 20 Weeks	Blood pressure <130/80 mmHg	65.0 Percentage of participants
Olmesartan Medoxomil/Amlodipine Tablets + Hydrochlorothiazide	Percentage of Participants Previously on an Angiotensin II Receptor Blocker Achieving the Blood Pressure Goals From Baseline to 20 Weeks	Blood pressure <120/80 mmHg	44.0 Percentage of participants

Secondary

Percentage of Participants Previously on a Nondihydropyridine Calcium Channel Blocker Achieving the Blood Pressure Goals From Baseline to 12 Weeks

Time frame: Baseline to 12 weeks

Population: Participants previously on a Nondihydropyridine Calcium Channel Blocker who have received at least one dose of study medication and who have a baseline value.

Arm	Measure	Group	Value (NUMBER)
Olmesartan Medoxomil/Amlodipine Tablets + Hydrochlorothiazide	Percentage of Participants Previously on a Nondihydropyridine Calcium Channel Blocker Achieving the Blood Pressure Goals From Baseline to 12 Weeks	Systolic blood pressure <140 mmHg	100.0 Percentage of participants
Olmesartan Medoxomil/Amlodipine Tablets + Hydrochlorothiazide	Percentage of Participants Previously on a Nondihydropyridine Calcium Channel Blocker Achieving the Blood Pressure Goals From Baseline to 12 Weeks	Systolic blood pressure <135 mmHg	90.0 Percentage of participants
Olmesartan Medoxomil/Amlodipine Tablets + Hydrochlorothiazide	Percentage of Participants Previously on a Nondihydropyridine Calcium Channel Blocker Achieving the Blood Pressure Goals From Baseline to 12 Weeks	Systolic blood pressure <130 mmHg	75.0 Percentage of participants
Olmesartan Medoxomil/Amlodipine Tablets + Hydrochlorothiazide	Percentage of Participants Previously on a Nondihydropyridine Calcium Channel Blocker Achieving the Blood Pressure Goals From Baseline to 12 Weeks	Systolic blood pressure <120 mmHg	25.0 Percentage of participants
Olmesartan Medoxomil/Amlodipine Tablets + Hydrochlorothiazide	Percentage of Participants Previously on a Nondihydropyridine Calcium Channel Blocker Achieving the Blood Pressure Goals From Baseline to 12 Weeks	Diastolic blood pressure <90 mmHg	100.0 Percentage of participants
Olmesartan Medoxomil/Amlodipine Tablets + Hydrochlorothiazide	Percentage of Participants Previously on a Nondihydropyridine Calcium Channel Blocker Achieving the Blood Pressure Goals From Baseline to 12 Weeks	Diastolic blood pressure <85 mmHg	95.0 Percentage of participants
Olmesartan Medoxomil/Amlodipine Tablets + Hydrochlorothiazide	Percentage of Participants Previously on a Nondihydropyridine Calcium Channel Blocker Achieving the Blood Pressure Goals From Baseline to 12 Weeks	Diastolic blood pressure <80 mmHg	75.0 Percentage of participants
Olmesartan Medoxomil/Amlodipine Tablets + Hydrochlorothiazide	Percentage of Participants Previously on a Nondihydropyridine Calcium Channel Blocker Achieving the Blood Pressure Goals From Baseline to 12 Weeks	Blood pressure <140/90 mmHg	100.0 Percentage of participants
Olmesartan Medoxomil/Amlodipine Tablets + Hydrochlorothiazide	Percentage of Participants Previously on a Nondihydropyridine Calcium Channel Blocker Achieving the Blood Pressure Goals From Baseline to 12 Weeks	Blood pressure <135/80 mmHg	70.0 Percentage of participants
Olmesartan Medoxomil/Amlodipine Tablets + Hydrochlorothiazide	Percentage of Participants Previously on a Nondihydropyridine Calcium Channel Blocker Achieving the Blood Pressure Goals From Baseline to 12 Weeks	Blood pressure <130/80 mmHg	65.0 Percentage of participants
Olmesartan Medoxomil/Amlodipine Tablets + Hydrochlorothiazide	Percentage of Participants Previously on a Nondihydropyridine Calcium Channel Blocker Achieving the Blood Pressure Goals From Baseline to 12 Weeks	Blood pressure <120/80 mmHg	20.0 Percentage of participants

Secondary

Percentage of Participants Previously on a Nondihydropyridine Calcium Channel Blocker Achieving the Blood Pressure Goals From Baseline to 20 Weeks

Time frame: Baseline to 20 weeks

Population: Participants previously on a Nondihydropyridine Calcium Channel Blocker who have received at least one dose of study medication and who have a baseline value.

Arm	Measure	Group	Value (NUMBER)
Olmesartan Medoxomil/Amlodipine Tablets + Hydrochlorothiazide	Percentage of Participants Previously on a Nondihydropyridine Calcium Channel Blocker Achieving the Blood Pressure Goals From Baseline to 20 Weeks	Systolic blood pressure <130 mmHg	95.0 Percentage of participants
Olmesartan Medoxomil/Amlodipine Tablets + Hydrochlorothiazide	Percentage of Participants Previously on a Nondihydropyridine Calcium Channel Blocker Achieving the Blood Pressure Goals From Baseline to 20 Weeks	Systolic blood pressure <120 mmHg	45.0 Percentage of participants
Olmesartan Medoxomil/Amlodipine Tablets + Hydrochlorothiazide	Percentage of Participants Previously on a Nondihydropyridine Calcium Channel Blocker Achieving the Blood Pressure Goals From Baseline to 20 Weeks	Systolic blood pressure <140 mmHg	100.0 Percentage of participants
Olmesartan Medoxomil/Amlodipine Tablets + Hydrochlorothiazide	Percentage of Participants Previously on a Nondihydropyridine Calcium Channel Blocker Achieving the Blood Pressure Goals From Baseline to 20 Weeks	Systolic blood pressure <135 mmHg	100.0 Percentage of participants
Olmesartan Medoxomil/Amlodipine Tablets + Hydrochlorothiazide	Percentage of Participants Previously on a Nondihydropyridine Calcium Channel Blocker Achieving the Blood Pressure Goals From Baseline to 20 Weeks	Diastolic blood pressure <90 mmHg	100.0 Percentage of participants
Olmesartan Medoxomil/Amlodipine Tablets + Hydrochlorothiazide	Percentage of Participants Previously on a Nondihydropyridine Calcium Channel Blocker Achieving the Blood Pressure Goals From Baseline to 20 Weeks	Diastolic blood pressure <85 mmHg	95.0 Percentage of participants
Olmesartan Medoxomil/Amlodipine Tablets + Hydrochlorothiazide	Percentage of Participants Previously on a Nondihydropyridine Calcium Channel Blocker Achieving the Blood Pressure Goals From Baseline to 20 Weeks	Diastolic blood pressure <80 mmHg	95.0 Percentage of participants
Olmesartan Medoxomil/Amlodipine Tablets + Hydrochlorothiazide	Percentage of Participants Previously on a Nondihydropyridine Calcium Channel Blocker Achieving the Blood Pressure Goals From Baseline to 20 Weeks	Blood pressure <140/90 mmHg	100.0 Percentage of participants
Olmesartan Medoxomil/Amlodipine Tablets + Hydrochlorothiazide	Percentage of Participants Previously on a Nondihydropyridine Calcium Channel Blocker Achieving the Blood Pressure Goals From Baseline to 20 Weeks	Blood pressure <135/80 mmHg	95.0 Percentage of participants
Olmesartan Medoxomil/Amlodipine Tablets + Hydrochlorothiazide	Percentage of Participants Previously on a Nondihydropyridine Calcium Channel Blocker Achieving the Blood Pressure Goals From Baseline to 20 Weeks	Blood pressure <130/80 mmHg	95.0 Percentage of participants
Olmesartan Medoxomil/Amlodipine Tablets + Hydrochlorothiazide	Percentage of Participants Previously on a Nondihydropyridine Calcium Channel Blocker Achieving the Blood Pressure Goals From Baseline to 20 Weeks	Blood pressure <120/80 mmHg	40.0 Percentage of participants

Secondary

Percentage of Patients Achieving Seated Blood Pressure Goal From Baseline to 4, 8, 12, 16, 20 Weeks

Time frame: Baseline to 4, 8, 12, 16, 20 weeks

Arm	Measure	Group	Value (NUMBER)
Olmesartan Medoxomil/Amlodipine Tablets + Hydrochlorothiazide	Percentage of Patients Achieving Seated Blood Pressure Goal From Baseline to 4, 8, 12, 16, 20 Weeks	4 weeks: <140/90 mm Hg, N=975	49.1 Percentage of Participants
Olmesartan Medoxomil/Amlodipine Tablets + Hydrochlorothiazide	Percentage of Patients Achieving Seated Blood Pressure Goal From Baseline to 4, 8, 12, 16, 20 Weeks	4 weeks: <135/80 mm Hg, N=975	23.0 Percentage of Participants
Olmesartan Medoxomil/Amlodipine Tablets + Hydrochlorothiazide	Percentage of Patients Achieving Seated Blood Pressure Goal From Baseline to 4, 8, 12, 16, 20 Weeks	4 weeks: <130/80 mm Hg, N=975	17.3 Percentage of Participants
Olmesartan Medoxomil/Amlodipine Tablets + Hydrochlorothiazide	Percentage of Patients Achieving Seated Blood Pressure Goal From Baseline to 4, 8, 12, 16, 20 Weeks	4 weeks: <120/80 mm Hg, N=975	7.8 Percentage of Participants
Olmesartan Medoxomil/Amlodipine Tablets + Hydrochlorothiazide	Percentage of Patients Achieving Seated Blood Pressure Goal From Baseline to 4, 8, 12, 16, 20 Weeks	8 weeks: <140/90 mm Hg, N=929	52.4 Percentage of Participants
Olmesartan Medoxomil/Amlodipine Tablets + Hydrochlorothiazide	Percentage of Patients Achieving Seated Blood Pressure Goal From Baseline to 4, 8, 12, 16, 20 Weeks	8 weeks: <135/80 mm Hg, N=929	29.8 Percentage of Participants
Olmesartan Medoxomil/Amlodipine Tablets + Hydrochlorothiazide	Percentage of Patients Achieving Seated Blood Pressure Goal From Baseline to 4, 8, 12, 16, 20 Weeks	8 weeks: <130/80 mm Hg, N=929	24.8 Percentage of Participants
Olmesartan Medoxomil/Amlodipine Tablets + Hydrochlorothiazide	Percentage of Patients Achieving Seated Blood Pressure Goal From Baseline to 4, 8, 12, 16, 20 Weeks	8 weeks: <120/80 mm Hg, N=929	11.2 Percentage of Participants
Olmesartan Medoxomil/Amlodipine Tablets + Hydrochlorothiazide	Percentage of Patients Achieving Seated Blood Pressure Goal From Baseline to 4, 8, 12, 16, 20 Weeks	12 weeks: <140/90 mm Hg, N=865	68.1 Percentage of Participants
Olmesartan Medoxomil/Amlodipine Tablets + Hydrochlorothiazide	Percentage of Patients Achieving Seated Blood Pressure Goal From Baseline to 4, 8, 12, 16, 20 Weeks	12 weeks: <135/80 mm Hg, N=865	40.0 Percentage of Participants
Olmesartan Medoxomil/Amlodipine Tablets + Hydrochlorothiazide	Percentage of Patients Achieving Seated Blood Pressure Goal From Baseline to 4, 8, 12, 16, 20 Weeks	12 weeks: <130/80 mm Hg, N=865	34.3 Percentage of Participants
Olmesartan Medoxomil/Amlodipine Tablets + Hydrochlorothiazide	Percentage of Patients Achieving Seated Blood Pressure Goal From Baseline to 4, 8, 12, 16, 20 Weeks	12 weeks: <120/80 mm Hg, N=865	17.6 Percentage of Participants
Olmesartan Medoxomil/Amlodipine Tablets + Hydrochlorothiazide	Percentage of Patients Achieving Seated Blood Pressure Goal From Baseline to 4, 8, 12, 16, 20 Weeks	16 weeks: <140/90mm Hg, N=797	77.8 Percentage of Participants
Olmesartan Medoxomil/Amlodipine Tablets + Hydrochlorothiazide	Percentage of Patients Achieving Seated Blood Pressure Goal From Baseline to 4, 8, 12, 16, 20 Weeks	16 weeks: <135/80mm Hg, N=797	51.3 Percentage of Participants
Olmesartan Medoxomil/Amlodipine Tablets + Hydrochlorothiazide	Percentage of Patients Achieving Seated Blood Pressure Goal From Baseline to 4, 8, 12, 16, 20 Weeks	16 weeks: <130/80mm Hg, N=797	46.2 Percentage of Participants
Olmesartan Medoxomil/Amlodipine Tablets + Hydrochlorothiazide	Percentage of Patients Achieving Seated Blood Pressure Goal From Baseline to 4, 8, 12, 16, 20 Weeks	16 weeks: <120/80mm Hg, N=797	28.7 Percentage of Participants
Olmesartan Medoxomil/Amlodipine Tablets + Hydrochlorothiazide	Percentage of Patients Achieving Seated Blood Pressure Goal From Baseline to 4, 8, 12, 16, 20 Weeks	20 weeks: <140/90 mm Hg, N=745	81.3 Percentage of Participants
Olmesartan Medoxomil/Amlodipine Tablets + Hydrochlorothiazide	Percentage of Patients Achieving Seated Blood Pressure Goal From Baseline to 4, 8, 12, 16, 20 Weeks	20 weeks: <135/80 mm Hg, N=745	55.6 Percentage of Participants
Olmesartan Medoxomil/Amlodipine Tablets + Hydrochlorothiazide	Percentage of Patients Achieving Seated Blood Pressure Goal From Baseline to 4, 8, 12, 16, 20 Weeks	20 weeks: <130/80 mm Hg, N=745	50.1 Percentage of Participants
Olmesartan Medoxomil/Amlodipine Tablets + Hydrochlorothiazide	Percentage of Patients Achieving Seated Blood Pressure Goal From Baseline to 4, 8, 12, 16, 20 Weeks	20 weeks: <120/80 mm Hg, N=745	28.2 Percentage of Participants

Secondary

Percentage of Patients Achieving Seated Diastolic Blood Pressure Goal From Baseline to 4, 8, 12, 16, 20 Weeks

Time frame: Baseline to 4, 8, 12, 16, 20 weeks

Arm	Measure	Group	Value (NUMBER)
Olmesartan Medoxomil/Amlodipine Tablets + Hydrochlorothiazide	Percentage of Patients Achieving Seated Diastolic Blood Pressure Goal From Baseline to 4, 8, 12, 16, 20 Weeks	4 weeks: <90 mm Hg, N=975	71.3 Percentage of participants
Olmesartan Medoxomil/Amlodipine Tablets + Hydrochlorothiazide	Percentage of Patients Achieving Seated Diastolic Blood Pressure Goal From Baseline to 4, 8, 12, 16, 20 Weeks	4weeks: <85 mm Hg, N=975	55.2 Percentage of participants
Olmesartan Medoxomil/Amlodipine Tablets + Hydrochlorothiazide	Percentage of Patients Achieving Seated Diastolic Blood Pressure Goal From Baseline to 4, 8, 12, 16, 20 Weeks	4 weeks: <80 mm Hg, N=975	34.2 Percentage of participants
Olmesartan Medoxomil/Amlodipine Tablets + Hydrochlorothiazide	Percentage of Patients Achieving Seated Diastolic Blood Pressure Goal From Baseline to 4, 8, 12, 16, 20 Weeks	8 weeks: <90 mm Hg, N=929	75.1 Percentage of participants
Olmesartan Medoxomil/Amlodipine Tablets + Hydrochlorothiazide	Percentage of Patients Achieving Seated Diastolic Blood Pressure Goal From Baseline to 4, 8, 12, 16, 20 Weeks	8 weeks: <85 mm Hg, N=929	57.1 Percentage of participants
Olmesartan Medoxomil/Amlodipine Tablets + Hydrochlorothiazide	Percentage of Patients Achieving Seated Diastolic Blood Pressure Goal From Baseline to 4, 8, 12, 16, 20 Weeks	8 weeks: <80 mm Hg, N=929	40.2 Percentage of participants
Olmesartan Medoxomil/Amlodipine Tablets + Hydrochlorothiazide	Percentage of Patients Achieving Seated Diastolic Blood Pressure Goal From Baseline to 4, 8, 12, 16, 20 Weeks	12 weeks: <90 mm Hg, N=865	84.3 Percentage of participants
Olmesartan Medoxomil/Amlodipine Tablets + Hydrochlorothiazide	Percentage of Patients Achieving Seated Diastolic Blood Pressure Goal From Baseline to 4, 8, 12, 16, 20 Weeks	12 weeks: <85 mm Hg, N=865	68.7 Percentage of participants
Olmesartan Medoxomil/Amlodipine Tablets + Hydrochlorothiazide	Percentage of Patients Achieving Seated Diastolic Blood Pressure Goal From Baseline to 4, 8, 12, 16, 20 Weeks	12 weeks: <80 mm Hg, N=865	49.5 Percentage of participants
Olmesartan Medoxomil/Amlodipine Tablets + Hydrochlorothiazide	Percentage of Patients Achieving Seated Diastolic Blood Pressure Goal From Baseline to 4, 8, 12, 16, 20 Weeks	16 weeks: <90 mm Hg, N=797	90.2 Percentage of participants
Olmesartan Medoxomil/Amlodipine Tablets + Hydrochlorothiazide	Percentage of Patients Achieving Seated Diastolic Blood Pressure Goal From Baseline to 4, 8, 12, 16, 20 Weeks	16 weeks: <85 mm Hg, N=797	76.9 Percentage of participants
Olmesartan Medoxomil/Amlodipine Tablets + Hydrochlorothiazide	Percentage of Patients Achieving Seated Diastolic Blood Pressure Goal From Baseline to 4, 8, 12, 16, 20 Weeks	16 weeks: <80 mm Hg, N=797	59.6 Percentage of participants
Olmesartan Medoxomil/Amlodipine Tablets + Hydrochlorothiazide	Percentage of Patients Achieving Seated Diastolic Blood Pressure Goal From Baseline to 4, 8, 12, 16, 20 Weeks	20 weeks: <90 mm Hg, N=745	89.7 Percentage of participants
Olmesartan Medoxomil/Amlodipine Tablets + Hydrochlorothiazide	Percentage of Patients Achieving Seated Diastolic Blood Pressure Goal From Baseline to 4, 8, 12, 16, 20 Weeks	20 weeks: <85 mm Hg, N=745	79.5 Percentage of participants
Olmesartan Medoxomil/Amlodipine Tablets + Hydrochlorothiazide	Percentage of Patients Achieving Seated Diastolic Blood Pressure Goal From Baseline to 4, 8, 12, 16, 20 Weeks	20 weeks: <80 mm Hg, N=745	62.0 Percentage of participants

Secondary

Percentage of Patients Achieving Seated Diastolic Blood Pressure Reduction Ranges From Baseline to 4, 8, 12, 16, 20 Weeks

Time frame: Baseline to 4, 8, 12, 16, 20 weeks

Arm	Measure	Group	Value (NUMBER)
Olmesartan Medoxomil/Amlodipine Tablets + Hydrochlorothiazide	Percentage of Patients Achieving Seated Diastolic Blood Pressure Reduction Ranges From Baseline to 4, 8, 12, 16, 20 Weeks	4 weeks: ≤ 10 mm Hg, N=975	61.3 Percentage of Participants
Olmesartan Medoxomil/Amlodipine Tablets + Hydrochlorothiazide	Percentage of Patients Achieving Seated Diastolic Blood Pressure Reduction Ranges From Baseline to 4, 8, 12, 16, 20 Weeks	4 weeks: >10 and ≤ 15 mm Hg, N=975	21.0 Percentage of Participants
Olmesartan Medoxomil/Amlodipine Tablets + Hydrochlorothiazide	Percentage of Patients Achieving Seated Diastolic Blood Pressure Reduction Ranges From Baseline to 4, 8, 12, 16, 20 Weeks	4 weeks: >15 and ≤ 20 mm Hg, N=975	10.5 Percentage of Participants
Olmesartan Medoxomil/Amlodipine Tablets + Hydrochlorothiazide	Percentage of Patients Achieving Seated Diastolic Blood Pressure Reduction Ranges From Baseline to 4, 8, 12, 16, 20 Weeks	4 weeks: >20 mm Hg, N=975	7.2 Percentage of Participants
Olmesartan Medoxomil/Amlodipine Tablets + Hydrochlorothiazide	Percentage of Patients Achieving Seated Diastolic Blood Pressure Reduction Ranges From Baseline to 4, 8, 12, 16, 20 Weeks	8 weeks: ≤ 10 mm Hg, N=929	54.7 Percentage of Participants
Olmesartan Medoxomil/Amlodipine Tablets + Hydrochlorothiazide	Percentage of Patients Achieving Seated Diastolic Blood Pressure Reduction Ranges From Baseline to 4, 8, 12, 16, 20 Weeks	8 weeks: >10 and ≤ 15 mm Hg, N=929	20.7 Percentage of Participants
Olmesartan Medoxomil/Amlodipine Tablets + Hydrochlorothiazide	Percentage of Patients Achieving Seated Diastolic Blood Pressure Reduction Ranges From Baseline to 4, 8, 12, 16, 20 Weeks	8 weeks: >15 and ≤ 20 mm Hg, N=929	14.1 Percentage of Participants
Olmesartan Medoxomil/Amlodipine Tablets + Hydrochlorothiazide	Percentage of Patients Achieving Seated Diastolic Blood Pressure Reduction Ranges From Baseline to 4, 8, 12, 16, 20 Weeks	8 weeks: >20 mm Hg, N=929	10.6 Percentage of Participants
Olmesartan Medoxomil/Amlodipine Tablets + Hydrochlorothiazide	Percentage of Patients Achieving Seated Diastolic Blood Pressure Reduction Ranges From Baseline to 4, 8, 12, 16, 20 Weeks	12 weeks: ≤ 10 mm Hg, N=865	43.8 Percentage of Participants
Olmesartan Medoxomil/Amlodipine Tablets + Hydrochlorothiazide	Percentage of Patients Achieving Seated Diastolic Blood Pressure Reduction Ranges From Baseline to 4, 8, 12, 16, 20 Weeks	12 weeks: >10 and ≤ 15 mm Hg, N=865	24.1 Percentage of Participants
Olmesartan Medoxomil/Amlodipine Tablets + Hydrochlorothiazide	Percentage of Patients Achieving Seated Diastolic Blood Pressure Reduction Ranges From Baseline to 4, 8, 12, 16, 20 Weeks	12 weeks: >15 and ≤ 20 mm Hg, N=865	15.8 Percentage of Participants
Olmesartan Medoxomil/Amlodipine Tablets + Hydrochlorothiazide	Percentage of Patients Achieving Seated Diastolic Blood Pressure Reduction Ranges From Baseline to 4, 8, 12, 16, 20 Weeks	12 weeks: >20 mm Hg, N=865	16.3 Percentage of Participants
Olmesartan Medoxomil/Amlodipine Tablets + Hydrochlorothiazide	Percentage of Patients Achieving Seated Diastolic Blood Pressure Reduction Ranges From Baseline to 4, 8, 12, 16, 20 Weeks	16 weeks: ≤ 10 mm Hg, N=797	30.4 Percentage of Participants
Olmesartan Medoxomil/Amlodipine Tablets + Hydrochlorothiazide	Percentage of Patients Achieving Seated Diastolic Blood Pressure Reduction Ranges From Baseline to 4, 8, 12, 16, 20 Weeks	16 weeks: >10 and ≤ 15 mm Hg, N=797	22.8 Percentage of Participants
Olmesartan Medoxomil/Amlodipine Tablets + Hydrochlorothiazide	Percentage of Patients Achieving Seated Diastolic Blood Pressure Reduction Ranges From Baseline to 4, 8, 12, 16, 20 Weeks	16 weeks: >15 and ≤ 20 mm Hg, N=797	21.5 Percentage of Participants
Olmesartan Medoxomil/Amlodipine Tablets + Hydrochlorothiazide	Percentage of Patients Achieving Seated Diastolic Blood Pressure Reduction Ranges From Baseline to 4, 8, 12, 16, 20 Weeks	16 weeks: >20 mm Hg, N=797	25.4 Percentage of Participants
Olmesartan Medoxomil/Amlodipine Tablets + Hydrochlorothiazide	Percentage of Patients Achieving Seated Diastolic Blood Pressure Reduction Ranges From Baseline to 4, 8, 12, 16, 20 Weeks	20 weeks: ≤ 10 mm Hg, N=745	31.4 Percentage of Participants
Olmesartan Medoxomil/Amlodipine Tablets + Hydrochlorothiazide	Percentage of Patients Achieving Seated Diastolic Blood Pressure Reduction Ranges From Baseline to 4, 8, 12, 16, 20 Weeks	20 weeks: >10 and ≤ 15 mm Hg, N=745	19.9 Percentage of Participants
Olmesartan Medoxomil/Amlodipine Tablets + Hydrochlorothiazide	Percentage of Patients Achieving Seated Diastolic Blood Pressure Reduction Ranges From Baseline to 4, 8, 12, 16, 20 Weeks	20 weeks: >15 and ≤ 20 mm Hg, N=745	22.6 Percentage of Participants
Olmesartan Medoxomil/Amlodipine Tablets + Hydrochlorothiazide	Percentage of Patients Achieving Seated Diastolic Blood Pressure Reduction Ranges From Baseline to 4, 8, 12, 16, 20 Weeks	20 weeks: >20 mm Hg, N=745	26.2 Percentage of Participants

Secondary

Percentage of Patients Achieving Seated Systolic Blood Pressure Goal From Baseline to 4, 8, 12, 16, 20 Weeks

Time frame: Baseline to 4, 8, 12, 16, 20 weeks

Arm	Measure	Group	Value (NUMBER)
Olmesartan Medoxomil/Amlodipine Tablets + Hydrochlorothiazide	Percentage of Patients Achieving Seated Systolic Blood Pressure Goal From Baseline to 4, 8, 12, 16, 20 Weeks	4 weeks: <140 mm Hg, N=975	54.2 Percentage of Participants
Olmesartan Medoxomil/Amlodipine Tablets + Hydrochlorothiazide	Percentage of Patients Achieving Seated Systolic Blood Pressure Goal From Baseline to 4, 8, 12, 16, 20 Weeks	4 weeks: <135 mm Hg, N=975	39.8 Percentage of Participants
Olmesartan Medoxomil/Amlodipine Tablets + Hydrochlorothiazide	Percentage of Patients Achieving Seated Systolic Blood Pressure Goal From Baseline to 4, 8, 12, 16, 20 Weeks	4 weeks: <130 mm Hg, N=975	25.3 Percentage of Participants
Olmesartan Medoxomil/Amlodipine Tablets + Hydrochlorothiazide	Percentage of Patients Achieving Seated Systolic Blood Pressure Goal From Baseline to 4, 8, 12, 16, 20 Weeks	4 weeks: <120 mm Hg, N=975	8.9 Percentage of Participants
Olmesartan Medoxomil/Amlodipine Tablets + Hydrochlorothiazide	Percentage of Patients Achieving Seated Systolic Blood Pressure Goal From Baseline to 4, 8, 12, 16, 20 Weeks	8 weeks: <140 mm Hg, N=929	57.2 Percentage of Participants
Olmesartan Medoxomil/Amlodipine Tablets + Hydrochlorothiazide	Percentage of Patients Achieving Seated Systolic Blood Pressure Goal From Baseline to 4, 8, 12, 16, 20 Weeks	8 weeks: <135 mm Hg, N=929	45.9 Percentage of Participants
Olmesartan Medoxomil/Amlodipine Tablets + Hydrochlorothiazide	Percentage of Patients Achieving Seated Systolic Blood Pressure Goal From Baseline to 4, 8, 12, 16, 20 Weeks	8 weeks: <130 mm Hg, N=929	35.0 Percentage of Participants
Olmesartan Medoxomil/Amlodipine Tablets + Hydrochlorothiazide	Percentage of Patients Achieving Seated Systolic Blood Pressure Goal From Baseline to 4, 8, 12, 16, 20 Weeks	8 weeks: <120 mm Hg, N=929	12.9 Percentage of Participants
Olmesartan Medoxomil/Amlodipine Tablets + Hydrochlorothiazide	Percentage of Patients Achieving Seated Systolic Blood Pressure Goal From Baseline to 4, 8, 12, 16, 20 Weeks	12 weeks: <140 mm Hg, N=865	72.6 Percentage of Participants
Olmesartan Medoxomil/Amlodipine Tablets + Hydrochlorothiazide	Percentage of Patients Achieving Seated Systolic Blood Pressure Goal From Baseline to 4, 8, 12, 16, 20 Weeks	12 weeks: <135 mm Hg, N=865	59.0 Percentage of Participants
Olmesartan Medoxomil/Amlodipine Tablets + Hydrochlorothiazide	Percentage of Patients Achieving Seated Systolic Blood Pressure Goal From Baseline to 4, 8, 12, 16, 20 Weeks	12 weeks: <130 mm Hg, N=865	45.3 Percentage of Participants
Olmesartan Medoxomil/Amlodipine Tablets + Hydrochlorothiazide	Percentage of Patients Achieving Seated Systolic Blood Pressure Goal From Baseline to 4, 8, 12, 16, 20 Weeks	12 weeks: <120 mm Hg, N=865	19.4 Percentage of Participants
Olmesartan Medoxomil/Amlodipine Tablets + Hydrochlorothiazide	Percentage of Patients Achieving Seated Systolic Blood Pressure Goal From Baseline to 4, 8, 12, 16, 20 Weeks	16 weeks: <140 mm Hg, N=797	80.9 Percentage of Participants
Olmesartan Medoxomil/Amlodipine Tablets + Hydrochlorothiazide	Percentage of Patients Achieving Seated Systolic Blood Pressure Goal From Baseline to 4, 8, 12, 16, 20 Weeks	16 weeks: <135 mm Hg, N=797	70.3 Percentage of Participants
Olmesartan Medoxomil/Amlodipine Tablets + Hydrochlorothiazide	Percentage of Patients Achieving Seated Systolic Blood Pressure Goal From Baseline to 4, 8, 12, 16, 20 Weeks	16 weeks: <130 mm Hg, N=797	58.9 Percentage of Participants
Olmesartan Medoxomil/Amlodipine Tablets + Hydrochlorothiazide	Percentage of Patients Achieving Seated Systolic Blood Pressure Goal From Baseline to 4, 8, 12, 16, 20 Weeks	16 weeks: <120 mm Hg, N=797	30.9 Percentage of Participants
Olmesartan Medoxomil/Amlodipine Tablets + Hydrochlorothiazide	Percentage of Patients Achieving Seated Systolic Blood Pressure Goal From Baseline to 4, 8, 12, 16, 20 Weeks	20 weeks: <140 mm Hg, N=745	84.3 Percentage of Participants
Olmesartan Medoxomil/Amlodipine Tablets + Hydrochlorothiazide	Percentage of Patients Achieving Seated Systolic Blood Pressure Goal From Baseline to 4, 8, 12, 16, 20 Weeks	20 weeks: <135 mm Hg, N=745	75.2 Percentage of Participants
Olmesartan Medoxomil/Amlodipine Tablets + Hydrochlorothiazide	Percentage of Patients Achieving Seated Systolic Blood Pressure Goal From Baseline to 4, 8, 12, 16, 20 Weeks	20 weeks: <130 mm Hg, N=745	64.2 Percentage of Participants
Olmesartan Medoxomil/Amlodipine Tablets + Hydrochlorothiazide	Percentage of Patients Achieving Seated Systolic Blood Pressure Goal From Baseline to 4, 8, 12, 16, 20 Weeks	20 weeks: <120 mm Hg, N=745	31.5 Percentage of Participants

Secondary

Percentage of Patients Achieving Seated Systolic Blood Pressure Reduction Ranges From Baseline to 4, 8, 12, 16, 20 Weeks

Time frame: Baseline to 4, 8, 12, 16, 20 weeks

Arm	Measure	Group	Value (NUMBER)
Olmesartan Medoxomil/Amlodipine Tablets + Hydrochlorothiazide	Percentage of Patients Achieving Seated Systolic Blood Pressure Reduction Ranges From Baseline to 4, 8, 12, 16, 20 Weeks	4 weeks: ≤ 15 mm Hg, N=975	51.4 Percentage of Participants
Olmesartan Medoxomil/Amlodipine Tablets + Hydrochlorothiazide	Percentage of Patients Achieving Seated Systolic Blood Pressure Reduction Ranges From Baseline to 4, 8, 12, 16, 20 Weeks	4 weeks: >15 and ≤ 30 mm Hg, N=975	36.6 Percentage of Participants
Olmesartan Medoxomil/Amlodipine Tablets + Hydrochlorothiazide	Percentage of Patients Achieving Seated Systolic Blood Pressure Reduction Ranges From Baseline to 4, 8, 12, 16, 20 Weeks	4 weeks: >30 and ≤ 45 mm Hg, N=975	10.5 Percentage of Participants
Olmesartan Medoxomil/Amlodipine Tablets + Hydrochlorothiazide	Percentage of Patients Achieving Seated Systolic Blood Pressure Reduction Ranges From Baseline to 4, 8, 12, 16, 20 Weeks	4 weeks: >45 mm Hg, N=975	1.5 Percentage of Participants
Olmesartan Medoxomil/Amlodipine Tablets + Hydrochlorothiazide	Percentage of Patients Achieving Seated Systolic Blood Pressure Reduction Ranges From Baseline to 4, 8, 12, 16, 20 Weeks	8 weeks: ≤ 15 mm Hg, N=929	45.8 Percentage of Participants
Olmesartan Medoxomil/Amlodipine Tablets + Hydrochlorothiazide	Percentage of Patients Achieving Seated Systolic Blood Pressure Reduction Ranges From Baseline to 4, 8, 12, 16, 20 Weeks	8 weeks: >15 and ≤ 30 mm Hg, N=929	37.7 Percentage of Participants
Olmesartan Medoxomil/Amlodipine Tablets + Hydrochlorothiazide	Percentage of Patients Achieving Seated Systolic Blood Pressure Reduction Ranges From Baseline to 4, 8, 12, 16, 20 Weeks	8 weeks: >30 and ≤ 45 mm Hg, N=929	14.3 Percentage of Participants
Olmesartan Medoxomil/Amlodipine Tablets + Hydrochlorothiazide	Percentage of Patients Achieving Seated Systolic Blood Pressure Reduction Ranges From Baseline to 4, 8, 12, 16, 20 Weeks	8 weeks: >45 mm Hg, N=929	2.3 Percentage of Participants
Olmesartan Medoxomil/Amlodipine Tablets + Hydrochlorothiazide	Percentage of Patients Achieving Seated Systolic Blood Pressure Reduction Ranges From Baseline to 4, 8, 12, 16, 20 Weeks	12 weeks: ≤ 15 mm Hg, N=865	30.5 Percentage of Participants
Olmesartan Medoxomil/Amlodipine Tablets + Hydrochlorothiazide	Percentage of Patients Achieving Seated Systolic Blood Pressure Reduction Ranges From Baseline to 4, 8, 12, 16, 20 Weeks	12 weeks: >15 and ≤ 30 mm Hg, N=865	43.1 Percentage of Participants
Olmesartan Medoxomil/Amlodipine Tablets + Hydrochlorothiazide	Percentage of Patients Achieving Seated Systolic Blood Pressure Reduction Ranges From Baseline to 4, 8, 12, 16, 20 Weeks	12 weeks: >30 and ≤ 45 mm Hg, N=865	22.4 Percentage of Participants
Olmesartan Medoxomil/Amlodipine Tablets + Hydrochlorothiazide	Percentage of Patients Achieving Seated Systolic Blood Pressure Reduction Ranges From Baseline to 4, 8, 12, 16, 20 Weeks	12 weeks: >45 mm Hg, N=865	3.9 Percentage of Participants
Olmesartan Medoxomil/Amlodipine Tablets + Hydrochlorothiazide	Percentage of Patients Achieving Seated Systolic Blood Pressure Reduction Ranges From Baseline to 4, 8, 12, 16, 20 Weeks	16 weeks: ≤ 15 mm Hg, N=797	23.2 Percentage of Participants
Olmesartan Medoxomil/Amlodipine Tablets + Hydrochlorothiazide	Percentage of Patients Achieving Seated Systolic Blood Pressure Reduction Ranges From Baseline to 4, 8, 12, 16, 20 Weeks	16 weeks: >15 and ≤ 30 mm Hg, N=797	35.9 Percentage of Participants
Olmesartan Medoxomil/Amlodipine Tablets + Hydrochlorothiazide	Percentage of Patients Achieving Seated Systolic Blood Pressure Reduction Ranges From Baseline to 4, 8, 12, 16, 20 Weeks	16 weeks: >30 and ≤ 45 mm Hg, N=797	32.0 Percentage of Participants
Olmesartan Medoxomil/Amlodipine Tablets + Hydrochlorothiazide	Percentage of Patients Achieving Seated Systolic Blood Pressure Reduction Ranges From Baseline to 4, 8, 12, 16, 20 Weeks	16 weeks: >45 mm Hg, N=797	8.9 Percentage of Participants
Olmesartan Medoxomil/Amlodipine Tablets + Hydrochlorothiazide	Percentage of Patients Achieving Seated Systolic Blood Pressure Reduction Ranges From Baseline to 4, 8, 12, 16, 20 Weeks	20 weeks: ≤ 15 mm Hg, N=745	20.4 Percentage of Participants
Olmesartan Medoxomil/Amlodipine Tablets + Hydrochlorothiazide	Percentage of Patients Achieving Seated Systolic Blood Pressure Reduction Ranges From Baseline to 4, 8, 12, 16, 20 Weeks	20 weeks: >15 and ≤ 30 mm Hg, N=745	36.2 Percentage of Participants
Olmesartan Medoxomil/Amlodipine Tablets + Hydrochlorothiazide	Percentage of Patients Achieving Seated Systolic Blood Pressure Reduction Ranges From Baseline to 4, 8, 12, 16, 20 Weeks	20 weeks: >30 and ≤ 45 mm Hg, N=745	34.0 Percentage of Participants
Olmesartan Medoxomil/Amlodipine Tablets + Hydrochlorothiazide	Percentage of Patients Achieving Seated Systolic Blood Pressure Reduction Ranges From Baseline to 4, 8, 12, 16, 20 Weeks	20 weeks: >45 mm Hg, N=745	9.4 Percentage of Participants

Secondary

Percentage of Patients With Metabolic Syndrome Achieving Seated Diastolic Blood Pressure Goal From Baseline to 4, 8, 12, 16, 20 Weeks

Time frame: Baseline to 4, 8, 12, 16, 20 weeks

Population: Subjects with metabolic syndrome (MS) who have a baseline and at least 1 post-baseline measurement and who received at least one dose of study medication. The number may vary due to missing data and the number of dropouts. MS is defined using waist size,and triglyceride, cholesterol, blood pressure, and body mass index values.

Arm	Measure	Group	Value (NUMBER)
Olmesartan Medoxomil/Amlodipine Tablets + Hydrochlorothiazide	Percentage of Patients With Metabolic Syndrome Achieving Seated Diastolic Blood Pressure Goal From Baseline to 4, 8, 12, 16, 20 Weeks	12 weeks: <90 mm Hg, N=457	90.4 Percentage of Participants
Olmesartan Medoxomil/Amlodipine Tablets + Hydrochlorothiazide	Percentage of Patients With Metabolic Syndrome Achieving Seated Diastolic Blood Pressure Goal From Baseline to 4, 8, 12, 16, 20 Weeks	4 weeks: <90 mm Hg, N=454	69.6 Percentage of Participants
Olmesartan Medoxomil/Amlodipine Tablets + Hydrochlorothiazide	Percentage of Patients With Metabolic Syndrome Achieving Seated Diastolic Blood Pressure Goal From Baseline to 4, 8, 12, 16, 20 Weeks	4 weeks: <85 mm Hg, N=454	53.5 Percentage of Participants
Olmesartan Medoxomil/Amlodipine Tablets + Hydrochlorothiazide	Percentage of Patients With Metabolic Syndrome Achieving Seated Diastolic Blood Pressure Goal From Baseline to 4, 8, 12, 16, 20 Weeks	4 weeks: <80 mm Hg, N=454	31.9 Percentage of Participants
Olmesartan Medoxomil/Amlodipine Tablets + Hydrochlorothiazide	Percentage of Patients With Metabolic Syndrome Achieving Seated Diastolic Blood Pressure Goal From Baseline to 4, 8, 12, 16, 20 Weeks	8 weeks: <90 mm Hg, N=457	82.1 Percentage of Participants
Olmesartan Medoxomil/Amlodipine Tablets + Hydrochlorothiazide	Percentage of Patients With Metabolic Syndrome Achieving Seated Diastolic Blood Pressure Goal From Baseline to 4, 8, 12, 16, 20 Weeks	8 weeks: <85 mm Hg, N=457	66.1 Percentage of Participants
Olmesartan Medoxomil/Amlodipine Tablets + Hydrochlorothiazide	Percentage of Patients With Metabolic Syndrome Achieving Seated Diastolic Blood Pressure Goal From Baseline to 4, 8, 12, 16, 20 Weeks	8 weeks: <80 mm Hg, N=457	43.5 Percentage of Participants
Olmesartan Medoxomil/Amlodipine Tablets + Hydrochlorothiazide	Percentage of Patients With Metabolic Syndrome Achieving Seated Diastolic Blood Pressure Goal From Baseline to 4, 8, 12, 16, 20 Weeks	12 weeks: <85 mm Hg, N=457	76.6 Percentage of Participants
Olmesartan Medoxomil/Amlodipine Tablets + Hydrochlorothiazide	Percentage of Patients With Metabolic Syndrome Achieving Seated Diastolic Blood Pressure Goal From Baseline to 4, 8, 12, 16, 20 Weeks	12 weeks: <80 mm Hg, N=457	56.5 Percentage of Participants
Olmesartan Medoxomil/Amlodipine Tablets + Hydrochlorothiazide	Percentage of Patients With Metabolic Syndrome Achieving Seated Diastolic Blood Pressure Goal From Baseline to 4, 8, 12, 16, 20 Weeks	16 weeks: <90 mm Hg, N=457	94.8 Percentage of Participants
Olmesartan Medoxomil/Amlodipine Tablets + Hydrochlorothiazide	Percentage of Patients With Metabolic Syndrome Achieving Seated Diastolic Blood Pressure Goal From Baseline to 4, 8, 12, 16, 20 Weeks	16 weeks: <85 mm Hg, N=457	83.2 Percentage of Participants
Olmesartan Medoxomil/Amlodipine Tablets + Hydrochlorothiazide	Percentage of Patients With Metabolic Syndrome Achieving Seated Diastolic Blood Pressure Goal From Baseline to 4, 8, 12, 16, 20 Weeks	16 weeks: <80 mm Hg, N=457	65.9 Percentage of Participants
Olmesartan Medoxomil/Amlodipine Tablets + Hydrochlorothiazide	Percentage of Patients With Metabolic Syndrome Achieving Seated Diastolic Blood Pressure Goal From Baseline to 4, 8, 12, 16, 20 Weeks	20 weeks: <90 mm Hg, N=457	95.4 Percentage of Participants
Olmesartan Medoxomil/Amlodipine Tablets + Hydrochlorothiazide	Percentage of Patients With Metabolic Syndrome Achieving Seated Diastolic Blood Pressure Goal From Baseline to 4, 8, 12, 16, 20 Weeks	20 weeks: <85 mm Hg, N=457	86.2 Percentage of Participants
Olmesartan Medoxomil/Amlodipine Tablets + Hydrochlorothiazide	Percentage of Patients With Metabolic Syndrome Achieving Seated Diastolic Blood Pressure Goal From Baseline to 4, 8, 12, 16, 20 Weeks	20 weeks: <80 mm Hg, N=457	72.0 Percentage of Participants

Secondary

Percentage of Patients With Metabolic Syndrome Achieving Seated Diastolic Blood Pressure Reduction Ranges From Baseline to 4, 8, 12, 16, 20 Weeks

Time frame: Baseline to 4, 8, 12, 16, 20 weeks

Arm	Measure	Group	Value (NUMBER)
Olmesartan Medoxomil/Amlodipine Tablets + Hydrochlorothiazide	Percentage of Patients With Metabolic Syndrome Achieving Seated Diastolic Blood Pressure Reduction Ranges From Baseline to 4, 8, 12, 16, 20 Weeks	4 weeks: ≤ 10 mm Hg, N=453	62.7 Percentage of Participants
Olmesartan Medoxomil/Amlodipine Tablets + Hydrochlorothiazide	Percentage of Patients With Metabolic Syndrome Achieving Seated Diastolic Blood Pressure Reduction Ranges From Baseline to 4, 8, 12, 16, 20 Weeks	4 weeks: >10 and ≤ 15 mm Hg, N=453	22.3 Percentage of Participants
Olmesartan Medoxomil/Amlodipine Tablets + Hydrochlorothiazide	Percentage of Patients With Metabolic Syndrome Achieving Seated Diastolic Blood Pressure Reduction Ranges From Baseline to 4, 8, 12, 16, 20 Weeks	4 weeks: >15 and ≤ 20 mm Hg, N=453	8.6 Percentage of Participants
Olmesartan Medoxomil/Amlodipine Tablets + Hydrochlorothiazide	Percentage of Patients With Metabolic Syndrome Achieving Seated Diastolic Blood Pressure Reduction Ranges From Baseline to 4, 8, 12, 16, 20 Weeks	4 weeks: >20 mm Hg, N=453	6.4 Percentage of Participants
Olmesartan Medoxomil/Amlodipine Tablets + Hydrochlorothiazide	Percentage of Patients With Metabolic Syndrome Achieving Seated Diastolic Blood Pressure Reduction Ranges From Baseline to 4, 8, 12, 16, 20 Weeks	8 weeks: ≤ 10 mm Hg, N=431	56.6 Percentage of Participants
Olmesartan Medoxomil/Amlodipine Tablets + Hydrochlorothiazide	Percentage of Patients With Metabolic Syndrome Achieving Seated Diastolic Blood Pressure Reduction Ranges From Baseline to 4, 8, 12, 16, 20 Weeks	8 weeks: >10 and ≤ 15 mm Hg, N=431	19.7 Percentage of Participants
Olmesartan Medoxomil/Amlodipine Tablets + Hydrochlorothiazide	Percentage of Patients With Metabolic Syndrome Achieving Seated Diastolic Blood Pressure Reduction Ranges From Baseline to 4, 8, 12, 16, 20 Weeks	8 weeks: >15 and ≤ 20 mm Hg, N=431	15.3 Percentage of Participants
Olmesartan Medoxomil/Amlodipine Tablets + Hydrochlorothiazide	Percentage of Patients With Metabolic Syndrome Achieving Seated Diastolic Blood Pressure Reduction Ranges From Baseline to 4, 8, 12, 16, 20 Weeks	8 weeks: >20 mm Hg, N=431	8.4 Percentage of Participants
Olmesartan Medoxomil/Amlodipine Tablets + Hydrochlorothiazide	Percentage of Patients With Metabolic Syndrome Achieving Seated Diastolic Blood Pressure Reduction Ranges From Baseline to 4, 8, 12, 16, 20 Weeks	12 weeks: ≤ 10 mm Hg, N=402	44.3 Percentage of Participants
Olmesartan Medoxomil/Amlodipine Tablets + Hydrochlorothiazide	Percentage of Patients With Metabolic Syndrome Achieving Seated Diastolic Blood Pressure Reduction Ranges From Baseline to 4, 8, 12, 16, 20 Weeks	12 weeks: >10 and ≤15 mm Hg, N=402	22.1 Percentage of Participants
Olmesartan Medoxomil/Amlodipine Tablets + Hydrochlorothiazide	Percentage of Patients With Metabolic Syndrome Achieving Seated Diastolic Blood Pressure Reduction Ranges From Baseline to 4, 8, 12, 16, 20 Weeks	12 weeks: >15 and ≤ 20 mm Hg, N=402	17.4 Percentage of Participants
Olmesartan Medoxomil/Amlodipine Tablets + Hydrochlorothiazide	Percentage of Patients With Metabolic Syndrome Achieving Seated Diastolic Blood Pressure Reduction Ranges From Baseline to 4, 8, 12, 16, 20 Weeks	12 weeks: >20 mm Hg, N=402	16.2 Percentage of Participants
Olmesartan Medoxomil/Amlodipine Tablets + Hydrochlorothiazide	Percentage of Patients With Metabolic Syndrome Achieving Seated Diastolic Blood Pressure Reduction Ranges From Baseline to 4, 8, 12, 16, 20 Weeks	16 weeks: ≤ 10 mm Hg, N=371	32.4 Percentage of Participants
Olmesartan Medoxomil/Amlodipine Tablets + Hydrochlorothiazide	Percentage of Patients With Metabolic Syndrome Achieving Seated Diastolic Blood Pressure Reduction Ranges From Baseline to 4, 8, 12, 16, 20 Weeks	16 weeks: >10 and ≤ 15 mm Hg, N=371	24.0 Percentage of Participants
Olmesartan Medoxomil/Amlodipine Tablets + Hydrochlorothiazide	Percentage of Patients With Metabolic Syndrome Achieving Seated Diastolic Blood Pressure Reduction Ranges From Baseline to 4, 8, 12, 16, 20 Weeks	16 weeks: >15 and ≤ 20 mm Hg, N=371	21.0 Percentage of Participants
Olmesartan Medoxomil/Amlodipine Tablets + Hydrochlorothiazide	Percentage of Patients With Metabolic Syndrome Achieving Seated Diastolic Blood Pressure Reduction Ranges From Baseline to 4, 8, 12, 16, 20 Weeks	16 weeks: >20 mm Hg, N=371	22.6 Percentage of Participants
Olmesartan Medoxomil/Amlodipine Tablets + Hydrochlorothiazide	Percentage of Patients With Metabolic Syndrome Achieving Seated Diastolic Blood Pressure Reduction Ranges From Baseline to 4, 8, 12, 16, 20 Weeks	20 weeks: ≤ 10 mm Hg, N=356	33.2 Percentage of Participants
Olmesartan Medoxomil/Amlodipine Tablets + Hydrochlorothiazide	Percentage of Patients With Metabolic Syndrome Achieving Seated Diastolic Blood Pressure Reduction Ranges From Baseline to 4, 8, 12, 16, 20 Weeks	20 weeks: >10 and ≤ 15 mm Hg, N=356	19.4 Percentage of Participants
Olmesartan Medoxomil/Amlodipine Tablets + Hydrochlorothiazide	Percentage of Patients With Metabolic Syndrome Achieving Seated Diastolic Blood Pressure Reduction Ranges From Baseline to 4, 8, 12, 16, 20 Weeks	20 weeks: >15 and ≤ 20 mm Hg, N=356	22.5 Percentage of Participants
Olmesartan Medoxomil/Amlodipine Tablets + Hydrochlorothiazide	Percentage of Patients With Metabolic Syndrome Achieving Seated Diastolic Blood Pressure Reduction Ranges From Baseline to 4, 8, 12, 16, 20 Weeks	20 weeks: >20 mm Hg, N=356	25.0 Percentage of Participants

Secondary

Percentage of Patients With Metabolic Syndrome Achieving Seated Systolic Blood Pressure Goal From Baseline to 4, 8, 12, 16, 20 Weeks

Time frame: Baseline to 4, 8, 12, 16, 20 weeks

Arm	Measure	Group	Value (NUMBER)
Olmesartan Medoxomil/Amlodipine Tablets + Hydrochlorothiazide	Percentage of Patients With Metabolic Syndrome Achieving Seated Systolic Blood Pressure Goal From Baseline to 4, 8, 12, 16, 20 Weeks	4 weeks: <140 mm Hg, N=454	56.4 Percentage of Participants
Olmesartan Medoxomil/Amlodipine Tablets + Hydrochlorothiazide	Percentage of Patients With Metabolic Syndrome Achieving Seated Systolic Blood Pressure Goal From Baseline to 4, 8, 12, 16, 20 Weeks	4 weeks: <135 mm Hg, N=454	41.4 Percentage of Participants
Olmesartan Medoxomil/Amlodipine Tablets + Hydrochlorothiazide	Percentage of Patients With Metabolic Syndrome Achieving Seated Systolic Blood Pressure Goal From Baseline to 4, 8, 12, 16, 20 Weeks	4 weeks: <130 mm Hg, N=454	27.1 Percentage of Participants
Olmesartan Medoxomil/Amlodipine Tablets + Hydrochlorothiazide	Percentage of Patients With Metabolic Syndrome Achieving Seated Systolic Blood Pressure Goal From Baseline to 4, 8, 12, 16, 20 Weeks	4 weeks: <120 mm Hg, N=454	7.9 Percentage of Participants
Olmesartan Medoxomil/Amlodipine Tablets + Hydrochlorothiazide	Percentage of Patients With Metabolic Syndrome Achieving Seated Systolic Blood Pressure Goal From Baseline to 4, 8, 12, 16, 20 Weeks	8 weeks: <140 mm Hg, N=457	67.6 Percentage of Participants
Olmesartan Medoxomil/Amlodipine Tablets + Hydrochlorothiazide	Percentage of Patients With Metabolic Syndrome Achieving Seated Systolic Blood Pressure Goal From Baseline to 4, 8, 12, 16, 20 Weeks	8 weeks: <135 mm Hg, N=457	54.3 Percentage of Participants
Olmesartan Medoxomil/Amlodipine Tablets + Hydrochlorothiazide	Percentage of Patients With Metabolic Syndrome Achieving Seated Systolic Blood Pressure Goal From Baseline to 4, 8, 12, 16, 20 Weeks	8 weeks: <130 mm Hg, N=457	40.9 Percentage of Participants
Olmesartan Medoxomil/Amlodipine Tablets + Hydrochlorothiazide	Percentage of Patients With Metabolic Syndrome Achieving Seated Systolic Blood Pressure Goal From Baseline to 4, 8, 12, 16, 20 Weeks	8 weeks: <120 mm Hg, N=457	16.2 Percentage of Participants
Olmesartan Medoxomil/Amlodipine Tablets + Hydrochlorothiazide	Percentage of Patients With Metabolic Syndrome Achieving Seated Systolic Blood Pressure Goal From Baseline to 4, 8, 12, 16, 20 Weeks	12 weeks: <140 mm Hg, N=457	81.4 Percentage of Participants
Olmesartan Medoxomil/Amlodipine Tablets + Hydrochlorothiazide	Percentage of Patients With Metabolic Syndrome Achieving Seated Systolic Blood Pressure Goal From Baseline to 4, 8, 12, 16, 20 Weeks	12 weeks: <135 mm Hg, N=457	67.2 Percentage of Participants
Olmesartan Medoxomil/Amlodipine Tablets + Hydrochlorothiazide	Percentage of Patients With Metabolic Syndrome Achieving Seated Systolic Blood Pressure Goal From Baseline to 4, 8, 12, 16, 20 Weeks	12 weeks: <130 mm Hg, N=457	54.1 Percentage of Participants
Olmesartan Medoxomil/Amlodipine Tablets + Hydrochlorothiazide	Percentage of Patients With Metabolic Syndrome Achieving Seated Systolic Blood Pressure Goal From Baseline to 4, 8, 12, 16, 20 Weeks	12 weeks: <120 mm Hg, N=457	27.6 Percentage of Participants
Olmesartan Medoxomil/Amlodipine Tablets + Hydrochlorothiazide	Percentage of Patients With Metabolic Syndrome Achieving Seated Systolic Blood Pressure Goal From Baseline to 4, 8, 12, 16, 20 Weeks	16 weeks: <140 mm Hg, N=457	88.8 Percentage of Participants
Olmesartan Medoxomil/Amlodipine Tablets + Hydrochlorothiazide	Percentage of Patients With Metabolic Syndrome Achieving Seated Systolic Blood Pressure Goal From Baseline to 4, 8, 12, 16, 20 Weeks	16 weeks: <135 mm Hg, N=457	80.3 Percentage of Participants
Olmesartan Medoxomil/Amlodipine Tablets + Hydrochlorothiazide	Percentage of Patients With Metabolic Syndrome Achieving Seated Systolic Blood Pressure Goal From Baseline to 4, 8, 12, 16, 20 Weeks	16 weeks: <130 mm Hg, N=457	67.0 Percentage of Participants
Olmesartan Medoxomil/Amlodipine Tablets + Hydrochlorothiazide	Percentage of Patients With Metabolic Syndrome Achieving Seated Systolic Blood Pressure Goal From Baseline to 4, 8, 12, 16, 20 Weeks	16 weeks: <120 mm Hg, N=457	39.0 Percentage of Participants
Olmesartan Medoxomil/Amlodipine Tablets + Hydrochlorothiazide	Percentage of Patients With Metabolic Syndrome Achieving Seated Systolic Blood Pressure Goal From Baseline to 4, 8, 12, 16, 20 Weeks	20 weeks: <140 mm Hg, N=457	91.5 Percentage of Participants
Olmesartan Medoxomil/Amlodipine Tablets + Hydrochlorothiazide	Percentage of Patients With Metabolic Syndrome Achieving Seated Systolic Blood Pressure Goal From Baseline to 4, 8, 12, 16, 20 Weeks	20 weeks: <135 mm Hg, N=457	85.6 Percentage of Participants
Olmesartan Medoxomil/Amlodipine Tablets + Hydrochlorothiazide	Percentage of Patients With Metabolic Syndrome Achieving Seated Systolic Blood Pressure Goal From Baseline to 4, 8, 12, 16, 20 Weeks	20 weeks: <130 mm Hg, N=457	74.8 Percentage of Participants
Olmesartan Medoxomil/Amlodipine Tablets + Hydrochlorothiazide	Percentage of Patients With Metabolic Syndrome Achieving Seated Systolic Blood Pressure Goal From Baseline to 4, 8, 12, 16, 20 Weeks	20 weeks: <120 mm Hg, N=457	47.1 Percentage of Participants

Secondary

Percentage of Patients With Metabolic Syndrome Achieving Seated Systolic Blood Pressure Reduction Ranges From Baseline to 4, 8, 12, 16, 20 Weeks

Time frame: Baseline to 4, 8, 12, 16, 20 weeks

Arm	Measure	Group	Value (NUMBER)
Olmesartan Medoxomil/Amlodipine Tablets + Hydrochlorothiazide	Percentage of Patients With Metabolic Syndrome Achieving Seated Systolic Blood Pressure Reduction Ranges From Baseline to 4, 8, 12, 16, 20 Weeks	12 weeks: >30 and ≤ 45 mm Hg, N=402	22.6 Percentage of Participants
Olmesartan Medoxomil/Amlodipine Tablets + Hydrochlorothiazide	Percentage of Patients With Metabolic Syndrome Achieving Seated Systolic Blood Pressure Reduction Ranges From Baseline to 4, 8, 12, 16, 20 Weeks	12 weeks: >45 mm Hg, N=402	3.2 Percentage of Participants
Olmesartan Medoxomil/Amlodipine Tablets + Hydrochlorothiazide	Percentage of Patients With Metabolic Syndrome Achieving Seated Systolic Blood Pressure Reduction Ranges From Baseline to 4, 8, 12, 16, 20 Weeks	4 weeks: ≤ 15 mm Hg, N=453	49.5 Percentage of Participants
Olmesartan Medoxomil/Amlodipine Tablets + Hydrochlorothiazide	Percentage of Patients With Metabolic Syndrome Achieving Seated Systolic Blood Pressure Reduction Ranges From Baseline to 4, 8, 12, 16, 20 Weeks	4 weeks: >15 and ≤ 30 mm Hg, N=453	38.4 Percentage of Participants
Olmesartan Medoxomil/Amlodipine Tablets + Hydrochlorothiazide	Percentage of Patients With Metabolic Syndrome Achieving Seated Systolic Blood Pressure Reduction Ranges From Baseline to 4, 8, 12, 16, 20 Weeks	4 weeks: >30 and ≤ 45 mm Hg, N=453	11.5 Percentage of Participants
Olmesartan Medoxomil/Amlodipine Tablets + Hydrochlorothiazide	Percentage of Patients With Metabolic Syndrome Achieving Seated Systolic Blood Pressure Reduction Ranges From Baseline to 4, 8, 12, 16, 20 Weeks	4 weeks: >45 mm Hg, N=453	0.7 Percentage of Participants
Olmesartan Medoxomil/Amlodipine Tablets + Hydrochlorothiazide	Percentage of Patients With Metabolic Syndrome Achieving Seated Systolic Blood Pressure Reduction Ranges From Baseline to 4, 8, 12, 16, 20 Weeks	8 weeks: ≤ 15 mm Hg, N=431	48.0 Percentage of Participants
Olmesartan Medoxomil/Amlodipine Tablets + Hydrochlorothiazide	Percentage of Patients With Metabolic Syndrome Achieving Seated Systolic Blood Pressure Reduction Ranges From Baseline to 4, 8, 12, 16, 20 Weeks	8 weeks: >15 and ≤ 30 mm Hg, N=431	35.5 Percentage of Participants
Olmesartan Medoxomil/Amlodipine Tablets + Hydrochlorothiazide	Percentage of Patients With Metabolic Syndrome Achieving Seated Systolic Blood Pressure Reduction Ranges From Baseline to 4, 8, 12, 16, 20 Weeks	8 weeks: >30 and ≤ 45 mm Hg, N=431	14.4 Percentage of Participants
Olmesartan Medoxomil/Amlodipine Tablets + Hydrochlorothiazide	Percentage of Patients With Metabolic Syndrome Achieving Seated Systolic Blood Pressure Reduction Ranges From Baseline to 4, 8, 12, 16, 20 Weeks	8 weeks: >45 mm Hg, N=431	2.1 Percentage of Participants
Olmesartan Medoxomil/Amlodipine Tablets + Hydrochlorothiazide	Percentage of Patients With Metabolic Syndrome Achieving Seated Systolic Blood Pressure Reduction Ranges From Baseline to 4, 8, 12, 16, 20 Weeks	12 weeks: ≤ 15 mm Hg, N=402	30.4 Percentage of Participants
Olmesartan Medoxomil/Amlodipine Tablets + Hydrochlorothiazide	Percentage of Patients With Metabolic Syndrome Achieving Seated Systolic Blood Pressure Reduction Ranges From Baseline to 4, 8, 12, 16, 20 Weeks	12 weeks: >15 and ≤ 30 mm Hg, N=402	43.8 Percentage of Participants
Olmesartan Medoxomil/Amlodipine Tablets + Hydrochlorothiazide	Percentage of Patients With Metabolic Syndrome Achieving Seated Systolic Blood Pressure Reduction Ranges From Baseline to 4, 8, 12, 16, 20 Weeks	16 weeks: ≤ 15 mm Hg, N=371	24.0 Percentage of Participants
Olmesartan Medoxomil/Amlodipine Tablets + Hydrochlorothiazide	Percentage of Patients With Metabolic Syndrome Achieving Seated Systolic Blood Pressure Reduction Ranges From Baseline to 4, 8, 12, 16, 20 Weeks	16 weeks: >15 and ≤ 30 mm Hg, N=371	37.7 Percentage of Participants
Olmesartan Medoxomil/Amlodipine Tablets + Hydrochlorothiazide	Percentage of Patients With Metabolic Syndrome Achieving Seated Systolic Blood Pressure Reduction Ranges From Baseline to 4, 8, 12, 16, 20 Weeks	16 weeks: >30 and ≤ 45 mm Hg, N=371	29.1 Percentage of Participants
Olmesartan Medoxomil/Amlodipine Tablets + Hydrochlorothiazide	Percentage of Patients With Metabolic Syndrome Achieving Seated Systolic Blood Pressure Reduction Ranges From Baseline to 4, 8, 12, 16, 20 Weeks	16 weeks: >45 mm Hg, N=371	9.2 Percentage of Participants
Olmesartan Medoxomil/Amlodipine Tablets + Hydrochlorothiazide	Percentage of Patients With Metabolic Syndrome Achieving Seated Systolic Blood Pressure Reduction Ranges From Baseline to 4, 8, 12, 16, 20 Weeks	20 weeks: ≤ 15 mm Hg, N=356	19.7 Percentage of Participants
Olmesartan Medoxomil/Amlodipine Tablets + Hydrochlorothiazide	Percentage of Patients With Metabolic Syndrome Achieving Seated Systolic Blood Pressure Reduction Ranges From Baseline to 4, 8, 12, 16, 20 Weeks	20 weeks: >15 and ≤ 30 mm Hg, N=356	36.5 Percentage of Participants
Olmesartan Medoxomil/Amlodipine Tablets + Hydrochlorothiazide	Percentage of Patients With Metabolic Syndrome Achieving Seated Systolic Blood Pressure Reduction Ranges From Baseline to 4, 8, 12, 16, 20 Weeks	20 weeks: >30 and ≤ 45 mm Hg, N=356	36.0 Percentage of Participants
Olmesartan Medoxomil/Amlodipine Tablets + Hydrochlorothiazide	Percentage of Patients With Metabolic Syndrome Achieving Seated Systolic Blood Pressure Reduction Ranges From Baseline to 4, 8, 12, 16, 20 Weeks	20 weeks: >45 mm Hg, N=356	7.9 Percentage of Participants

Secondary

Percentage of Type 2 Diabetic Patients Achieving Seated Diastolic Blood Pressure Goal From Baseline to 4, 8, 12, 16, 20 Weeks

Time frame: Baseline to 4, 8, 12, 16, 20 weeks

Population: The analysis population consists of those type 2 diabetic participants who have a baseline and at least 1 post-baseline measurement and who received at least one dose of study medication. However, the number of participants included may vary because of missing data and the number of dropouts.

Arm	Measure	Group	Value (NUMBER)
Olmesartan Medoxomil/Amlodipine Tablets + Hydrochlorothiazide	Percentage of Type 2 Diabetic Patients Achieving Seated Diastolic Blood Pressure Goal From Baseline to 4, 8, 12, 16, 20 Weeks	20 weeks: <85 mm Hg, N=190	90.5 Percentage of Participants
Olmesartan Medoxomil/Amlodipine Tablets + Hydrochlorothiazide	Percentage of Type 2 Diabetic Patients Achieving Seated Diastolic Blood Pressure Goal From Baseline to 4, 8, 12, 16, 20 Weeks	20 weeks: <80 mm Hg, N=190	76.8 Percentage of Participants
Olmesartan Medoxomil/Amlodipine Tablets + Hydrochlorothiazide	Percentage of Type 2 Diabetic Patients Achieving Seated Diastolic Blood Pressure Goal From Baseline to 4, 8, 12, 16, 20 Weeks	4 weeks: <90 mm Hg, N=190	75.8 Percentage of Participants
Olmesartan Medoxomil/Amlodipine Tablets + Hydrochlorothiazide	Percentage of Type 2 Diabetic Patients Achieving Seated Diastolic Blood Pressure Goal From Baseline to 4, 8, 12, 16, 20 Weeks	4 weeks: <85 mm Hg, N=190	64.2 Percentage of Participants
Olmesartan Medoxomil/Amlodipine Tablets + Hydrochlorothiazide	Percentage of Type 2 Diabetic Patients Achieving Seated Diastolic Blood Pressure Goal From Baseline to 4, 8, 12, 16, 20 Weeks	4 weeks: <80 mm Hg, N=190	39.0 Percentage of Participants
Olmesartan Medoxomil/Amlodipine Tablets + Hydrochlorothiazide	Percentage of Type 2 Diabetic Patients Achieving Seated Diastolic Blood Pressure Goal From Baseline to 4, 8, 12, 16, 20 Weeks	8 weeks: <90 mm Hg, N=190	85.8 Percentage of Participants
Olmesartan Medoxomil/Amlodipine Tablets + Hydrochlorothiazide	Percentage of Type 2 Diabetic Patients Achieving Seated Diastolic Blood Pressure Goal From Baseline to 4, 8, 12, 16, 20 Weeks	8 weeks: <85 mm Hg, N=190	72.6 Percentage of Participants
Olmesartan Medoxomil/Amlodipine Tablets + Hydrochlorothiazide	Percentage of Type 2 Diabetic Patients Achieving Seated Diastolic Blood Pressure Goal From Baseline to 4, 8, 12, 16, 20 Weeks	8 weeks: <80 mm Hg, N=190	51.1 Percentage of Participants
Olmesartan Medoxomil/Amlodipine Tablets + Hydrochlorothiazide	Percentage of Type 2 Diabetic Patients Achieving Seated Diastolic Blood Pressure Goal From Baseline to 4, 8, 12, 16, 20 Weeks	12 weeks: <90 mm Hg, N=190	94.2 Percentage of Participants
Olmesartan Medoxomil/Amlodipine Tablets + Hydrochlorothiazide	Percentage of Type 2 Diabetic Patients Achieving Seated Diastolic Blood Pressure Goal From Baseline to 4, 8, 12, 16, 20 Weeks	12 weeks: <85 mm Hg, N=190	83.2 Percentage of Participants
Olmesartan Medoxomil/Amlodipine Tablets + Hydrochlorothiazide	Percentage of Type 2 Diabetic Patients Achieving Seated Diastolic Blood Pressure Goal From Baseline to 4, 8, 12, 16, 20 Weeks	12 weeks: <80 mm Hg, N=190	63.7 Percentage of Participants
Olmesartan Medoxomil/Amlodipine Tablets + Hydrochlorothiazide	Percentage of Type 2 Diabetic Patients Achieving Seated Diastolic Blood Pressure Goal From Baseline to 4, 8, 12, 16, 20 Weeks	16 weeks: <90 mm Hg, N=190	97.9 Percentage of Participants
Olmesartan Medoxomil/Amlodipine Tablets + Hydrochlorothiazide	Percentage of Type 2 Diabetic Patients Achieving Seated Diastolic Blood Pressure Goal From Baseline to 4, 8, 12, 16, 20 Weeks	16 weeks: <85 mm Hg, N=190	89.0 Percentage of Participants
Olmesartan Medoxomil/Amlodipine Tablets + Hydrochlorothiazide	Percentage of Type 2 Diabetic Patients Achieving Seated Diastolic Blood Pressure Goal From Baseline to 4, 8, 12, 16, 20 Weeks	16 weeks: <80 mm Hg, N=190	70.5 Percentage of Participants
Olmesartan Medoxomil/Amlodipine Tablets + Hydrochlorothiazide	Percentage of Type 2 Diabetic Patients Achieving Seated Diastolic Blood Pressure Goal From Baseline to 4, 8, 12, 16, 20 Weeks	20 weeks: <90 mm Hg, N=190	99.0 Percentage of Participants

Secondary

Percentage of Type 2 Diabetic Patients Achieving Seated Diastolic Blood Pressure Reduction Ranges From Baseline to 4, 8, 12, 16, 20 Weeks

Time frame: Baseline to 4, 8, 12, 16, 20 weeks

Population: The analysis population consists of those type 2 diabetic participants who have a baseline and at least 1 post-baseline measurement and who received at least one dose of study medication. However, the number of participants included will vary because of missing data and the number of dropouts.

Arm	Measure	Group	Value (NUMBER)
Olmesartan Medoxomil/Amlodipine Tablets + Hydrochlorothiazide	Percentage of Type 2 Diabetic Patients Achieving Seated Diastolic Blood Pressure Reduction Ranges From Baseline to 4, 8, 12, 16, 20 Weeks	4 weeks: ≤ 10 mm Hg, N=189	67.7 Percentage of Participants
Olmesartan Medoxomil/Amlodipine Tablets + Hydrochlorothiazide	Percentage of Type 2 Diabetic Patients Achieving Seated Diastolic Blood Pressure Reduction Ranges From Baseline to 4, 8, 12, 16, 20 Weeks	4 weeks: >10 and ≤ 15 mm Hg, N=189	16.9 Percentage of Participants
Olmesartan Medoxomil/Amlodipine Tablets + Hydrochlorothiazide	Percentage of Type 2 Diabetic Patients Achieving Seated Diastolic Blood Pressure Reduction Ranges From Baseline to 4, 8, 12, 16, 20 Weeks	4 weeks: >15 and ≤ 20 mm Hg, N=189	11.6 Percentage of Participants
Olmesartan Medoxomil/Amlodipine Tablets + Hydrochlorothiazide	Percentage of Type 2 Diabetic Patients Achieving Seated Diastolic Blood Pressure Reduction Ranges From Baseline to 4, 8, 12, 16, 20 Weeks	4 weeks: >20 mm Hg, N=189	3.7 Percentage of Participants
Olmesartan Medoxomil/Amlodipine Tablets + Hydrochlorothiazide	Percentage of Type 2 Diabetic Patients Achieving Seated Diastolic Blood Pressure Reduction Ranges From Baseline to 4, 8, 12, 16, 20 Weeks	8 weeks: ≤ 10 mm Hg, N=181	60.8 Percentage of Participants
Olmesartan Medoxomil/Amlodipine Tablets + Hydrochlorothiazide	Percentage of Type 2 Diabetic Patients Achieving Seated Diastolic Blood Pressure Reduction Ranges From Baseline to 4, 8, 12, 16, 20 Weeks	8 weeks: >10 and ≤ 15 mm Hg, N=181	20.4 Percentage of Participants
Olmesartan Medoxomil/Amlodipine Tablets + Hydrochlorothiazide	Percentage of Type 2 Diabetic Patients Achieving Seated Diastolic Blood Pressure Reduction Ranges From Baseline to 4, 8, 12, 16, 20 Weeks	8 weeks: >15 and ≤ 20 mm Hg, N=181	14.9 Percentage of Participants
Olmesartan Medoxomil/Amlodipine Tablets + Hydrochlorothiazide	Percentage of Type 2 Diabetic Patients Achieving Seated Diastolic Blood Pressure Reduction Ranges From Baseline to 4, 8, 12, 16, 20 Weeks	8 weeks: >20 mm Hg, N=181	3.9 Percentage of Participants
Olmesartan Medoxomil/Amlodipine Tablets + Hydrochlorothiazide	Percentage of Type 2 Diabetic Patients Achieving Seated Diastolic Blood Pressure Reduction Ranges From Baseline to 4, 8, 12, 16, 20 Weeks	12 weeks: ≤ 10 mm Hg, N=170	41.2 Percentage of Participants
Olmesartan Medoxomil/Amlodipine Tablets + Hydrochlorothiazide	Percentage of Type 2 Diabetic Patients Achieving Seated Diastolic Blood Pressure Reduction Ranges From Baseline to 4, 8, 12, 16, 20 Weeks	12 weeks: >10 and ≤15 mm Hg, N=170	32.4 Percentage of Participants
Olmesartan Medoxomil/Amlodipine Tablets + Hydrochlorothiazide	Percentage of Type 2 Diabetic Patients Achieving Seated Diastolic Blood Pressure Reduction Ranges From Baseline to 4, 8, 12, 16, 20 Weeks	12 weeks: >15 and ≤ 20 mm Hg, N=170	12.9 Percentage of Participants
Olmesartan Medoxomil/Amlodipine Tablets + Hydrochlorothiazide	Percentage of Type 2 Diabetic Patients Achieving Seated Diastolic Blood Pressure Reduction Ranges From Baseline to 4, 8, 12, 16, 20 Weeks	12 weeks: >20 mm Hg, N=170	13.5 Percentage of Participants
Olmesartan Medoxomil/Amlodipine Tablets + Hydrochlorothiazide	Percentage of Type 2 Diabetic Patients Achieving Seated Diastolic Blood Pressure Reduction Ranges From Baseline to 4, 8, 12, 16, 20 Weeks	16 weeks: ≤ 10 mm Hg, N=156	32.7 Percentage of Participants
Olmesartan Medoxomil/Amlodipine Tablets + Hydrochlorothiazide	Percentage of Type 2 Diabetic Patients Achieving Seated Diastolic Blood Pressure Reduction Ranges From Baseline to 4, 8, 12, 16, 20 Weeks	16 weeks: >10 and ≤ 15 mm Hg, N=156	26.9 Percentage of Participants
Olmesartan Medoxomil/Amlodipine Tablets + Hydrochlorothiazide	Percentage of Type 2 Diabetic Patients Achieving Seated Diastolic Blood Pressure Reduction Ranges From Baseline to 4, 8, 12, 16, 20 Weeks	16 weeks: >15 and ≤ 20 mm Hg, N=156	21.8 Percentage of Participants
Olmesartan Medoxomil/Amlodipine Tablets + Hydrochlorothiazide	Percentage of Type 2 Diabetic Patients Achieving Seated Diastolic Blood Pressure Reduction Ranges From Baseline to 4, 8, 12, 16, 20 Weeks	16 weeks: >20 mm Hg, N=156	18.6 Percentage of Participants
Olmesartan Medoxomil/Amlodipine Tablets + Hydrochlorothiazide	Percentage of Type 2 Diabetic Patients Achieving Seated Diastolic Blood Pressure Reduction Ranges From Baseline to 4, 8, 12, 16, 20 Weeks	20 weeks: ≤ 10 mm Hg, N=150	37.3 Percentage of Participants
Olmesartan Medoxomil/Amlodipine Tablets + Hydrochlorothiazide	Percentage of Type 2 Diabetic Patients Achieving Seated Diastolic Blood Pressure Reduction Ranges From Baseline to 4, 8, 12, 16, 20 Weeks	20 weeks: >10 and ≤ 15 mm Hg, N=150	18.0 Percentage of Participants
Olmesartan Medoxomil/Amlodipine Tablets + Hydrochlorothiazide	Percentage of Type 2 Diabetic Patients Achieving Seated Diastolic Blood Pressure Reduction Ranges From Baseline to 4, 8, 12, 16, 20 Weeks	20 weeks: >15 and ≤ 20 mm Hg, N=150	26.0 Percentage of Participants
Olmesartan Medoxomil/Amlodipine Tablets + Hydrochlorothiazide	Percentage of Type 2 Diabetic Patients Achieving Seated Diastolic Blood Pressure Reduction Ranges From Baseline to 4, 8, 12, 16, 20 Weeks	20 weeks: >20 mm Hg, N=150	18.7 Percentage of Participants

Secondary

Percentage of Type 2 Diabetic Patients Achieving Seated Systolic Blood Pressure Goal From Baseline to 4, 8, 12, 16, 20 Weeks

Time frame: Baseline to 4, 8, 12, 16, 20 weeks

Arm	Measure	Group	Value (NUMBER)
Olmesartan Medoxomil/Amlodipine Tablets + Hydrochlorothiazide	Percentage of Type 2 Diabetic Patients Achieving Seated Systolic Blood Pressure Goal From Baseline to 4, 8, 12, 16, 20 Weeks	4 weeks: <140 mm Hg, N=190	54.7 Percentage of Participants
Olmesartan Medoxomil/Amlodipine Tablets + Hydrochlorothiazide	Percentage of Type 2 Diabetic Patients Achieving Seated Systolic Blood Pressure Goal From Baseline to 4, 8, 12, 16, 20 Weeks	4 weeks: <135 mm Hg, N=190	41.1 Percentage of Participants
Olmesartan Medoxomil/Amlodipine Tablets + Hydrochlorothiazide	Percentage of Type 2 Diabetic Patients Achieving Seated Systolic Blood Pressure Goal From Baseline to 4, 8, 12, 16, 20 Weeks	4 weeks: <130 mm Hg, N=190	26.3 Percentage of Participants
Olmesartan Medoxomil/Amlodipine Tablets + Hydrochlorothiazide	Percentage of Type 2 Diabetic Patients Achieving Seated Systolic Blood Pressure Goal From Baseline to 4, 8, 12, 16, 20 Weeks	4 weeks: <120 mm Hg, N=190	10.0 Percentage of Participants
Olmesartan Medoxomil/Amlodipine Tablets + Hydrochlorothiazide	Percentage of Type 2 Diabetic Patients Achieving Seated Systolic Blood Pressure Goal From Baseline to 4, 8, 12, 16, 20 Weeks	8 weeks: <140 mm Hg, N=190	69.0 Percentage of Participants
Olmesartan Medoxomil/Amlodipine Tablets + Hydrochlorothiazide	Percentage of Type 2 Diabetic Patients Achieving Seated Systolic Blood Pressure Goal From Baseline to 4, 8, 12, 16, 20 Weeks	8 weeks: <135 mm Hg, N=190	56.3 Percentage of Participants
Olmesartan Medoxomil/Amlodipine Tablets + Hydrochlorothiazide	Percentage of Type 2 Diabetic Patients Achieving Seated Systolic Blood Pressure Goal From Baseline to 4, 8, 12, 16, 20 Weeks	8 weeks: <130 mm Hg, N=190	42.6 Percentage of Participants
Olmesartan Medoxomil/Amlodipine Tablets + Hydrochlorothiazide	Percentage of Type 2 Diabetic Patients Achieving Seated Systolic Blood Pressure Goal From Baseline to 4, 8, 12, 16, 20 Weeks	8 weeks: <120 mm Hg, N=190	15.8 Percentage of Participants
Olmesartan Medoxomil/Amlodipine Tablets + Hydrochlorothiazide	Percentage of Type 2 Diabetic Patients Achieving Seated Systolic Blood Pressure Goal From Baseline to 4, 8, 12, 16, 20 Weeks	12 weeks: <140 mm Hg, N=190	81.6 Percentage of Participants
Olmesartan Medoxomil/Amlodipine Tablets + Hydrochlorothiazide	Percentage of Type 2 Diabetic Patients Achieving Seated Systolic Blood Pressure Goal From Baseline to 4, 8, 12, 16, 20 Weeks	12 weeks: <135 mm Hg, N=190	69.5 Percentage of Participants
Olmesartan Medoxomil/Amlodipine Tablets + Hydrochlorothiazide	Percentage of Type 2 Diabetic Patients Achieving Seated Systolic Blood Pressure Goal From Baseline to 4, 8, 12, 16, 20 Weeks	12 weeks: <130 mm Hg, N=190	57.9 Percentage of Participants
Olmesartan Medoxomil/Amlodipine Tablets + Hydrochlorothiazide	Percentage of Type 2 Diabetic Patients Achieving Seated Systolic Blood Pressure Goal From Baseline to 4, 8, 12, 16, 20 Weeks	12 weeks: <120 mm Hg, N=190	30.0 Percentage of Participants
Olmesartan Medoxomil/Amlodipine Tablets + Hydrochlorothiazide	Percentage of Type 2 Diabetic Patients Achieving Seated Systolic Blood Pressure Goal From Baseline to 4, 8, 12, 16, 20 Weeks	16 weeks: <140 mm Hg, N=190	87.9 Percentage of Participants
Olmesartan Medoxomil/Amlodipine Tablets + Hydrochlorothiazide	Percentage of Type 2 Diabetic Patients Achieving Seated Systolic Blood Pressure Goal From Baseline to 4, 8, 12, 16, 20 Weeks	16 weeks: <135 mm Hg, N=190	79.0 Percentage of Participants
Olmesartan Medoxomil/Amlodipine Tablets + Hydrochlorothiazide	Percentage of Type 2 Diabetic Patients Achieving Seated Systolic Blood Pressure Goal From Baseline to 4, 8, 12, 16, 20 Weeks	16 weeks: <130 mm Hg, N=190	69.0 Percentage of Participants
Olmesartan Medoxomil/Amlodipine Tablets + Hydrochlorothiazide	Percentage of Type 2 Diabetic Patients Achieving Seated Systolic Blood Pressure Goal From Baseline to 4, 8, 12, 16, 20 Weeks	16 weeks: <120 mm Hg, N=190	39.5 Percentage of Participants
Olmesartan Medoxomil/Amlodipine Tablets + Hydrochlorothiazide	Percentage of Type 2 Diabetic Patients Achieving Seated Systolic Blood Pressure Goal From Baseline to 4, 8, 12, 16, 20 Weeks	20 weeks: <140 mm Hg, N=190	91.1 Percentage of Participants
Olmesartan Medoxomil/Amlodipine Tablets + Hydrochlorothiazide	Percentage of Type 2 Diabetic Patients Achieving Seated Systolic Blood Pressure Goal From Baseline to 4, 8, 12, 16, 20 Weeks	20 weeks: <135 mm Hg, N=190	84.2 Percentage of Participants
Olmesartan Medoxomil/Amlodipine Tablets + Hydrochlorothiazide	Percentage of Type 2 Diabetic Patients Achieving Seated Systolic Blood Pressure Goal From Baseline to 4, 8, 12, 16, 20 Weeks	20 weeks: <130 mm Hg, N=190	75.3 Percentage of Participants
Olmesartan Medoxomil/Amlodipine Tablets + Hydrochlorothiazide	Percentage of Type 2 Diabetic Patients Achieving Seated Systolic Blood Pressure Goal From Baseline to 4, 8, 12, 16, 20 Weeks	20 weeks: <120 mm Hg, N=190	48.4 Percentage of Participants

Secondary

Percentage of Type 2 Diabetic Patients Achieving Seated Systolic Blood Pressure Reduction Ranges From Baseline to 4, 8, 12, 16, 20 Weeks

Time frame: Baseline to 4, 8, 12, 16, 20 weeks

Arm	Measure	Group	Value (NUMBER)
Olmesartan Medoxomil/Amlodipine Tablets + Hydrochlorothiazide	Percentage of Type 2 Diabetic Patients Achieving Seated Systolic Blood Pressure Reduction Ranges From Baseline to 4, 8, 12, 16, 20 Weeks	8 weeks: >45 mm Hg, N=181	0.0 Percentage of Participants
Olmesartan Medoxomil/Amlodipine Tablets + Hydrochlorothiazide	Percentage of Type 2 Diabetic Patients Achieving Seated Systolic Blood Pressure Reduction Ranges From Baseline to 4, 8, 12, 16, 20 Weeks	12 weeks: >45 mm Hg, N=170	3.5 Percentage of Participants
Olmesartan Medoxomil/Amlodipine Tablets + Hydrochlorothiazide	Percentage of Type 2 Diabetic Patients Achieving Seated Systolic Blood Pressure Reduction Ranges From Baseline to 4, 8, 12, 16, 20 Weeks	16 weeks: ≤ 15 mm Hg, N=156	28.2 Percentage of Participants
Olmesartan Medoxomil/Amlodipine Tablets + Hydrochlorothiazide	Percentage of Type 2 Diabetic Patients Achieving Seated Systolic Blood Pressure Reduction Ranges From Baseline to 4, 8, 12, 16, 20 Weeks	4 weeks: ≤ 15 mm Hg, N=189	56.1 Percentage of Participants
Olmesartan Medoxomil/Amlodipine Tablets + Hydrochlorothiazide	Percentage of Type 2 Diabetic Patients Achieving Seated Systolic Blood Pressure Reduction Ranges From Baseline to 4, 8, 12, 16, 20 Weeks	4 weeks: >15 and ≤ 30 mm Hg, N=189	36.0 Percentage of Participants
Olmesartan Medoxomil/Amlodipine Tablets + Hydrochlorothiazide	Percentage of Type 2 Diabetic Patients Achieving Seated Systolic Blood Pressure Reduction Ranges From Baseline to 4, 8, 12, 16, 20 Weeks	4 weeks: >30 and ≤ 45 mm Hg, N=189	7.9 Percentage of Participants
Olmesartan Medoxomil/Amlodipine Tablets + Hydrochlorothiazide	Percentage of Type 2 Diabetic Patients Achieving Seated Systolic Blood Pressure Reduction Ranges From Baseline to 4, 8, 12, 16, 20 Weeks	4 weeks: >45 mm Hg, N=189	0.0 Percentage of Participants
Olmesartan Medoxomil/Amlodipine Tablets + Hydrochlorothiazide	Percentage of Type 2 Diabetic Patients Achieving Seated Systolic Blood Pressure Reduction Ranges From Baseline to 4, 8, 12, 16, 20 Weeks	8 weeks: ≤ 15 mm Hg, N=181	54.1 Percentage of Participants
Olmesartan Medoxomil/Amlodipine Tablets + Hydrochlorothiazide	Percentage of Type 2 Diabetic Patients Achieving Seated Systolic Blood Pressure Reduction Ranges From Baseline to 4, 8, 12, 16, 20 Weeks	8 weeks: >15 and ≤ 30 mm Hg, N=181	34.3 Percentage of Participants
Olmesartan Medoxomil/Amlodipine Tablets + Hydrochlorothiazide	Percentage of Type 2 Diabetic Patients Achieving Seated Systolic Blood Pressure Reduction Ranges From Baseline to 4, 8, 12, 16, 20 Weeks	8 weeks: >30 and ≤ 45 mm Hg, N=181	11.6 Percentage of Participants
Olmesartan Medoxomil/Amlodipine Tablets + Hydrochlorothiazide	Percentage of Type 2 Diabetic Patients Achieving Seated Systolic Blood Pressure Reduction Ranges From Baseline to 4, 8, 12, 16, 20 Weeks	12 weeks: ≤ 15 mm Hg, N=170	35.3 Percentage of Participants
Olmesartan Medoxomil/Amlodipine Tablets + Hydrochlorothiazide	Percentage of Type 2 Diabetic Patients Achieving Seated Systolic Blood Pressure Reduction Ranges From Baseline to 4, 8, 12, 16, 20 Weeks	12 weeks: >15 and ≤ 30 mm Hg, N=170	38.2 Percentage of Participants
Olmesartan Medoxomil/Amlodipine Tablets + Hydrochlorothiazide	Percentage of Type 2 Diabetic Patients Achieving Seated Systolic Blood Pressure Reduction Ranges From Baseline to 4, 8, 12, 16, 20 Weeks	12 weeks: >30 and ≤ 45 mm Hg, N=170	22.9 Percentage of Participants
Olmesartan Medoxomil/Amlodipine Tablets + Hydrochlorothiazide	Percentage of Type 2 Diabetic Patients Achieving Seated Systolic Blood Pressure Reduction Ranges From Baseline to 4, 8, 12, 16, 20 Weeks	16 weeks: >15 and ≤ 30 mm Hg, N=156	40.4 Percentage of Participants
Olmesartan Medoxomil/Amlodipine Tablets + Hydrochlorothiazide	Percentage of Type 2 Diabetic Patients Achieving Seated Systolic Blood Pressure Reduction Ranges From Baseline to 4, 8, 12, 16, 20 Weeks	16 weeks: >30 and ≤ 45 mm Hg, N=156	26.3 Percentage of Participants
Olmesartan Medoxomil/Amlodipine Tablets + Hydrochlorothiazide	Percentage of Type 2 Diabetic Patients Achieving Seated Systolic Blood Pressure Reduction Ranges From Baseline to 4, 8, 12, 16, 20 Weeks	16 weeks: >45 mm Hg, N=156	5.1 Percentage of Participants
Olmesartan Medoxomil/Amlodipine Tablets + Hydrochlorothiazide	Percentage of Type 2 Diabetic Patients Achieving Seated Systolic Blood Pressure Reduction Ranges From Baseline to 4, 8, 12, 16, 20 Weeks	20 weeks: ≤ 15 mm Hg, N=150	26.0 Percentage of Participants
Olmesartan Medoxomil/Amlodipine Tablets + Hydrochlorothiazide	Percentage of Type 2 Diabetic Patients Achieving Seated Systolic Blood Pressure Reduction Ranges From Baseline to 4, 8, 12, 16, 20 Weeks	20 weeks: >15 and ≤ 30 mm Hg, N=150	40.0 Percentage of Participants
Olmesartan Medoxomil/Amlodipine Tablets + Hydrochlorothiazide	Percentage of Type 2 Diabetic Patients Achieving Seated Systolic Blood Pressure Reduction Ranges From Baseline to 4, 8, 12, 16, 20 Weeks	20 weeks: >30 and ≤ 45 mm Hg, N=150	26.7 Percentage of Participants
Olmesartan Medoxomil/Amlodipine Tablets + Hydrochlorothiazide	Percentage of Type 2 Diabetic Patients Achieving Seated Systolic Blood Pressure Reduction Ranges From Baseline to 4, 8, 12, 16, 20 Weeks	20 weeks: >45 mm Hg, N=150	7.3 Percentage of Participants

Secondary

The Percentage of Subjects Achieving Seated Diastolic BP Goal (<90 mmHg for Non-diabetics or < 80 mmHg for Subjects With Diabetes) From Baseline to 12 Weeks

Time frame: baseline to 12 weeks

Population: The analysis population consists of those participants who have a baseline and at least 1 post-baseline measurement and who received at least one dose of study medication.

Arm	Measure	Value (NUMBER)
Olmesartan Medoxomil/Amlodipine Tablets + Hydrochlorothiazide	The Percentage of Subjects Achieving Seated Diastolic BP Goal (<90 mmHg for Non-diabetics or < 80 mmHg for Subjects With Diabetes) From Baseline to 12 Weeks	84.3 Percentage of participants

95% CI: [81.8, 86.5]

Secondary

The Percentage of Subjects Who Achieve BP Goal (<140/90 mmHg for Non-diabetics or <130/80 mmHg for Diabetics) From Baseline to 12 and 20 Weeks

Time frame: Baseline to 12 and 20 weeks

Population: The analysis population consists of those participants who have a baseline and at least 1 post-baseline measurement and who received at least one dose of study medication.

Arm	Measure	Group	Value (NUMBER)
Olmesartan Medoxomil/Amlodipine Tablets + Hydrochlorothiazide	The Percentage of Subjects Who Achieve BP Goal (<140/90 mmHg for Non-diabetics or <130/80 mmHg for Diabetics) From Baseline to 12 and 20 Weeks	12 weeks	71.3 Percentage of participants
Olmesartan Medoxomil/Amlodipine Tablets + Hydrochlorothiazide	The Percentage of Subjects Who Achieve BP Goal (<140/90 mmHg for Non-diabetics or <130/80 mmHg for Diabetics) From Baseline to 12 and 20 Weeks	20 weeks	84.8 Percentage of participants

Comparison: 12 week analysis95% CI: [68.3, 74.1]

Comparison: 20 week analysis95% CI: [82.4, 87]

Source: ClinicalTrials.gov · Data processed: Mar 25, 2026

A Dose Escalation Study of a Combination Antihypertensive Drug in the Treatment of Various Groups of Patients Who do Not Respond to Single Drug Treatment of Their High Blood Pressure

Conditions

Brief summary

Related papers

Interventions

Sponsors

Study design

Eligibility

Inclusion criteria

Exclusion criteria

Design outcomes

Primary

Secondary

Countries

Participant flow

Recruitment details

Participants by arm

Withdrawals & dropouts

Baseline characteristics

Adverse events

Outcome results

The Percentage of Patients Who Achieve Seated Systolic Blood Pressure Goal (<140 mm Hg for Non-diabetics and <130 mm Hg for Diabetics) From Baseline to 12 Weeks

Change From Baseline to Week 12 in Ambulatory Systolic and Diastolic Blood Pressure Values

Change From Baseline to Week 20 in Ambulatory Systolic and Diastolic Blood Pressure Values

Change in Mean Seated Diastolic Blood Pressure From Baseline to 4, 8, 12, 16, 20 Weeks

Change in Mean Seated Systolic Blood Pressure From Baseline to 4, 8, 12, 16, 20 Weeks

Percentage of African American/Black Patients Achieving Seated Blood Pressure Goal From Baseline to 4, 8, 12, 16, 20 Weeks

Percentage of African American/Black Patients Achieving Seated Diastolic Blood Pressure Goal From Baseline to 4, 8, 12, 16, 20 Weeks

Percentage of African American/Black Patients Achieving Seated Diastolic Blood Pressure Reduction Ranges From Baseline to 4, 8, 12, 16, 20 Weeks

Percentage of African American/Black Patients Achieving Seated Systolic Blood Pressure Goal From Baseline to 4, 8, 12, 16, 20 Weeks

Percentage of African American/Black Patients Achieving Seated Systolic Blood Pressure Reduction Ranges From Baseline to 4, 8, 12, 16, 20 Weeks

Percentage of Asain Patients Achieving Seated Diastolic Blood Pressure Goal From Baseline to 4, 8, 12, 16, 20 Weeks

Percentage of Asian Patients Achieving Seated Diastolic Blood Pressure Reduction Ranges From Baseline to 4, 8, 12, 16, 20 Weeks

Percentage of Asian Patients Achieving Seated Systolic Blood Pressure Goal From Baseline to 4, 8, 12, 16, 20 Weeks

Percentage of Asian Patients Achieving Seated Systolic Blood Pressure Reduction Ranges From Baseline to 4, 8, 12, 16, 20 Weeks

Percentage of Elderly Patients Achieving Seated Diastolic Blood Pressure Goal From Baseline to 4, 8, 12, 16, 20 Weeks

Percentage of Elderly Patients Achieving Seated Diastolic Blood Pressure Reduction Ranges From Baseline to 4, 8, 12, 16, 20 Weeks

Percentage of Elderly Patients Achieving Seated Systolic Blood Pressure Goal From Baseline to 4, 8, 12, 16, 20 Weeks

Percentage of Elderly Patients Achieving Seated Systolic Blood Pressure Reduction Ranges From Baseline to 4, 8, 12, 16, 20 Weeks

Percentage of Hispanic Patients Achieving Seated Diastolic Blood Pressure Goal From Baseline to 4, 8, 12, 16, 20 Weeks

Percentage of Hispanic Patients Achieving Seated Diastolic Blood Pressure Reduction Ranges From Baseline to 4, 8, 12, 16, 20 Weeks

Percentage of Hispanic Patients Achieving Seated Systolic Blood Pressure Goal From Baseline to 4, 8, 12, 16, 20 Weeks

Percentage of Hispanic Patients Achieving Seated Systolic Blood Pressure Reduction Ranges From Baseline to 4, 8, 12, 16, 20 Weeks

Percentage of Obese Patients Achieving Seated Diastolic Blood Pressure Goal From Baseline to 4, 8, 12, 16, 20 Weeks

Percentage of Obese Patients Achieving Seated Diastolic Blood Pressure Reduction Ranges From Baseline to 4, 8, 12, 16, 20 Weeks

Percentage of Obese Patients Achieving Seated Systolic Blood Pressure Goal From Baseline to 4, 8, 12, 16, 20 Weeks

Percentage of Obese Patients Achieving Seated Systolic Blood Pressure Reduction Ranges From Baseline to 4, 8, 12, 16, 20 Weeks

Percentage of Participants Achieving the Mean 24-hour Blood Pressure Goals, as Measured by Ambulatory Blood Pressure Monitor, From Baseline to 12 Weeks

Percentage of Participants Achieving the Mean 24-hour Blood Pressure Goals, as Measured by Ambulatory Blood Pressure Monitor, From Baseline to 20 Weeks

Percentage of Participants Achieving the Mean Daytime Blood Pressure Goals, as Measured by Ambulatory Blood Pressure Monitor, From Baseline to 12 Weeks

Percentage of Participants Achieving the Mean Daytime Blood Pressure Goals, as Measured by Ambulatory Blood Pressure Monitor, From Baseline to 20 Weeks

Percentage of Participants Achieving the Mean Nighttime Blood Pressure Goals, as Measured by Ambulatory Blood Pressure Monitor, From Baseline to 12 Weeks

Percentage of Participants Achieving the Mean Nighttime Blood Pressure Goals, as Measured by Ambulatory Blood Pressure Monitor, From Baseline to 20 Weeks

Percentage of Participants Previously on a Beta Blocker Achieving the Blood Pressure Goals From Baseline to 12 Weeks

Percentage of Participants Previously on a Beta Blocker Achieving the Blood Pressure Goals From Baseline to 20 Weeks

Percentage of Participants Previously on a Dihydropyridine Calcium Channel Blocker Achieving the Blood Pressure Goals From Baseline to 12 Weeks

Percentage of Participants Previously on a Dihydropyridine Calcium Channel Blocker Achieving the Blood Pressure Goals From Baseline to 20 Weeks

Percentage of Participants Previously on a Diuretic Achieving the Blood Pressure Goals From Baseline to 12 Weeks

Percentage of Participants Previously on a Diuretic Achieving the Blood Pressure Goals From Baseline to 20 Weeks

Percentage of Participants Previously on an Angiotensin Converting Enzyme Inhibitor Achieving the Blood Pressure Goals From Baseline to 12 Weeks

Percentage of Participants Previously on an Angiotensin Converting Enzyme Inhibitor Achieving the Blood Pressure Goals From Baseline to 20 Weeks

Percentage of Participants Previously on an Angiotensin II Receptor Blocker Achieving the Blood Pressure Goals From Baseline to 12 Weeks

Percentage of Participants Previously on an Angiotensin II Receptor Blocker Achieving the Blood Pressure Goals From Baseline to 20 Weeks

Percentage of Participants Previously on a Nondihydropyridine Calcium Channel Blocker Achieving the Blood Pressure Goals From Baseline to 12 Weeks

Percentage of Participants Previously on a Nondihydropyridine Calcium Channel Blocker Achieving the Blood Pressure Goals From Baseline to 20 Weeks

Percentage of Patients Achieving Seated Blood Pressure Goal From Baseline to 4, 8, 12, 16, 20 Weeks

Percentage of Patients Achieving Seated Diastolic Blood Pressure Goal From Baseline to 4, 8, 12, 16, 20 Weeks

Percentage of Patients Achieving Seated Diastolic Blood Pressure Reduction Ranges From Baseline to 4, 8, 12, 16, 20 Weeks

Percentage of Patients Achieving Seated Systolic Blood Pressure Goal From Baseline to 4, 8, 12, 16, 20 Weeks

Percentage of Patients Achieving Seated Systolic Blood Pressure Reduction Ranges From Baseline to 4, 8, 12, 16, 20 Weeks

Percentage of Patients With Metabolic Syndrome Achieving Seated Diastolic Blood Pressure Goal From Baseline to 4, 8, 12, 16, 20 Weeks

Percentage of Patients With Metabolic Syndrome Achieving Seated Diastolic Blood Pressure Reduction Ranges From Baseline to 4, 8, 12, 16, 20 Weeks

Percentage of Patients With Metabolic Syndrome Achieving Seated Systolic Blood Pressure Goal From Baseline to 4, 8, 12, 16, 20 Weeks

Percentage of Patients With Metabolic Syndrome Achieving Seated Systolic Blood Pressure Reduction Ranges From Baseline to 4, 8, 12, 16, 20 Weeks

Percentage of Type 2 Diabetic Patients Achieving Seated Diastolic Blood Pressure Goal From Baseline to 4, 8, 12, 16, 20 Weeks

Percentage of Type 2 Diabetic Patients Achieving Seated Diastolic Blood Pressure Reduction Ranges From Baseline to 4, 8, 12, 16, 20 Weeks

Percentage of Type 2 Diabetic Patients Achieving Seated Systolic Blood Pressure Goal From Baseline to 4, 8, 12, 16, 20 Weeks

Percentage of Type 2 Diabetic Patients Achieving Seated Systolic Blood Pressure Reduction Ranges From Baseline to 4, 8, 12, 16, 20 Weeks

The Percentage of Subjects Achieving Seated Diastolic BP Goal (<90 mmHg for Non-diabetics or < 80 mmHg for Subjects With Diabetes) From Baseline to 12 Weeks

The Percentage of Subjects Who Achieve BP Goal (<140/90 mmHg for Non-diabetics or <130/80 mmHg for Diabetics) From Baseline to 12 and 20 Weeks